Atlas · 1,694 targets

Cancer targets A to Z

Genes, proteins and cell features that treatments aim at, from EGFR and HER2 to newer targets in early trials.

Search targets in the Atlas All 19,500+ records

A

A1CF: A1CF (APOBEC1 complementation factor) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
ABCB1: ABCB1 (ATP-dependent translocase ABCB1) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Ovarian cancer, Non-small-cell lung c...Open in Atlas onco.cc
ABCC1: ABCC1 (ATP-binding cassette sub-family C member 1) is an enzyme. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer.Open in Atlas onco.cc
ABCC10: ABCC10 (ATP-binding cassette sub-family C member 10) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-small-cell lung cancer.Open in Atlas onco.cc
ABCC3: ABCC3 (ATP-binding cassette sub-family C member 3) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer.Open in Atlas onco.cc
ABCC4: ABCC4 (ATP-binding cassette sub-family C member 4) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Angiosarcoma.Open in Atlas onco.cc
ABCG2: ABCG2 (Broad substrate specificity ATP-binding cassette transporter ABCG2) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer.Open in Atlas onco.cc
ABI1: ABI1 (Abl interactor 1) is a gene. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Breast cancer.Open in Atlas onco.cc
ABL1: ABL1 is the kinase half of the BCR::ABL1 fusion that causes chronic myeloid leukaemia. The CML drugs bind the ABL1 kinase domain, most in its ATP pocket and asciminib in a separate pocket that locks it shut.Open in Atlas onco.cc
ABL2: ABL2 (Tyrosine-protein kinase ABL2) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to dia...Open in Atlas onco.cc
ABO: ABO (Histo-blood group ABO system transferase) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
ACKR3: ACKR3 (Atypical chemokine receptor 3) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Ovarian cancer, Colorectal can...Open in Atlas onco.cc
ACOXL: ACOXL (Acyl-coenzyme A oxidase-like protein) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Leukaemia.Open in Atlas onco.cc
ACSL3: ACSL3 (Fatty acid CoA ligase Acsl3) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Acute myeloid leukaemia.Open in Atlas onco.cc
ACSL6: ACSL6 (Long-chain-fatty-acid--CoA ligase 6) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Sar...Open in Atlas onco.cc
ACSM3: ACSM3 (Acyl-coenzyme A synthetase ACSM3, mitochondrial) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Glioma & gli...Open in Atlas onco.cc
ACTA1: ACTA1 (Actin, alpha skeletal muscle) is an enzyme. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-small-cell lung cancer.Open in Atlas onco.cc
ACTA2: ACTA2 (Actin, aortic smooth muscle) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Leukaemia.Open in Atlas onco.cc
ACTB: ACTB (Actin, cytoplasmic 1) is an enzyme. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.Open in Atlas onco.cc
ACTG1: ACTG1 (Actin, cytoplasmic 2) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
ACTL6A: ACTL6A (Actin-like protein 6A) is a protein that switches other genes on and off. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ov...Open in Atlas onco.cc
ACVR1 (ALK2): ACVR1 (ALK2) is the receptor that raises hepcidin, the hormone that hides iron from the bone marrow. Momelotinib and pacritinib block it as well as JAK2, which is why they improve, rather than worsen, the low red-cell counts of myelofibrosis.Open in Atlas onco.cc
ACVR1B: ACVR1B (Activin receptor type-1B) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied...Open in Atlas onco.cc
ACVR2A: ACVR2A (Activin receptor type-2A) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis o...Open in Atlas onco.cc
ADAM29: ADAM29 (Disintegrin and metalloproteinase domain-containing protein 29) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Breast cancer.Open in Atlas onco.cc
ADAMTS9: ADAMTS9 (A disintegrin and metalloproteinase with thrombospondin motifs 9) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient coh...Open in Atlas onco.cc
Adenosine A2A receptor (ADORA2A): The A2A receptor is where adenosine lands on a T cell and tells it to rest. Oral antagonists, cousins of caffeine, are in phase 2 combinations with PD-1 blockade and chemotherapy.Open in Atlas onco.cc
Adenosine deaminase (ADA): Adenosine deaminase is an enzyme that breaks down adenosine and deoxyadenosine; blocking it with pentostatin poisons lymphocytes, which is why the drug works in hairy cell leukaemia and some T-cell cancers.Open in Atlas onco.cc
ADH1B: ADH1B (All-trans-retinol dehydrogenase [NAD(+)] ADH1B) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Oesophageal cancer.Open in Atlas onco.cc
ADRA1A: ADRA1A (Alpha-1A adrenergic receptor) is a receptor that reads hormone signals inside the cell nucleus. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Neuroendocrine tumours and Prostate ca...Open in Atlas onco.cc
ADRA1B: ADRA1B (Alpha-1B adrenergic receptor) is a receptor that reads hormone signals inside the cell nucleus. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Neuroendocrine tumours.Open in Atlas onco.cc
ADRA1D: ADRA1D (Alpha-1D adrenergic receptor) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Neuroendocrine tumours.Open in Atlas onco.cc
ADRA2A: ADRA2A (Alpha-2A adrenergic receptor) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Neuroendocrine tumours.Open in Atlas onco.cc
ADRA2B: ADRA2B (Alpha-2B adrenergic receptor) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.Open in Atlas onco.cc
ADRA2C: ADRA2C (Alpha-2C adrenergic receptor) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.Open in Atlas onco.cc
ADRM1: ADRM1 (Proteasomal ubiquitin receptor ADRM1) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.Open in Atlas onco.cc
AEBP1: AEBP1 (Adipocyte enhancer-binding protein 1) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Melanoma.Open in Atlas onco.cc
AFDN: AFDN (Afadin) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast...Open in Atlas onco.cc
AFF1: AFF1 (AF4/FMR2 family member 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Leukaemi...Open in Atlas onco.cc
AFF3: AFF3 (AF4/FMR2 family member 3) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer,...Open in Atlas onco.cc
AFF4: AFF4 (AF4/FMR2 family member 4) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular...Open in Atlas onco.cc
AGGF1: AGGF1 (Angiogenic factor with G patch and FHA domains 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
AGK: AGK (Acylglycerol kinase, mitochondrial) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
AGR2: AGR2 (Anterior gradient protein 2 homolog) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer.Open in Atlas onco.cc
AGTRAP: AGTRAP (Type-1 angiotensin II receptor-associated protein) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
AIMP2: AIMP2 (Aminoacyl tRNA synthase complex-interacting multifunctional protein 2) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer.Open in Atlas onco.cc
AJUBA: AJUBA (LIM domain-containing protein ajuba) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Head and neck squ...Open in Atlas onco.cc
AKAP9: AKAP9 (A-kinase anchor protein 9) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder &...Open in Atlas onco.cc
AKT: AKT is a central survival kinase downstream of PI3K, blocked by capivasertib in breast and now prostate cancer.Open in Atlas onco.cc
ALCAM: ALCAM (CD166 antigen) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer.Open in Atlas onco.cc
ALDH1A2: ALDH1A2 (Retinal dehydrogenase 2) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Head and neck squamous cell carcinoma.Open in Atlas onco.cc
ALDH2: ALDH2 (Aldehyde dehydrogenase, mitochondrial) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target and an oncogene driver, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied...Open in Atlas onco.cc
ALK: ALK is a gene fusion driver in about 4 to 5% of non-small-cell lung cancers that responds to a succession of ALK inhibitor pills. Lorlatinib kept about 60% of patients progression-free at five years, alectinib is approved after surgery, and neladalkib targe...Open in Atlas onco.cc
ALPK1: ALPK1 (Alpha-protein kinase 1) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to...Open in Atlas onco.cc
AMER1: AMER1 (APC membrane recruitment protein 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer,...Open in Atlas onco.cc
Androgen receptor: The hormone switch that drives prostate cancer, attacked by castration and by pills that block the receptor.Open in Atlas onco.cc
ANGPT1: ANGPT1 (Angiopoietin-1) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.Open in Atlas onco.cc
ANK1: ANK1 (Ankyrin-1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer, Prostate...Open in Atlas onco.cc
ANKRD11: ANKRD11 (Ankyrin repeat domain-containing protein 11) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Non-Hod...Open in Atlas onco.cc
ANO7: ANO7 (Anoctamin-7) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer.Open in Atlas onco.cc
AP3B1: AP3B1 (AP-3 complex subunit beta-1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
APBB1IP: APBB1IP (Amyloid beta A4 precursor protein-binding family B member 1-interacting protein) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
APC: APC (Adenomatous polyposis coli protein) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and an approved or late-stage drug is recorded agai...Open in Atlas onco.cc
APH1A: APH1A (Gamma-secretase subunit APH-1A) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Desmoid tumour.Open in Atlas onco.cc
APH1B: APH1B (Gamma-secretase subunit APH-1B) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Desmoid tumour.Open in Atlas onco.cc
APOBEC3B: APOBEC3B (DNA dC->dU-editing enzyme APOBEC-3B) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Skin cancer.Open in Atlas onco.cc
APOE: APOE (Apolipoprotein E) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
ARAF: ARAF (Serine/threonine-protein kinase A-Raf) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its varian...Open in Atlas onco.cc
AREG: AREG (Amphiregulin) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Head and neck squamous cell carcinoma and Non-small-c...Open in Atlas onco.cc
ARHGAP26: ARHGAP26 (Rho GTPase-activating protein 26) is a gene. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Gastric & gastro-oesophageal junction cancer, Breast cancer, Leukaemia and 2...Open in Atlas onco.cc
ARHGAP35: ARHGAP35 (Rho GTPase-activating protein 35) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug...Open in Atlas onco.cc
ARHGAP5: ARHGAP5 (Rho GTPase-activating protein 5) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied...Open in Atlas onco.cc
ARHGEF10: ARHGEF10 (Rho guanine nucleotide exchange factor 10) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient co...Open in Atlas onco.cc
ARHGEF10L: ARHGEF10L (Rho guanine nucleotide exchange factor 10-like protein) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Ti...Open in Atlas onco.cc
ARHGEF12: ARHGEF12 (Rho guanine nucleotide exchange factor 12) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation anal...Open in Atlas onco.cc
ARHGEF5: ARHGEF5 (Rho guanine nucleotide exchange factor 5) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Breast cancer.Open in Atlas onco.cc
ARID1A: ARID1A (AT-rich interactive domain-containing protein 1A) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to...Open in Atlas onco.cc
ARID1B: ARID1B (AT-rich interactive domain-containing protein 1B) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prog...Open in Atlas onco.cc
ARID2: ARID2 (AT-rich interactive domain-containing protein 2) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, progno...Open in Atlas onco.cc
ARID5B: ARID5B (AT-rich interactive domain-containing protein 5B) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Leukaemia, Non-Hodgkin lymphoma and Acute lymphoblast...Open in Atlas onco.cc
ARNT: ARNT (Aryl hydrocarbon receptor nuclear translocator) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target and a tumour suppressor, and an approved or late-stage drug is recorded against it. Tied to Skin...Open in Atlas onco.cc
Aromatase (CYP19A1): The enzyme that turns androgens into oestrogen in fat, muscle and breast tissue after the menopause. Aromatase inhibitors remove the oestrogen that drives most breast cancers in post-menopausal women.Open in Atlas onco.cc
ARRB1: ARRB1 (Beta-arrestin-1) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
ARRB2: ARRB2 (Beta-arrestin-2) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
ASCL1: ASCL1 (Achaete-scute homolog 1) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Atypical teratoid/rhabdoid tumour.Open in Atlas onco.cc
ASNS: ASNS (Asparagine synthetase [glutamine-hydrolysing]) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer.Open in Atlas onco.cc
ASPSCR1: ASPSCR1 (Tether containing UBX domain for GLUT4) is a gene. The public catalogues list it as a drug target and a fusion partner, and the evidence so far is association rather than a proven role. Tied to Sarcomas.Open in Atlas onco.cc
ASS1: ASS1 (Argininosuccinate synthase) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer and Sarcomas.Open in Atlas onco.cc
ASXL1: ASXL1 (Polycomb group protein ASXL1) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug respons...Open in Atlas onco.cc
ASXL2: ASXL2 (Putative Polycomb group protein ASXL2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Ti...Open in Atlas onco.cc
ATF1: ATF1 (Cyclic AMP-dependent transcription factor ATF-1) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Sarcomas, Colorectal cance...Open in Atlas onco.cc
ATF7IP: ATF7IP (Activating transcription factor 7-interacting protein 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied...Open in Atlas onco.cc
ATG12: ATG12 (Ubiquitin-like protein ATG12) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pancreatic ductal adenocarcinoma.Open in Atlas onco.cc
ATG7: ATG7 (Ubiquitin-like modifier-activating enzyme ATG7) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug r...Open in Atlas onco.cc
ATIC: ATIC (Bifunctional purine biosynthesis protein ATIC) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Lung cancer.Open in Atlas onco.cc
ATM: ATM is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker and a DNA repair gene, and clinical evidence ties its variant...Open in Atlas onco.cc
ATP1A1: ATP1A1 (Sodium/potassium-transporting ATPase subunit alpha-1) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target and an oncogene driver, and clinical evidence ties its variants to diagnosis, prognosis or dru...Open in Atlas onco.cc
ATP2B3: ATP2B3 (Plasma membrane calcium-transporting ATPase 3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient...Open in Atlas onco.cc
ATP4A: ATP4A (Potassium-transporting ATPase alpha chain 1) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Gastric & gastro-oesophageal junction cancer and Non-Hodgkin lymphoma.Open in Atlas onco.cc
ATP4B: ATP4B (Potassium-transporting ATPase subunit beta) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Gastric & gastro-oesophageal junction cancer and Non-Hodgkin lymphoma.Open in Atlas onco.cc
ATP7B: ATP7B (Copper-transporting ATPase 2) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer.Open in Atlas onco.cc
ATR: ATR is a DNA-damage alarm kinase. Blocking it makes tumours with broken repair systems collapse under their own replication stress.Open in Atlas onco.cc
ATRX: ATRX (Chromatin remodeler ATRX) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnos...Open in Atlas onco.cc
ATXN1L: ATXN1L (Ataxin-1-like) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pancreatic ductal adenocarcin...Open in Atlas onco.cc
ATXN7: ATXN7 (Ataxin-7) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Thyroid cancer.Open in Atlas onco.cc
AURKA: AURKA (Aurora kinase A) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug respon...Open in Atlas onco.cc
AURKB: AURKB (Aurora kinase B) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug respon...Open in Atlas onco.cc
AXIN1: AXIN1 (Axin-1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcinoma, Oesophageal cancer,...Open in Atlas onco.cc
AXIN2: AXIN2 (Axin-2) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Skin cancer, Lung cancer and 2 more.Open in Atlas onco.cc
AXL: A receptor that helps cancer cells survive stress, resist treatment and spread. Cabozantinib is among the multi-kinase drugs that block it, and dedicated AXL inhibitors and antibody-drug conjugates are in trials.Open in Atlas onco.cc

B

B2M: B2M (Beta-2-microglobulin) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis o...Open in Atlas onco.cc
B4GALT1: B4GALT1 (Beta-1,4-galactosyltransferase 1) is an enzyme. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Renal cell carcinoma.Open in Atlas onco.cc
B7-H3: B7-H3 is an immune checkpoint-like surface protein found on 60 to 70% of small-cell lung cancers and 80 to 90% of castration-resistant prostate cancers, with little on normal tissue. It is used as an ADC address, chiefly by ifinatamab deruxtecan, now in pha...Open in Atlas onco.cc
B7-H4 (VTCN1): B7-H4 is a checkpoint-like protein that many breast, ovarian and endometrial tumours carry on their surface. Antibody-drug conjugates such as puxitatug samrotecan and HS-20089 use it as a docking site to deliver a chemotherapy payload.Open in Atlas onco.cc
BACH2: BACH2 (Transcription regulator protein BACH2) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer and Basal ce...Open in Atlas onco.cc
BAG4: BAG4 (BAG family molecular chaperone regulator 4) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
BAK1: BAK1 (Bcl-2 homologous antagonist/killer) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Leukaemia, Non-Hodgkin lymphoma and Acute lymphoblastic leukaemia.Open in Atlas onco.cc
BAP1: BAP1 (Ubiquitin carboxyl-terminal hydrolase BAP1) is an enzyme. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied t...Open in Atlas onco.cc
BARD1: BARD1 (BRCA1-associated RING domain protein 1) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis,...Open in Atlas onco.cc
BAX: BAX is the protein that opens the mitochondria to start cell death. BCL-2 keeps it in check in leukaemia cells; venetoclax and sonrotoclax free it, so the mitochondria leak cytochrome c and the cell dies.Open in Atlas onco.cc
BAZ1A: BAZ1A (Bromodomain adjacent to zinc finger domain protein 1A) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to...Open in Atlas onco.cc
BCL-2: A protein that stops cells from self-destructing. Venetoclax removes that protection and has transformed leukaemia treatment.Open in Atlas onco.cc
BCL10: BCL10 (B-cell lymphoma/leukaemia 10) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis...Open in Atlas onco.cc
BCL11A: BCL11A (BCL11 transcription factor A) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug respon...Open in Atlas onco.cc
BCL11B: BCL11B (B-cell lymphoma/leukaemia 11B) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Vulvar cancer, Non-Hodgkin ly...Open in Atlas onco.cc
BCL3: BCL3 (B-cell lymphoma 3 protein) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Colorectal cancer.Open in Atlas onco.cc
BCL6: BCL6 (B-cell lymphoma 6 protein) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis o...Open in Atlas onco.cc
BCL7A: BCL7A (B-cell CLL/lymphoma 7 protein family member A) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosi...Open in Atlas onco.cc
BCL9: BCL9 (B-cell CLL/lymphoma 9 protein) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient...Open in Atlas onco.cc
BCL9L: BCL9L (B-cell CLL/lymphoma 9-like protein) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer,...Open in Atlas onco.cc
BCLAF1: BCLAF1 (Bcl-2-associated transcription factor 1) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied t...Open in Atlas onco.cc
BCMA: BCMA is a survival receptor on plasma cells, and the target that made CAR-T and bispecifics work in multiple myeloma.Open in Atlas onco.cc
BCOR: BCOR (BCL-6 corepressor) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to L...Open in Atlas onco.cc
BCORL1: BCORL1 (BCL-6 corepressor-like protein 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer,...Open in Atlas onco.cc
BCR::ABL1 (Philadelphia chromosome): The fusion that defines chronic myeloid leukaemia and a quarter of adult acute lymphoblastic leukaemia; the first cancer driver ever switched off by a pill.Open in Atlas onco.cc
BIK: BIK (Bcl-2-interacting killer) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer.Open in Atlas onco.cc
BIM (BCL2L11): BIM is a pro-death protein that leukaemia cells keep clamped by BCL-2. Venetoclax and sonrotoclax are BH3 mimetics: they copy the part of BIM that binds BCL-2, so BIM is released, the mitochondria leak and the cell dies.Open in Atlas onco.cc
BIRC3: BIRC3 (Baculoviral IAP repeat-containing protein 3) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a biomarker and a fusion partner, and clinical evidence ties its variants to diagno...Open in Atlas onco.cc
BIRC5: BIRC5 (Baculoviral IAP repeat-containing protein 5) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to...Open in Atlas onco.cc
BIRC6: BIRC6 (Dual E2 ubiquitin-conjugating enzyme/E3 ubiquitin-protein ligase BIRC6) is an enzyme. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug re...Open in Atlas onco.cc
BIRC7: BIRC7 (Baculoviral IAP repeat-containing protein 7) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer.Open in Atlas onco.cc
BLK: BLK (Tyrosine-protein kinase Blk) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to L...Open in Atlas onco.cc
BLM: BLM (RecQ-like DNA helicase BLM) is an enzyme. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role. Tied to Leukaemia, Colorectal cancer, Breast cancer and 4 more.Open in Atlas onco.cc
BMP2: BMP2 (Bone morphogenetic protein 2) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Colorectal cancer.Open in Atlas onco.cc
BMP4: BMP4 (Bone morphogenetic protein 4) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Colorectal cancer.Open in Atlas onco.cc
BMP5: BMP5 (Bone morphogenetic protein 5) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Colorectal cancer.Open in Atlas onco.cc
BMP6: BMP6 (Bone morphogenetic protein 6) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer.Open in Atlas onco.cc
BMP7: BMP7 (Bone morphogenetic protein 7) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Burkitt lymphoma.Open in Atlas onco.cc
BMPR1A: BMPR1A (Bone morphogenetic protein receptor type-1A) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of pa...Open in Atlas onco.cc
BNC2: BNC2 (Zinc finger protein basonuclin-2) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Skin cancer and Basal cell carcinoma.Open in Atlas onco.cc
BRAF: BRAF is a signalling kinase mutated in half of melanomas; blocking it with two drugs at once became a template for targeted therapy.Open in Atlas onco.cc
BRCA1 / BRCA2 (HRD): DNA repair genes. Inheriting a broken copy raises breast and ovarian cancer risk, but tumours that lose them become uniquely vulnerable to PARP inhibitors and platinum.Open in Atlas onco.cc
BRD4: BRD4 is a reader protein that docks on acetylated DNA packaging and pulls in the machinery that switches growth genes such as MYC on. BET inhibitors such as pelabresib and ZEN-3694 block that docking; in NUT carcinoma the cancer's own driver is a BRD4 fusion.Open in Atlas onco.cc
BRD7: BRD7 (Bromodomain-containing protein 7) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcin...Open in Atlas onco.cc
BRIP1: BRIP1 (Fanconi anaemia group J protein) is an enzyme. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Ovarian cancer,...Open in Atlas onco.cc
BTC: BTC (Probetacellulin) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
BTG1: BTG1 (BTG anti-proliferation factor 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnos...Open in Atlas onco.cc
BTG2: BTG2 (BTG anti-proliferation factor 2) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug respo...Open in Atlas onco.cc
BTK (Bruton tyrosine kinase): The signalling enzyme that B-cell cancers use to survive. Blocking it turned chronic lymphocytic leukaemia into a disease controlled by a daily pill.Open in Atlas onco.cc
BTLA: BTLA is a brake on T and B cells that is pressed by HVEM, a molecule many tumours carry. An antibody that blocks it is being tested with PD-1 blockade in small-cell lung cancer.Open in Atlas onco.cc
BUB1: BUB1 is one of the kinases that stops a dividing cell pulling its chromosomes apart before every one is attached. Inhibitors exist in the laboratory; none has reached patients.Open in Atlas onco.cc
BUB1B: BUB1B (Mitotic checkpoint serine/threonine-protein kinase BUB1 beta) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. In the public catalogues the evidence so far is association rather than a proven role. Tied to Co...Open in Atlas onco.cc

C

C11orf65: C11orf65 (chromosome 11 open reading frame 65) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Breast cancer, Colorectal cancer, Ovarian cancer and 4 more.Open in Atlas onco.cc
CACNA1D: CACNA1D (Voltage-dependent L-type calcium channel subunit alpha-1D) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a tumour suppressor, and clinical evidence ties its variants to...Open in Atlas onco.cc
CACNA1G: CACNA1G (Voltage-dependent T-type calcium channel subunit alpha-1G) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.Open in Atlas onco.cc
CACNA1H: CACNA1H (Voltage-dependent T-type calcium channel subunit alpha-1H) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.Open in Atlas onco.cc
CACNA1I: CACNA1I (Voltage-dependent T-type calcium channel subunit alpha-1I) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.Open in Atlas onco.cc
CADM2: CADM2 (Cell adhesion molecule 2) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Melanoma.Open in Atlas onco.cc
CALR: CALR (Calreticulin) is a gene. The public catalogues list it as a drug target, a biomarker and a fusion partner, and an approved or late-stage drug is recorded against it. Tied to Myeloproliferative neoplasms, Essential thrombocythaemia and Primary myelofib...Open in Atlas onco.cc
CAMTA1: CAMTA1 (Calmodulin-binding transcription activator 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Sarcomas, Pros...Open in Atlas onco.cc
Cannabinoid receptor 1: The CB1 cannabinoid receptor is how dronabinol and nabilone, synthetic cannabinoids approved for chemotherapy nausea that other drugs fail to control, act on the brain; their place is behind the 5-HT3 and NK1 antagonists.Open in Atlas onco.cc
CANT1: CANT1 (Soluble calcium-activated nucleotidase 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Oesophageal cancer...Open in Atlas onco.cc
CARD11: CARD11 (Caspase recruitment domain-containing protein 11) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, p...Open in Atlas onco.cc
CARS1: CARS1 (Cysteine--tRNA ligase, cytoplasmic) is an enzyme. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Skin cancer, Lung cancer and Melanoma.Open in Atlas onco.cc
CASP10: CASP10 (Caspase-10) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Gastric & gastro-oesophageal junction cancer and Non-Hodgkin lymphoma.Open in Atlas onco.cc
CASP8: CASP8 (Caspase-8) is an enzyme. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Head and neck squamous cell ca...Open in Atlas onco.cc
CASR: CASR (Extracellular calcium-sensing receptor) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.Open in Atlas onco.cc
CASZ1: CASZ1 (Zinc finger protein castor homolog 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer.Open in Atlas onco.cc
CBFA2T3: CBFA2T3 (Transcriptional corepressor CBFA2T3) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Leukaemia, Breast cancer, Lung canc...Open in Atlas onco.cc
CBFB: CBFB (Core-binding factor subunit beta) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patie...Open in Atlas onco.cc
CBL: CBL (E3 ubiquitin-protein ligase CBL) is an enzyme. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Myeloproli...Open in Atlas onco.cc
CBLB: CBLB (E3 ubiquitin-protein ligase CBL-B) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lun...Open in Atlas onco.cc
CBLC: CBLC (E3 ubiquitin-protein ligase CBL-C) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer.Open in Atlas onco.cc
CCAR1: CCAR1 (Cell division cycle and apoptosis regulator protein 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to...Open in Atlas onco.cc
CCDC170: CCDC170 (Coiled-coil domain-containing protein 170) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Breast cancer.Open in Atlas onco.cc
CCDC6: CCDC6 (Coiled-coil domain-containing protein 6) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target and a tumour suppressor, and an approved or late-stage drug is recorded against it. Tied to Lung cance...Open in Atlas onco.cc
CCDC88C: CCDC88C (coiled-coil and HOOK domain protein 88C) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
CCN2: CCN2 (CCN family member 2) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.Open in Atlas onco.cc
CCNB1IP1: CCNB1IP1 (E3 ubiquitin-protein ligase CCNB1IP1) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Skin cancer.Open in Atlas onco.cc
CCND1: CCND1 (G1/S-specific cyclin-D1) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker, a fusion partner and a DNA repair gene, and an approved or late-stage dr...Open in Atlas onco.cc
CCND2: CCND2 (G1/S-specific cyclin-D2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, progno...Open in Atlas onco.cc
CCND3: CCND3 (G1/S-specific cyclin-D3) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or dr...Open in Atlas onco.cc
CCNE1: CCNE1 (G1/S-specific cyclin-E1) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer, Breast cancer,...Open in Atlas onco.cc
CCNE2: CCNE2 (G1/S-specific cyclin-E2) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer.Open in Atlas onco.cc
CCNH: CCNH (Cyclin-H) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
CCNT1: CCNT1 (Cyclin-T1) is a protein that switches other genes on and off. In the public catalogues it is called a cancer driver by mutation analysis of patient cohorts. Tied to Acute myeloid leukaemia.Open in Atlas onco.cc
CCR4: CCR4 is a chemokine receptor on skin-homing and regulatory T cells, and on the malignant cells of cutaneous T-cell lymphoma and adult T-cell leukaemia; mogamulizumab removes those cells.Open in Atlas onco.cc
CCR6: CCR6 marks the T cells that patrol mucosal surfaces such as the gut and airway, and it is the usual way of picking out the Th17 type of helper cell.Open in Atlas onco.cc
CCR7: CCR7 (C-C chemokine receptor type 7) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Diffuse large B-cell lym...Open in Atlas onco.cc
CD112 (nectin-2): CD112 is a widespread cell-adhesion molecule that can either encourage a T cell (through CD226) or hold it back (through PVRIG and TIGIT), depending on which receptor grabs it first.Open in Atlas onco.cc
CD11b: CD11b is carried by most of the myeloid immune cells, and together with CD33 it is part of how myeloid-derived suppressor cells are defined: the cells that hold back a response against a tumour.Open in Atlas onco.cc
CD11c: CD11c identifies dendritic cells, the cells that carry pieces of a tumour to the lymph node and show them to T cells. Without that step, a T cell never learns the cancer is there.Open in Atlas onco.cc
CD123: CD123 is the interleukin-3 receptor alpha chain, present on every blastic plasmacytoid dendritic cell neoplasm and on the blasts and leukaemia stem cells of 70 to 80% of acute myeloid leukaemias. Tagraxofusp and pivekimab sunirine target it in that rare neo...Open in Atlas onco.cc
CD137 (4-1BB, TNFRSF9): 4-1BB is a switch on activated T cells that makes them live longer and kill better. Rather than press it everywhere, new bispecific antibodies press it only on T cells that are already touching a tumour cell marked by PD-L1 or HER2.Open in Atlas onco.cc
CD14: CD14 is how a monocyte is recognised: the circulating cell that becomes a macrophage once it enters tissue. Splitting monocytes by CD14 and CD16 is the first step in describing the myeloid side of a tumour.Open in Atlas onco.cc
CD141: CD141 marks the rare dendritic cells that are best at showing tumour material to killer T cells. The same protein, under its other name thrombomodulin, is part of how blood clotting is kept in check.Open in Atlas onco.cc
CD155 (PVR): CD155 is the molecule on tumour cells that TIGIT and CD96 read; normal tissue barely shows it, many tumours show a lot. Every TIGIT antibody works by breaking the CD155 handshake.Open in Atlas onco.cc
CD163: CD163 marks the macrophages that help a tumour rather than attack it. It is the usual way of counting those cells in a tumour sample, which is why it appears whenever tumour-associated macrophages are discussed.Open in Atlas onco.cc
CD19: CD19 is a marker on B cells and B-cell cancers, and was the target of the first CAR-T therapies ever approved.Open in Atlas onco.cc
CD1c: CD1c marks one of the two main dendritic cell types. Unlike most antigen presentation, CD1 molecules show fats rather than protein fragments to T cells.Open in Atlas onco.cc
CD20: CD20 is a B-cell marker; rituximab against it was the first antibody approved for cancer, in 1997.Open in Atlas onco.cc
CD200: CD200 (OX-2 membrane glycoprotein) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.Open in Atlas onco.cc
CD209: CD209 (CD209 antigen) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Gastric...Open in Atlas onco.cc
CD22: CD22 is a B-cell surface protein and the docking site for the leukaemia ADC inotuzumab ozogamicin.Open in Atlas onco.cc
CD235a: CD235a marks red blood cells. In an immune test its job is the opposite of the others: it is used to find red cells so they can be excluded, because there are far too many of them to leave in.Open in Atlas onco.cc
CD24: CD24 is a second 'don't eat me' badge after CD47: tumours show it to Siglec-10 on macrophages, which then leave them alone. Blocking antibodies are in first-in-human trials.Open in Atlas onco.cc
CD25 (IL-2 receptor alpha): CD25 is the part of the interleukin-2 receptor found on activated T cells and on some lymphoma cells; denileukin diftitox uses it as a doorway to deliver a toxin.Open in Atlas onco.cc
CD27: CD27 is an accelerator on most T cells that is pressed by CD70. Agonist antibodies against it reached phase 2 in lymphoma; its partner CD70 is a separate target for antibodies and CAR-T cells.Open in Atlas onco.cc
CD28: CD28 is the second signal a T cell needs before it attacks. Many CAR-T cells carry a piece of CD28 inside them to fire harder, ipilimumab works by stopping CTLA-4 from hogging CD28's partners, and a new bispecific antibody presses CD28 directly on T cells t...Open in Atlas onco.cc
CD3: CD3 is the switch on every T cell. Bispecific drugs grab it with one arm and the tumour with the other, forcing the T cell to attack.Open in Atlas onco.cc
CD30: CD30 is a protein on the malignant Reed-Sternberg cells of Hodgkin lymphoma and on some T-cell lymphomas, and the address for the ADC brentuximab vedotin.Open in Atlas onco.cc
CD33: CD33 is a myeloid surface marker on the blasts of 85 to 90% of acute myeloid leukaemias and on normal myeloid cells, so drugs against it also hit healthy marrow. It is the target of gemtuzumab ozogamicin, the first ADC ever approved (2000), withdrawn in 201...Open in Atlas onco.cc
CD34: CD34 marks the blood-forming stem cells that a transplant is counted in, and it also stains blood vessels, which is how new vessel growth in a tumour is measured.Open in Atlas onco.cc
CD38: CD38 is a myeloma surface enzyme and the target of daratumumab, which is now given as a quick under-the-skin injection.Open in Atlas onco.cc
CD39 (ENTPD1): CD39 is the first of two enzymes that turn the ATP spilt by dying tumour cells into adenosine, which sedates T cells. Blocking it keeps the ATP alarm ringing; one antibody has completed phase 2 in pancreatic cancer.Open in Atlas onco.cc
CD3D: CD3D (T-cell surface glycoprotein CD3 delta chain) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Non-Hodgkin lymphoma, Multiple myeloma, Leukaemia and 5 more.Open in Atlas onco.cc
CD3G: CD3G (T-cell surface glycoprotein CD3 gamma chain) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Non-Hodgkin lymphoma, Multiple myeloma, Leukaemia and 5 more.Open in Atlas onco.cc
CD4: CD4 is the marker of helper T cells, the cells that direct an immune response rather than kill infected or cancerous cells themselves. A CD4 count is how the strength of that arm of the immune system is measured.Open in Atlas onco.cc
CD40: CD40 sits on the cells that teach T cells what to attack. Agonist antibodies press it to turn cold tumours hot; the strongest signals so far are in pancreatic cancer with chemotherapy.Open in Atlas onco.cc
CD44: CD44 (CD44 antigen) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer, Ovarian cancer, Colorectal...Open in Atlas onco.cc
CD47: CD47 is the 'don't eat me' signal: it binds SIRP-alpha on macrophages to stop them engulfing the cell, and over 90% of AML blasts and large B-cell lymphoma cells display it. Blocking it should let macrophages eat tumour cells, but red cells carry CD47 too,...Open in Atlas onco.cc
CD52: CD52 is a small protein on nearly all lymphocytes and the target of alemtuzumab, a profoundly immunosuppressive antibody once used in CLL and now mostly in transplant conditioning, T-cell leukaemia and multiple sclerosis.Open in Atlas onco.cc
CD56: CD56 identifies natural killer cells, the part of the immune system that kills without needing to be taught what to look for. The same marker appears on neuroendocrine cancers, which is why it is used in diagnosis as well.Open in Atlas onco.cc
CD57: CD57 appears on immune cells that have divided many times and are near the end of their working life. It is the usual way of telling a worn-out T cell from a fresh one.Open in Atlas onco.cc
CD58: CD58 (Lymphocyte function-associated antigen 3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug respons...Open in Atlas onco.cc
CD62L: CD62L is the ticket a lymphocyte needs to get into a lymph node. Whether a T cell carries it separates the cells held in reserve from the ones already out working in tissue.Open in Atlas onco.cc
CD66b: CD66b marks neutrophils, and specifically neutrophils that have been activated. It is the marker used to pick out the granulocyte-like suppressor cells that accumulate in people with advanced cancer.Open in Atlas onco.cc
CD69: CD69 appears within hours of a lymphocyte being activated, so it is the quickest way to tell that something has just woken the immune system up. It also keeps T cells inside a tissue rather than letting them drift back to the blood.Open in Atlas onco.cc
CD7: A T-cell surface marker kept on most T-cell leukaemias; CAR-T cells against it must be engineered not to kill each other, and they have produced remissions in T-ALL where nothing else worked.Open in Atlas onco.cc
CD70: CD70 is a protein normally only on activated immune cells, but permanently switched on in kidney cancer and some leukaemias.Open in Atlas onco.cc
CD73 / adenosine axis: CD73 is an enzyme on tumour and immune cells that converts AMP into adenosine, which switches off T and natural killer cells through A2A and A2B receptors. Oleclumab (anti-CD73) with durvalumab slowed progression in a phase 2 lung cancer trial and quemliclu...Open in Atlas onco.cc
CD74: CD74 (HLA class II histocompatibility antigen gamma chain) is a gene. The public catalogues list it as a drug target and a fusion partner, and an approved or late-stage drug is recorded against it. Tied to Lung cancer and Non-small-cell lung cancer.Open in Atlas onco.cc
CD79A: CD79A (B-cell antigen receptor complex-associated protein alpha chain) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Colorectal cancer, Non-Hodgkin lymphoma and Skin cancer.Open in Atlas onco.cc
CD79b: Part of the B-cell receptor found on nearly all B-cell lymphomas; the target of the ADC polatuzumab vedotin and a frequently mutated gene in brain and testicular lymphoma.Open in Atlas onco.cc
CD8: CD8 marks the T cells that kill: the ones that recognise a cancer cell and destroy it. How many CD8 cells sit inside a tumour, and where, is one of the few immune measurements that predicts how a cancer will behave.Open in Atlas onco.cc
CD80 (B7-1): B7-1 is a molecule on antigen-presenting cells that gives T cells their go signal through CD28, but it also feeds the CTLA-4 brake and can pair with PD-L1. Anti-PD-L1 antibodies such as sugemalimab and adebrelimab are built to stop PD-L1 binding both PD-1 a...Open in Atlas onco.cc
CD83: CD83 (CD83 antigen) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.Open in Atlas onco.cc
CD86 (B7-2): CD86 is one of the two B7 molecules on antigen-presenting cells that either wake a T cell up (through CD28) or calm it down (through CTLA-4). Ipilimumab works by stopping CTLA-4 from hogging CD86 and CD80.Open in Atlas onco.cc
CD96: CD96 sits on T and NK cells and binds CD155, the same molecule TIGIT reads on tumour cells. It is the least tested of that family; one blocking antibody is in phase 2 platform trials in lung cancer.Open in Atlas onco.cc
CDA: CDA (Cytidine deaminase) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myeloproliferative neoplasms and Myelodysplastic syndromes / neoplasms.Open in Atlas onco.cc
CDC37: CDC37 (Hsp90 co-chaperone Cdc37) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
CDC50A: CDC50A (Cell cycle control protein 50A) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.Open in Atlas onco.cc
CDC73: CDC73 (Parafibromin) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Endometrial cancer, Colorectal c...Open in Atlas onco.cc
CDCA7: CDCA7 (Cell division cycle-associated protein 7) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer.Open in Atlas onco.cc
CDH1: CDH1 (Cadherin-1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug re...Open in Atlas onco.cc
CDH10: CDH10 (Cadherin-10) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Pancreatic ductal adenoc...Open in Atlas onco.cc
CDH11: CDH11 (Cadherin-11) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Oesoph...Open in Atlas onco.cc
CDH6: CDH6 is an adhesion protein from kidney development that reappears on ovarian and kidney cancers.Open in Atlas onco.cc
CDK12: CDK12 (Cyclin-dependent kinase 12) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clin...Open in Atlas onco.cc
CDK2: CDK2 (Cyclin-dependent kinase 2) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnos...Open in Atlas onco.cc
CDK4/6: CDK4/6 is the engine that pushes a cell to copy its DNA. Blocking it alongside hormone therapy roughly doubled the time hormone-driven breast cancer stays controlled.Open in Atlas onco.cc
CDK5: CDK5 (Cyclin-dependent kinase 5) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied...Open in Atlas onco.cc
CDK9: CDK9 (Cyclin-dependent kinase 9) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnos...Open in Atlas onco.cc
CDKAL1: CDKAL1 (Threonylcarbamoyladenosine tRNA methylthiotransferase) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
CDKN1A: CDKN1A (Cyclin-dependent kinase inhibitor 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diag...Open in Atlas onco.cc
CDKN1B: CDKN1B (Cyclin-dependent kinase inhibitor 1B) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to dia...Open in Atlas onco.cc
CDKN2A: CDKN2A (Cyclin-dependent kinase inhibitor 2A) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to dia...Open in Atlas onco.cc
CDKN2B: CDKN2B (Cyclin-dependent kinase 4 inhibitor B) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pancreatic ductal adenocarcinoma, Renal cell...Open in Atlas onco.cc
CDKN2C: CDKN2C (Cyclin-dependent kinase 4 inhibitor C) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied...Open in Atlas onco.cc
CDX2: CDX2 (Homeobox protein CDX-2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorec...Open in Atlas onco.cc
CEACAM1: CEACAM1 (Cell adhesion molecule CEACAM1) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer and Hepatocellular carcinoma.Open in Atlas onco.cc
CEACAM5: The classic 'CEA' tumour marker measured in blood, also present on the cell surface where ADCs can reach it.Open in Atlas onco.cc
CEBPA: CEBPA (CCAAT/enhancer-binding protein alpha) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, pr...Open in Atlas onco.cc
CELF2: CELF2 (CUGBP Elav-like family member 2) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
CEP43: CEP43 (Centrosomal protein 43) is a gene. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Leukaemia, Non-Hodgkin lymphoma and Acute lymphoblastic leukaemia.Open in Atlas onco.cc
CEP89: CEP89 (Centrosomal protein of 89 kDa) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer.Open in Atlas onco.cc
Cereblon (CRBN): The protein that lenalidomide and pomalidomide latch onto. Bound drug changes which proteins the cell tags for destruction, degrading the myeloma transcription factors Ikaros and Aiolos.Open in Atlas onco.cc
CFLAR: CFLAR (CASP8 and FADD-like apoptosis regulator) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer.Open in Atlas onco.cc
CHCHD7: CHCHD7 (Coiled-coil-helix-coiled-coil-helix domain-containing protein 7) is a gene. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Oral cavity cancer.Open in Atlas onco.cc
CHD2: CHD2 (ATP-dependent chromatin remodeler CHD2) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to L...Open in Atlas onco.cc
CHD4: CHD4 (ATP-dependent chromatin remodeler CHD4) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to E...Open in Atlas onco.cc
CHD7: CHD7 (ATP-dependent chromatin remodeler CHD7) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Medulloblastoma.Open in Atlas onco.cc
CHD8: CHD8 (ATP-dependent chromatin remodeler CHD8) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Burkitt lymphoma.Open in Atlas onco.cc
CHEK1: CHEK1 (Serine/threonine-protein kinase Chk1) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variant...Open in Atlas onco.cc
CHEK2: CHEK2 (Serine/threonine-protein kinase Chk2) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver, a biomarker and a DNA repair gene, and clinical evide...Open in Atlas onco.cc
CHMP4C: CHMP4C (Charged multivesicular body protein 4c) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
CHRDL1: CHRDL1 (Chordin-like protein 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts.Open in Atlas onco.cc
CHRNA3: CHRNA3 (Neuronal acetylcholine receptor subunit alpha-3) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
CHRNA4: CHRNA4 (Neuronal acetylcholine receptor subunit alpha-4) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer.Open in Atlas onco.cc
CHRNA5: CHRNA5 (Neuronal acetylcholine receptor subunit alpha-5) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Lung cancer.Open in Atlas onco.cc
CIC: CIC (Protein capicua homolog) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug...Open in Atlas onco.cc
CIITA: CIITA (MHC class II transactivator) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants...Open in Atlas onco.cc
CIP2A: CIP2A (cellular inhibitor of PP2A) is a gene. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pancreatic ductal adenocarcinoma.Open in Atlas onco.cc
Claudin 18.2: A tight-junction protein normally hidden in the stomach lining that becomes exposed in gastric and pancreatic cancers.Open in Atlas onco.cc
Claudin 6: A tight-junction protein normally found only in the embryo that reappears in ovarian, testicular, endometrial and lung cancers, making it a clean target for ADCs and CAR-T.Open in Atlas onco.cc
CLCN6: CLCN6 (H(+)/Cl(-) exchange transporter 6) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
CLIP1: CLIP1 (CAP-Gly domain-containing linker protein 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Lung cance...Open in Atlas onco.cc
CLPTM1L: CLPTM1L (Lipid scramblase CLPTM1L) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
CLTC: CLTC (Clathrin heavy chain 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer,...Open in Atlas onco.cc
CLTCL1: CLTCL1 (Clathrin heavy chain 2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcinoma, Pro...Open in Atlas onco.cc
CMTR2: CMTR2 (Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase 2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied...Open in Atlas onco.cc
CNBP: CNBP (CCHC-type zinc finger nucleic acid binding protein) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
CNKSR1: CNKSR1 (Connector enhancer of kinase suppressor of ras 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
CNKSR2: CNKSR2 (Connector enhancer of kinase suppressor of ras 2) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
CNOT3: CNOT3 (CCR4-NOT transcription complex subunit 3) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer, Le...Open in Atlas onco.cc
CNOT9: CNOT9 (CCR4-NOT transcription complex subunit 9) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Melanoma.Open in Atlas onco.cc
CNTRL: CNTRL (Centriolin) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to L...Open in Atlas onco.cc
COL1A1: COL1A1 (Collagen alpha-1(I) chain) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient co...Open in Atlas onco.cc
COL2A1: COL2A1 (Collagen alpha-1(II) chain) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Thyroid cancer and Papill...Open in Atlas onco.cc
COL6A3: COL6A3 (Collagen alpha-3(VI) chain) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target and a tumour suppressor, and an approved or late-stage drug is recorded against it. Tied to Melanoma.Open in Atlas onco.cc
COL6A6: COL6A6 (Collagen alpha-6(VI) chain) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Pancreatic ductal adenoca...Open in Atlas onco.cc
COX-2 (PTGS2): COX-2 makes the inflammatory prostaglandins that help tumours grow; aspirin and celecoxib block it, which is why they reduce colorectal polyps and are studied for cancer prevention.Open in Atlas onco.cc
CPEB3: CPEB3 (Cytoplasmic polyadenylation element-binding protein 3) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Basal...Open in Atlas onco.cc
CPSF6: CPSF6 (Cleavage and polyadenylation specificity factor subunit 6) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Leukaemia.Open in Atlas onco.cc
CPVL: CPVL (Probable serine carboxypeptidase CPVL) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Skin cancer and Basal cell carcinoma.Open in Atlas onco.cc
CRAF (RAF1): CRAF is BRAF's sibling in the growth-signal relay; sorafenib and regorafenib were designed against it, and it is the route by which RAS-mutant tumours escape BRAF-only drugs.Open in Atlas onco.cc
CREB1: CREB1 (Cyclic AMP-responsive element-binding protein 1) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Breast cancer, Sarcomas,...Open in Atlas onco.cc
CREB3L1: CREB3L1 (Cyclic AMP-responsive element-binding protein 3-like protein 1) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Sarcomas, Lung cancer and Breast cancer.Open in Atlas onco.cc
CREB3L2: CREB3L2 (Cyclic AMP-responsive element-binding protein 3-like protein 2) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Sarcomas...Open in Atlas onco.cc
CREBBP: CREBBP (CREB-binding protein) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis,...Open in Atlas onco.cc
CRKL: CRKL (Crk-like protein) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer and Non-small-cell lung...Open in Atlas onco.cc
CRLF2: CRLF2 (Cytokine receptor-like factor 2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug...Open in Atlas onco.cc
CRTC1: CRTC1 (CREB-regulated transcription coactivator 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied...Open in Atlas onco.cc
CRTC3: CRTC3 (CREB-regulated transcription coactivator 3) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Oral cavity cancer.Open in Atlas onco.cc
CSF1: CSF1 (Macrophage colony-stimulating factor 1) is a gene. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Tenosynovial giant cell tumour.Open in Atlas onco.cc
CSF1R: The receptor that macrophages depend on; blocking it shrinks tenosynovial giant cell tumour (a CSF1-driven tumour) and depletes tumour-supporting macrophages, though the latter has not yet helped patients with common cancers.Open in Atlas onco.cc
CSF2RB: CSF2RB (Cytokine receptor common subunit beta) is a gene. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Sarcomas, Leukaemia, Myeloproliferative neoplasms and 1 more.Open in Atlas onco.cc
CSK: CSK (Tyrosine-protein kinase CSK) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
CSMD3: CSMD3 (CUB and sushi domain-containing protein 3) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Ti...Open in Atlas onco.cc
CSNK1A1: CSNK1A1 (Casein kinase I isoform alpha) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
CSNK1E: CSNK1E (Casein kinase I isoform epsilon) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Non-Hodgki...Open in Atlas onco.cc
CSPG4: CSPG4 (Chondroitin sulfate proteoglycan 4) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer.Open in Atlas onco.cc
CTAG1B: CTAG1B (Cancer/testis antigen 1) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Multiple myeloma.Open in Atlas onco.cc
CTAG2: CTAG2 (Cancer/testis antigen 2) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Multiple myeloma.Open in Atlas onco.cc
CTCF: CTCF (Transcriptional repressor CTCF) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to...Open in Atlas onco.cc
CTLA-4: The first immune brake ever targeted for cancer; releasing it won a Nobel Prize and cures a fraction of melanomas.Open in Atlas onco.cc
CTNNA1: CTNNA1 (Catenin alpha-1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Gastric & gas...Open in Atlas onco.cc
CTNNA2: CTNNA2 (Catenin alpha-2) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer, He...Open in Atlas onco.cc
CTNNB1: CTNNB1 (Catenin beta-1) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and an approved or late-stage drug is recorded against it....Open in Atlas onco.cc
CTNND2: CTNND2 (Catenin delta-2) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Oesophageal cancer, Ov...Open in Atlas onco.cc
CTR9: CTR9 (RNA polymerase-associated protein CTR9 homolog) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Wilms tumour.Open in Atlas onco.cc
CTSH: CTSH (Pro-cathepsin H) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
CTSS: CTSS (Cathepsin S) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Skin cancer and Basal cell carcinoma.Open in Atlas onco.cc
CUL1: CUL1 (Cullin-1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
CUL3: CUL3 (Cullin-3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug resp...Open in Atlas onco.cc
CUL4A: CUL4A (Cullin-4A) is a gene. The public catalogues list it as a drug target and a DNA repair gene, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma, Myelodysplastic syndromes / neoplasms and 2 more.Open in Atlas onco.cc
CUL7: CUL7 (Cullin-7) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Glioma & glioblastoma.Open in Atlas onco.cc
CUX1: CUX1 (Homeobox protein cut-like 1) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Skin cancer,...Open in Atlas onco.cc
CX3CL1: CX3CL1 (Fractalkine) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-small-cell lung cancer.Open in Atlas onco.cc
CXCL10: CXCL10 (C-X-C motif chemokine 10) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Osteosarcoma.Open in Atlas onco.cc
CXCR3: CXCR3 is the receptor a killer T cell uses to find its way into a tumour. If the tumour is not making the signals it listens for, the T cells never arrive, which is one way a tumour stays cold.Open in Atlas onco.cc
CXCR4: A chemokine receptor that anchors blood cells in the marrow and helps cancer cells home to it; mutated in a third of Waldenström patients and targeted by plerixafor for stem-cell mobilisation.Open in Atlas onco.cc
CXCR5: CXCR5 is what draws immune cells into the follicles where B cells are trained. The same signal builds the lymph-node-like structures that sometimes form inside tumours and are linked to better outcomes.Open in Atlas onco.cc
CYLD: CYLD (Ubiquitin carboxyl-terminal hydrolase CYLD) is an enzyme. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial cancer, Breas...Open in Atlas onco.cc
CYP11A1 (cholesterol side-chain cleavage enzyme): CYP11A1 is the first enzyme in making every steroid hormone from cholesterol; the historic breast cancer drug aminoglutethimide blocked it, cutting oestrogen and adrenal steroids, before aromatase inhibitors made that approach precise.Open in Atlas onco.cc
CYP11B1: CYP11B1 (Cytochrome P450 11B1, mitochondrial) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Renal cell carcinoma.Open in Atlas onco.cc
CYP17A1 (17-alpha-hydroxylase/17,20-lyase): The enzyme that makes androgens in the testes, the adrenal glands and prostate tumours themselves. Abiraterone blocks it, cutting androgen production below what castration alone achieves.Open in Atlas onco.cc
CYP1B1: CYP1B1 (Cytochrome P450 1B1) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Skin cancer, Melanoma and Basal cell carcinoma.Open in Atlas onco.cc
CYP2C8: CYP2C8 (Cytochrome P450 2C8) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Mesothelioma, Melanoma and Pleural meso...Open in Atlas onco.cc
CYP2D6: CYP2D6 (Cytochrome P450 2D6) is an enzyme. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer.Open in Atlas onco.cc
CYSLTR2: CYSLTR2 (Cysteinyl leukotriene receptor 2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis...Open in Atlas onco.cc

D

DAXX: DAXX (Death domain-associated protein 6) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Neuroendocrine tumou...Open in Atlas onco.cc
DAZAP1: DAZAP1 (DAZ-associated protein 1) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Mantle cell lymphoma.Open in Atlas onco.cc
DCAF12L2: DCAF12L2 (DDB1- and CUL4-associated factor 12-like protein 2) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient...Open in Atlas onco.cc
DCC: DCC (Netrin receptor DCC) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response....Open in Atlas onco.cc
DCLK1: DCLK1 is a kinase gene from neuronal development that also marks a rare stem-like cell population in the gut, studied as a colorectal and pancreatic cancer stem-cell marker.Open in Atlas onco.cc
DCLRE1B: DCLRE1B (5' exonuclease Apollo) is an enzyme. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role.Open in Atlas onco.cc
DCTN1: DCTN1 (Dynactin subunit 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
DDB1: DDB1 (DNA damage-binding protein 1) is a gene. The public catalogues list it as a drug target and a DNA repair gene, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma, Myelodysplastic syndromes / neopl...Open in Atlas onco.cc
DDB2: DDB2 (DNA damage-binding protein 2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a DNA repair gene, and it is called a cancer driver by mutation analysis of patient...Open in Atlas onco.cc
DDIT3: DDIT3 (DDIT3 upstream open reading frame protein) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Sarcomas and Liposarcoma.Open in Atlas onco.cc
DDR2 receptor kinase: DDR2 is a receptor that senses collagen; mutations in it occur in a small share of squamous lung cancers, and dasatinib inhibits it.Open in Atlas onco.cc
DDX10: DDX10 (Probable ATP-dependent RNA helicase DDX10) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Breast cancer and Skin cancer.Open in Atlas onco.cc
DDX3X: DDX3X (ATP-dependent RNA helicase DDX3X) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug res...Open in Atlas onco.cc
DDX41: DDX41 (Probable ATP-dependent RNA helicase DDX41) is an enzyme. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Myeloproliferative neoplasms, Myelodysplastic...Open in Atlas onco.cc
DDX43: DDX43 (Probable ATP-dependent RNA helicase DDX43) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Uveal melanoma.Open in Atlas onco.cc
DDX5: DDX5 (Probable ATP-dependent RNA helicase DDX5) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Colorectal cancer and Skin cancer.Open in Atlas onco.cc
DDX6: DDX6 (Probable ATP-dependent RNA helicase DDX6) is an enzyme. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Sarcomas, Lung can...Open in Atlas onco.cc
DEFA1: DEFA1 (Neutrophil defensin 1) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer.Open in Atlas onco.cc
DEK: DEK (DEK proto-oncogene) is a gene. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Breast cancer and Gastric & gastro-oesophageal junction cancer.Open in Atlas onco.cc
DGCR8: DGCR8 (Microprocessor complex subunit DGCR8) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to...Open in Atlas onco.cc
DHX9: DHX9 (ATP-dependent RNA helicase A) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcinoma.Open in Atlas onco.cc
DICER1: DICER1 (Endoribonuclease Dicer) is an enzyme. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer, Sarcomas, Brain an...Open in Atlas onco.cc
Dihydrofolate reductase (DHFR): The enzyme that recycles folate so cells can build DNA. Methotrexate blocks it, which is why folinic acid rescue after high-dose methotrexate matters.Open in Atlas onco.cc
DIS3: DIS3 (Exosome complex exonuclease RRP44) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Multiple myeloma.Open in Atlas onco.cc
DKK1: DKK1 (Dickkopf-related protein 1) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer.Open in Atlas onco.cc
DLC1: DLC1 (Rho GTPase-activating protein 7) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
DLL1: DLL1 (Delta-like protein 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
DLL3: A protein that appears on the surface of small-cell lung cancer cells, now hit by a drug that pulls T cells onto them.Open in Atlas onco.cc
DLL4: DLL4 (Delta-like protein 4) is a protein on the cell surface. The public catalogues list it as a drug target and an antigen, and clinical evidence ties its variants to diagnosis, prognosis or drug response.Open in Atlas onco.cc
DLST: DLST (Dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate dehydrogenase complex, mitochondrial) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Neuroendocrine tumours.Open in Atlas onco.cc
DNA methyltransferase 3A (DNMT3A): DNMT3A writes new methyl marks on DNA; it is one of the most commonly mutated genes in acute myeloid leukaemia and is trapped by the hypomethylating drugs azacitidine and decitabine.Open in Atlas onco.cc
DNA polymerase alpha (POLA1): DNA polymerase alpha starts every new DNA strand; nucleoside chemotherapies such as cytarabine, fludarabine and gemcitabine are converted inside cells into fake building blocks that jam this and the other replicative polymerases.Open in Atlas onco.cc
DNA2: DNA2 (DNA replication ATP-dependent helicase/nuclease DNA2) is an enzyme. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role.Open in Atlas onco.cc
DNAH11: DNAH11 (Dynein axonemal heavy chain 11) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
DNAJB1: DNAJB1 (DnaJ homolog subfamily B member 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
DNAJC1: DNAJC1 (DnaJ homolog subfamily C member 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
DNAJC12: DNAJC12 is a co-chaperone gene that is strongly expressed in oestrogen receptor-positive (luminal) breast cancers and is used as a luminal marker.Open in Atlas onco.cc
DNM2: DNM2 (Dynamin-2) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Leukaemia, Non-Hodgkin lymphoma, Colorectal cancer and 3 more.Open in Atlas onco.cc
DNMT1 (DNA methyltransferase 1): The enzyme that copies methylation marks onto newly made DNA, keeping genes silenced. Azacitidine and decitabine trap and destroy it, waking silenced tumour suppressor genes in blood cancers.Open in Atlas onco.cc
DNMT3B: DNMT3B (DNA (cytosine-5)-methyltransferase 3B) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
DOCK8: DOCK8 (Dedicator of cytokinesis protein 8) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
Dopamine D2 receptor: The dopamine D2 receptor is how cabergoline and bromocriptine shrink prolactin-secreting pituitary tumours without surgery, and it is the target of the antiemetics metoclopramide and prochlorperazine used during chemotherapy.Open in Atlas onco.cc
DOT1L: DOT1L (Histone-lysine N-methyltransferase, H3 lysine-79 specific) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tie...Open in Atlas onco.cc
DPYD: DPYD (Dihydropyrimidine dehydrogenase [NADP(+)]) is an enzyme. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Head and neck squamous cell carcinoma and Gastric & gastro-oeso...Open in Atlas onco.cc
DRD5: DRD5 (Dopamine receptor D5) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Glioma & glioblastoma.Open in Atlas onco.cc
DROSHA: DROSHA (Ribonuclease 3) is an enzyme. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Brain and spinal cord tu...Open in Atlas onco.cc
DSP: DSP (Desmoplakin) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Nasopharyngeal carcinoma.Open in Atlas onco.cc
DTX1: DTX1 (E3 ubiquitin-protein ligase DTX1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied...Open in Atlas onco.cc
DUSP16: DUSP16 (Dual specificity protein phosphatase 16) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal c...Open in Atlas onco.cc
DUSP2: DUSP2 (Dual specificity protein phosphatase 2) is an enzyme. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.Open in Atlas onco.cc
DUSP6: DUSP6 (Dual specificity protein phosphatase 6) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.Open in Atlas onco.cc

E

E2F7: E2F7 is an unusual member of the E2F family that represses genes rather than activating them, helping cells pause after DNA damage.Open in Atlas onco.cc
EBF1: EBF1 (Transcription factor COE1) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. T...Open in Atlas onco.cc
EBF2: EBF2 (Transcription factor COE2) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
ECSCR: ECSCR (Endothelial cell-specific chemotaxis regulator) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.Open in Atlas onco.cc
EDNRA: EDNRA (Endothelin-1 receptor) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Prostate cancer.Open in Atlas onco.cc
EED: EED (Polycomb protein EED) is a protein that switches other genes on and off. The public catalogues list it as a drug target, and the evidence so far is association rather than a proven role.Open in Atlas onco.cc
EFTUD2: EFTUD2 (116 kDa U5 small nuclear ribonucleoprotein component) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Multip...Open in Atlas onco.cc
EGF: EGF (Pro-epidermal growth factor) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Head and neck squamous cell carcinoma.Open in Atlas onco.cc
EGFR: A growth receptor that is mutated in some lung cancers and overproduced in others; the first great success of targeted pills.Open in Atlas onco.cc
EGR2: EGR2 (E3 SUMO-protein ligase EGR2) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Chronic lymphocytic leukaemia.Open in Atlas onco.cc
EHBP1: EHBP1 (EH domain-binding protein 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer.Open in Atlas onco.cc
EIF1AX: EIF1AX (Eukaryotic translation initiation factor 1A, X-chromosomal) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to di...Open in Atlas onco.cc
EIF2AK3: EIF2AK3 (Eukaryotic translation initiation factor 2-alpha kinase 3) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
EIF3E: EIF3E (Eukaryotic translation initiation factor 3 subunit E) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Cervica...Open in Atlas onco.cc
EIF4A1: EIF4A1 (Eukaryotic initiation factor 4A-I) is an enzyme. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Burkitt lymphoma.Open in Atlas onco.cc
EIF4A2: EIF4A2 (Eukaryotic initiation factor 4A-II) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer.Open in Atlas onco.cc
EIF4EBP1: EIF4EBP1 (Eukaryotic translation initiation factor 4E-binding protein 1) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer a...Open in Atlas onco.cc
ELAC2: ELAC2 (Zinc phosphodiesterase ELAC protein 2) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer.Open in Atlas onco.cc
ELF3: ELF3 (ETS-related transcription factor Elf-3) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to B...Open in Atlas onco.cc
ELF4: ELF4 (ETS-related transcription factor Elf-4) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Ti...Open in Atlas onco.cc
ELK4: ELK4 (ETS domain-containing protein Elk-4) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Head and neck squamous ce...Open in Atlas onco.cc
ELL: ELL (RNA polymerase II elongation factor ELL) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient...Open in Atlas onco.cc
ELN: ELN (Elastin) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer and Cutaneous squamous cell carci...Open in Atlas onco.cc
Elongation factor 2 (EEF2): EEF2 is the ribosome's motor for moving along messenger RNA; the CML drug omacetaxine stalls protein production by acting at this step.Open in Atlas onco.cc
ELP1: ELP1 (Elongator complex protein 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Medulloblastoma.Open in Atlas onco.cc
ELP4: ELP4 (Elongator complex protein 4) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Renal cell carcinoma.Open in Atlas onco.cc
EML4: EML4 (Echinoderm microtubule-associated protein-like 4) is a gene. The public catalogues list it as a drug target and a fusion partner, and an approved or late-stage drug is recorded against it. Tied to Lung cancer, Thyroid cancer and Non-small-cell lung ca...Open in Atlas onco.cc
EMSY: EMSY (BRCA2-interacting transcriptional repressor EMSY) is a protein that switches other genes on and off. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or...Open in Atlas onco.cc
EOMES: EOMES (Eomesodermin homolog) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Non-Hodgkin lymphoma.Open in Atlas onco.cc
EP300: EP300 (Histone acetyltransferase p300) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, progn...Open in Atlas onco.cc
EpCAM: An adhesion protein on almost all carcinoma cells and the capture molecule for circulating tumour cell tests; the target of the first bispecific antibody ever approved (catumaxomab, 2009).Open in Atlas onco.cc
EPHA1: EPHA1 (Ephrin type-A receptor 1) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Thyroid cancer and...Open in Atlas onco.cc
EPHA10: EPHA10 (Ephrin type-A receptor 10) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Thyroid cancer and Neuroendocrine tumours.Open in Atlas onco.cc
EphA2 receptor: EphA2 is a cell-guidance receptor that many solid tumours overexpress; dasatinib and regorafenib block it among their many kinase targets, and it is being tested as an antibody-drug conjugate and CAR-T target.Open in Atlas onco.cc
EPHA3: EPHA3 (Ephrin type-A receptor 3) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver and a tumour suppressor, and an approved or late-stage drug is rec...Open in Atlas onco.cc
EPHA4: EPHA4 (Ephrin type-A receptor 4) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Thyroid cancer and...Open in Atlas onco.cc
EPHA5: EPHA5 (Ephrin type-A receptor 5) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Thyroid cancer and...Open in Atlas onco.cc
EPHA6: EPHA6 (Ephrin type-A receptor 6) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Thyroid cancer and...Open in Atlas onco.cc
EPHA7: EPHA7 (Ephrin type-A receptor 7) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver and a tumour suppressor, and an approved or late-stage drug is rec...Open in Atlas onco.cc
EPHA8: EPHA8 (Ephrin type-A receptor 8) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Neuroendocrine tum...Open in Atlas onco.cc
EPHB1: EPHB1 (Ephrin type-B receptor 1) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Thyroid cancer and...Open in Atlas onco.cc
EPHB2: EPHB2 (Ephrin type-B receptor 2) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Pr...Open in Atlas onco.cc
EPHB3: EPHB3 (Ephrin type-B receptor 3) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Thyroid cancer and...Open in Atlas onco.cc
EPHB4: EPHB4 (Ephrin type-B receptor 4) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Co...Open in Atlas onco.cc
EPS15: EPS15 (Epidermal growth factor receptor substrate 15) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. T...Open in Atlas onco.cc
ERBIN: ERBIN (Erbin) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
ERC1: ERC1 (ELKS/Rab6-interacting/CAST family member 1) is a gene. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role.Open in Atlas onco.cc
ERCC1: ERCC1 (DNA excision repair protein ERCC-1) is a gene. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Bladder & urothelial cancer, M...Open in Atlas onco.cc
ERCC2: ERCC2 (General transcription and DNA repair factor IIH helicase subunit XPD) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a biomarker and a DNA repair gene, and clinical evidence t...Open in Atlas onco.cc
ERCC3: ERCC3 (General transcription and DNA repair factor IIH helicase/translocase subunit XPB) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, a tumour suppressor, a biomarker and a DNA repair gene, and...Open in Atlas onco.cc
ERCC4: ERCC4 (DNA repair endonuclease XPF) is an enzyme. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Skin cancer, Myeloproli...Open in Atlas onco.cc
ERCC5: ERCC5 (DNA excision repair protein ERCC-5) is an enzyme. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer, Skin cancer...Open in Atlas onco.cc
ERCC6: ERCC6 (Chimeric ERCC6-PGBD3 protein) is a gene. The public catalogues list it as a drug target, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer and Lung cancer.Open in Atlas onco.cc
EREG: EREG (Proepiregulin) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer and Non-small-cell lung cancer.Open in Atlas onco.cc
ERG: ERG (Transcriptional regulator ERG) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response...Open in Atlas onco.cc
ERLIN2: ERLIN2 (Erlin-2) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
ERRFI1: ERRFI1 (ERBB receptor feedback inhibitor 1) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Biliary tract cancer and Non-small-cell lung can...Open in Atlas onco.cc
Erythropoietin receptor (EPOR): The receptor that tells the marrow to make red blood cells. Epoetin stimulates it to treat chemotherapy-induced anaemia, used with care because it can raise the risk of blood clots and, in some cancers, tumour growth.Open in Atlas onco.cc
ESR2: ESR2 (Oestrogen receptor beta) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Breast cancer and Prostate cancer.Open in Atlas onco.cc
ESRP1: ESRP1 (Epithelial splicing regulatory protein 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
ESRRA: ESRRA (Steroid hormone receptor ERR1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Salivary gland cancers and Ade...Open in Atlas onco.cc
Estrogen receptor (ERα): The hormone switch that drives most breast cancers. Blocking or destroying it is the oldest and most effective targeted therapy.Open in Atlas onco.cc
ETNK1: ETNK1 (Ethanolamine kinase 1) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. In the public catalogues the evidence so far is association rather than a proven role. Tied to Leukaemia, Breast cancer and Myeloprolife...Open in Atlas onco.cc
ETS1: ETS1 (ETS proto-oncogene 1, transcription factor) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell...Open in Atlas onco.cc
ETS2: ETS2 (ETS proto-oncogene 2, transcription factor) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to No...Open in Atlas onco.cc
ETV1: ETV1 (ETS translocation variant 1) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagn...Open in Atlas onco.cc
ETV4: ETV4 (ETS translocation variant 4) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Ti...Open in Atlas onco.cc
ETV5: ETV5 (ETS translocation variant 5) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Ti...Open in Atlas onco.cc
ETV6: ETV6 (Transcription factor ETV6) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis o...Open in Atlas onco.cc
EWSR1-FLI1 fusion: The fused gene that defines Ewing sarcoma: an aberrant transcription factor that has resisted 30 years of drug design.Open in Atlas onco.cc
EXO1: EXO1 (Exonuclease 1) is an enzyme. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role. Tied to Breast cancer.Open in Atlas onco.cc
Exportin-1 (XPO1): The export pump that carries tumour suppressor proteins such as p53 out of the nucleus, where they cannot act. Selinexor blocks it so those brakes stay in the nucleus and cancer cells die.Open in Atlas onco.cc
EXT1: EXT1 (Exostosin-1) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Sarcomas, Breast cancer, Ovarian cancer and 2 more.Open in Atlas onco.cc
EXT2: EXT2 (Exostosin-2) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Ovarian cancer, Skin cancer and Breast cancer.Open in Atlas onco.cc
EZH2: EZH2 is an enzyme that silences genes. The first drug against it treated a rare sarcoma and some lymphomas until it was withdrawn in 2026 for causing second blood cancers.Open in Atlas onco.cc
EZR: EZR (Ezrin) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Lung cancer.Open in Atlas onco.cc

F

FAAP20: FAAP20 (Fanconi anaemia core complex-associated protein 20) is a gene. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response.Open in Atlas onco.cc
FAK (PTK2): FAK is the kinase that tells a cell it is anchored to its surroundings, letting it survive, move and resist drugs. Defactinib, given with the RAF/MEK inhibitor avutometinib, removes that escape route in low-grade serous ovarian cancer; other FAK inhibitors...Open in Atlas onco.cc
FAM114A2: FAM114A2 (family with sequence similarity 114 member A2) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
FAM131B: FAM131B (family with sequence similarity 131 member B) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
FAM135B: FAM135B (family with sequence similarity 135 member B) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient...Open in Atlas onco.cc
FAM174B: FAM174B (Membrane protein FAM174B) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer, Medulloblastoma...Open in Atlas onco.cc
FANCA: FANCA (Fanconi anaemia group A protein) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, progno...Open in Atlas onco.cc
FANCB: FANCB (Fanconi anaemia group B protein) is a gene. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role.Open in Atlas onco.cc
FANCC: FANCC (Fanconi anaemia group C protein) is a gene. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Leukaemia, Pancrea...Open in Atlas onco.cc
FANCD2: FANCD2 (Fanconi anaemia group D2 protein) is a gene. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role. Tied to Leukaemia, Myeloproliferative neoplasms, Breast cancer and 5 more.Open in Atlas onco.cc
FANCE: FANCE (Fanconi anaemia group E protein) is a gene. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role. Tied to Leukaemia, Colorectal cancer, Myeloproliferative neoplasms and 2 more.Open in Atlas onco.cc
FANCF: FANCF (Fanconi anaemia group F protein) is a gene. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role. Tied to Leukaemia, Skin cancer and Melanoma.Open in Atlas onco.cc
FANCG: FANCG (Fanconi anaemia group G protein) is a gene. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role. Tied to Leukaemia, Myeloproliferative neoplasms, Colorectal cancer and 2 more.Open in Atlas onco.cc
FANCI: FANCI (Fanconi anaemia group I protein) is a gene. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role.Open in Atlas onco.cc
FANCL: FANCL (E3 ubiquitin-protein ligase FANCL) is an enzyme. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer.Open in Atlas onco.cc
FANCM: FANCM (Fanconi anaemia group M protein) is an enzyme. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role. Tied to Breast cancer and Ovarian cancer.Open in Atlas onco.cc
FAP: FAP (fibroblast activation protein) sits on the cancer-associated fibroblasts that scaffold more than 90% of epithelial cancers and is almost absent from normal adult tissue. FAPI PET tracers therefore light up tumours with high contrast, including pancreat...Open in Atlas onco.cc
FAS: FAS (Tumour necrosis factor receptor superfamily member 6) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagn...Open in Atlas onco.cc
FAT1: FAT1 (Protocadherin Fat 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis o...Open in Atlas onco.cc
FAT2: FAT2 (Protocadherin Fat 2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Vulvar cancer.Open in Atlas onco.cc
FAT3: FAT3 (Protocadherin Fat 3) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Pa...Open in Atlas onco.cc
FAT4: FAT4 (Protocadherin Fat 4) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer,...Open in Atlas onco.cc
FBLN2: FBLN2 (Fibulin-2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Pancreatic ductal ad...Open in Atlas onco.cc
FBN2: FBN2 (Fibrillin-2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Neuroblastoma.Open in Atlas onco.cc
FBXO11: FBXO11 (F-box only protein 11) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug resp...Open in Atlas onco.cc
FBXW11: FBXW11 (F-box/WD repeat-containing protein 11) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.Open in Atlas onco.cc
FBXW7: FBXW7 (F-box/WD repeat-containing protein 7) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker and a DNA repair gene, and clinical evidence ties i...Open in Atlas onco.cc
FCGR2A: FCGR2A (Low affinity immunoglobulin gamma Fc region receptor II-a) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer and HER2-po...Open in Atlas onco.cc
FCGR2B: FCGR2B (Low affinity immunoglobulin gamma Fc region receptor II-b) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, progno...Open in Atlas onco.cc
FCGR3A: FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer and HER2-p...Open in Atlas onco.cc
FcRH5 (FCRL5): FcRH5 is a surface protein found almost only on B cells and myeloma plasma cells, which makes it a target for T-cell engaging antibodies in multiple myeloma.Open in Atlas onco.cc
FCRL4: FCRL4 (Fc receptor-like protein 4) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Pancr...Open in Atlas onco.cc
FDPS: FDPS (Farnesyl pyrophosphate synthase) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Prostate cancer, Multiple myeloma and Breast cancer.Open in Atlas onco.cc
FERMT2: FERMT2 (Fermitin family homolog 2) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
FES: FES (Tyrosine-protein kinase Fes/Fps) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. In the public catalogues the evidence so far is association rather than a proven role. Tied to Skin cancer, Leukaemia and Colore...Open in Atlas onco.cc
FEV: FEV (FEV transcription factor, ETS family member) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role.Open in Atlas onco.cc
FGA: FGA (Fibrinogen alpha chain) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.Open in Atlas onco.cc
FGB: FGB (Fibrinogen beta chain) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.Open in Atlas onco.cc
FGD1: FGD1 (FYVE, RhoGEF and PH domain-containing protein 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer.Open in Atlas onco.cc
FGD5: FGD5 (FYVE, RhoGEF and PH domain-containing protein 5) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Acute myeloid...Open in Atlas onco.cc
FGF1: FGF1 (Fibroblast growth factor 1) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.Open in Atlas onco.cc
FGF10: FGF10 (Fibroblast growth factor 10) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
FGF13: FGF13 (Fibroblast growth factor 13) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer.Open in Atlas onco.cc
FGF16: FGF16 (Fibroblast growth factor 16) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
FGF17: FGF17 (Fibroblast growth factor 17) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
FGF18: FGF18 (Fibroblast growth factor 18) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
FGF19: FGF19 (Fibroblast growth factor 19) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Hepatocellular carcinoma and Ovarian cancer.Open in Atlas onco.cc
FGF2: FGF2 (Fibroblast growth factor 2) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Acute myeloid leukaemia.Open in Atlas onco.cc
FGF20: FGF20 (Fibroblast growth factor 20) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
FGF22: FGF22 (Fibroblast growth factor 22) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
FGF23: FGF23 (Fibroblast growth factor 23) is a protein on the cell surface. The public catalogues list it as a drug target and an antigen, and an approved or late-stage drug is recorded against it.Open in Atlas onco.cc
FGF3: FGF3 (Fibroblast growth factor 3) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer and Hepatocellular carcinoma.Open in Atlas onco.cc
FGF4: FGF4 (Fibroblast growth factor 4) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Hepatocellular carcinoma.Open in Atlas onco.cc
FGF5: FGF5 (Fibroblast growth factor 5) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
FGF6: FGF6 (Fibroblast growth factor 6) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
FGF7: FGF7 (Fibroblast growth factor 7) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.Open in Atlas onco.cc
FGF8: FGF8 (Fibroblast growth factor 8) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
FGF9: FGF9 (Fibroblast growth factor 9) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
FGFR1: A growth receptor amplified in squamous lung cancer and fused in a rare blood cancer. Pemigatinib is approved for the FGFR1-rearranged myeloid and lymphoid neoplasm, and pan-FGFR drugs block FGFR1 too, which is why they raise blood phosphate.Open in Atlas onco.cc
FGFR1OP2: FGFR1OP2 (FGFR1 oncogene partner 2) is a gene. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Leukaemia.Open in Atlas onco.cc
FGFR2: FGFR2 is a growth receptor fused in bile-duct cancer and overproduced in gastric cancer.Open in Atlas onco.cc
FGFR3: A growth-factor receptor that is mutated or fused in a sizeable minority of bladder cancers. Erdafitinib blocks it and is the first targeted drug approved for urothelial cancer selected by a genomic test.Open in Atlas onco.cc
FGFR4: FGFR4 (Fibroblast growth factor receptor 4) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, a tumour suppressor and a biomarker, and an approved or late-stage drug is...Open in Atlas onco.cc
FGG: FGG (Fibrinogen gamma chain) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.Open in Atlas onco.cc
FGL1: FGL1 is a liver protein that some tumours secrete; it binds LAG-3 on T cells and switches them off, separately from the MHC class II route. It explains part of how LAG-3 blockade works.Open in Atlas onco.cc
FGR: FGR (Tyrosine-protein kinase Fgr) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myelop...Open in Atlas onco.cc
FH: FH (Fumarate hydratase, mitochondrial) is an enzyme. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Neuroendocrine tumours, Skin ca...Open in Atlas onco.cc
FHIT: FHIT (Bis(5'-adenosyl)-triphosphatase) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug respo...Open in Atlas onco.cc
FIP1L1: FIP1L1 (Pre-mRNA 3'-end-processing factor FIP1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
FKBP12 (FKBP1A): FKBP12 is the small protein that rapamycin-type drugs grab first; the drug-FKBP12 pair then clamps onto mTOR and switches off its growth signalling.Open in Atlas onco.cc
FLCN: FLCN (Folliculin) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Rena...Open in Atlas onco.cc
FLG: FLG (Filaggrin) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Skin cancer, Mesothelioma, Acute myeloid leukaemia a...Open in Atlas onco.cc
FLT3: FLT3 is a kinase mutated in about a third of acute myeloid leukaemias, where adding an inhibitor to chemotherapy improves survival.Open in Atlas onco.cc
FLT3LG: FLT3LG (Fms-related tyrosine kinase 3 ligand) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Acute myeloid leukaemia.Open in Atlas onco.cc
FMN1: FMN1 (Formin-1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
FMN2: FMN2 (Formin-2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a DNA repair gene, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Pancreatic ductal adeno...Open in Atlas onco.cc
FN1: FN1 (Fibronectin) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Melanoma.Open in Atlas onco.cc
FNDC3B: FNDC3B (Fibronectin type III domain-containing protein 3B) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to No...Open in Atlas onco.cc
FNTB: FNTB (Protein farnesyltransferase subunit beta) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer.Open in Atlas onco.cc
Folate receptor alpha: Folate receptor alpha is a vitamin receptor that ovarian cancer cells carry in large numbers, used as the docking site for the ADC mirvetuximab.Open in Atlas onco.cc
FOS: FOS (Fos proto-oncogene, AP-1 transcription factor subunit) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer.Open in Atlas onco.cc
FOSB: FOSB (FosB proto-oncogene, AP-1 transcription factor subunit) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.Open in Atlas onco.cc
FOXA1: FOXA1 (Hepatocyte nuclear factor 3-alpha) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, progn...Open in Atlas onco.cc
FOXA2: FOXA2 (Hepatocyte nuclear factor 3-beta) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Endometrial cancer.Open in Atlas onco.cc
FOXC2: FOXC2 (Forkhead box protein C2) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer.Open in Atlas onco.cc
FOXE1: FOXE1 (Forkhead box protein E1) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Thyroid cancer.Open in Atlas onco.cc
FOXF1: FOXF1 (Forkhead box protein F1) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer.Open in Atlas onco.cc
FOXL2: FOXL2 (Forkhead box protein L2) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer.Open in Atlas onco.cc
FOXO1: FOXO1 (Forkhead box protein O1) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or...Open in Atlas onco.cc
FOXO3: FOXO3 (Forkhead box protein O3) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer,...Open in Atlas onco.cc
FOXO4: FOXO4 (Forkhead box protein O4) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role.Open in Atlas onco.cc
FOXP1: FOXP1 (Forkhead box protein P1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug respo...Open in Atlas onco.cc
FOXP3: FOXP3 (Forkhead box protein P3) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer.Open in Atlas onco.cc
FOXP4: FOXP4 (Forkhead box protein P4) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
FOXR2: FOXR2 (Forkhead box protein R2) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.Open in Atlas onco.cc
FRK kinase: FRK is a SRC-related kinase that mostly acts as a brake on growth; it is a minor off-target of approved kinase inhibitors and is lost or mutated in some liver and brain cancers.Open in Atlas onco.cc
FRS2: FRS2 (Fibroblast growth factor receptor substrate 2) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
FRS3: FRS3 (Fibroblast growth factor receptor substrate 3) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
FTO: FTO (Alpha-ketoglutarate-dependent dioxygenase FTO) is an enzyme. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer.Open in Atlas onco.cc
FUBP1: FUBP1 (Far upstream element-binding protein 1) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or dr...Open in Atlas onco.cc
FUS: FUS (RNA-binding protein FUS) is a gene. The public catalogues list it as a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Sarcomas, Hepatocellular carcinoma and Liposarcoma.Open in Atlas onco.cc
FXR1: FXR1 (RNA-binding protein FXR1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
FYN: FYN (Tyrosine-protein kinase Fyn) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Non-Hodgkin lymph...Open in Atlas onco.cc

G

G-CSF receptor (CSF3R): The receptor that tells the bone marrow to make neutrophils. Filgrastim and pegfilgrastim stimulate it to shorten the dangerous low-neutrophil period after chemotherapy, cutting the risk of febrile neutropenia.Open in Atlas onco.cc
GAB1: GAB1 (GRB2-associated-binding protein 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
GAB2: GAB2 (GRB2-associated-binding protein 2) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Leukaemia, Myeloproliferative neoplasms and Chronic myeloid leukaemia.Open in Atlas onco.cc
GABRG3: GABRG3 (Gamma-aminobutyric acid receptor subunit gamma-3) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.Open in Atlas onco.cc
GADD45A: GADD45A (Growth arrest and DNA damage-inducible protein GADD45 alpha) is a gene. The public catalogues list it as a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer.Open in Atlas onco.cc
Galectin-9 (LGALS9): Galectin-9 is a sugar-binding protein that presses TIM-3 on T cells and can kill the helper T cells that carry it. Tumour blood vessels make more of it than normal ones.Open in Atlas onco.cc
GALNT14: GALNT14 (Polypeptide N-acetylgalactosaminyltransferase 14) is an enzyme. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Hepatocellular carcinoma.Open in Atlas onco.cc
Gamma-secretase (PSEN1): The membrane enzyme that releases the active part of Notch. Nirogacestat blocks it and became the first drug approved for desmoid tumours, the aggressive but non-metastasising growths driven by Wnt signalling.Open in Atlas onco.cc
GART (trifunctional purine synthesis enzyme): GART is one of the enzymes that builds purines from scratch; pemetrexed blocks it alongside thymidylate synthase, which is why the drug starves fast-growing lung and mesothelioma cells.Open in Atlas onco.cc
GAS6: GAS6 (Growth arrest-specific protein 6) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer.Open in Atlas onco.cc
GATA1: GATA1 (Erythroid transcription factor) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Myeloproliferative neoplasms, L...Open in Atlas onco.cc
GATA2: GATA2 (Endothelial transcription factor GATA-2) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis,...Open in Atlas onco.cc
GATA3: GATA3 (Trans-acting T-cell-specific transcription factor GATA-3) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its varia...Open in Atlas onco.cc
GD2 (disialoganglioside): GD2 is a sugar-fat molecule on the surface of neuroblastoma cells (and some other childhood and adult tumours) with almost none on normal tissue except nerves, which is why anti-GD2 drugs cause pain.Open in Atlas onco.cc
GDF7: GDF7 (Growth/differentiation factor 7) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
GHSR: GHSR (Growth hormone secretagogue receptor type 1) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.Open in Atlas onco.cc
GITR (TNFRSF18): GITR is an accelerator on T cells that agonist antibodies tried to press to boost immunotherapy. Several reached early trials; one programme was dropped for reasons unrelated to safety.Open in Atlas onco.cc
GLI1: GLI1 (Transcription activator GLI1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Sarcomas and Leiomyosarcoma.Open in Atlas onco.cc
Glucocorticoid receptor (NR3C1): The receptor that steroid hormones switch on inside cells. In lymphoid cancers, dexamethasone and prednisone acting through it kill malignant lymphocytes directly, which is why steroids sit inside leukaemia, lymphoma and myeloma regimens as well as easing n...Open in Atlas onco.cc
Glutathione reductase: Glutathione reductase regenerates the cell's main antioxidant; the nitrosourea carmustine inhibits it as a side action to its DNA cross-linking, which adds to the drug's toxicity as well as its effect.Open in Atlas onco.cc
Glypican-3: Glypican-3 is a fetal liver protein that reappears in liver cancer, giving CAR-T and bispecifics a clean target.Open in Atlas onco.cc
GM-CSF receptor (CSF2RA): The GM-CSF receptor is what sargramostim switches on to speed the recovery of white cells after leukaemia chemotherapy and stem cell transplantation, and it is the signal that tumour vaccines such as talimogene use to recruit immune cells.Open in Atlas onco.cc
GMPS: GMPS (GMP synthase [glutamine-hydrolysing]) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hep...Open in Atlas onco.cc
GNA11: GNA11 (Guanine nucleotide-binding protein subunit alpha-11) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, progn...Open in Atlas onco.cc
GNA13: GNA13 (Guanine nucleotide-binding protein subunit alpha-13) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diag...Open in Atlas onco.cc
GNAI2: GNAI2 (Guanine nucleotide-binding protein G(i) subunit alpha-2) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or dru...Open in Atlas onco.cc
GNAQ: GNAQ (Guanine nucleotide-binding protein G(q) subunit alpha) is an enzyme. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug respo...Open in Atlas onco.cc
GNAS: GNAS (Neuroendocrine secretory protein 55) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, p...Open in Atlas onco.cc
GNB1: GNB1 (Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Leukaemia, Non-Hodgkin lymphoma and Acute lymphoblastic leukaemia.Open in Atlas onco.cc
GnRH receptor (GNRHR): The pituitary receptor that starts the hormone chain leading to testosterone and oestrogen. Agonists overstimulate it into silence and antagonists block it outright, the basis of medical castration in prostate cancer and ovarian suppression in breast cancer.Open in Atlas onco.cc
GOLGA4: GOLGA4 (Golgin subfamily A member 4) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
GOLGA5: GOLGA5 (Golgin subfamily A member 5) is a gene. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role.Open in Atlas onco.cc
GOLGB1: GOLGB1 (Golgin subfamily B member 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
GOPC: GOPC (Golgi-associated PDZ and coiled-coil motif-containing protein) is a gene. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role.Open in Atlas onco.cc
gp100 (PMEL): gp100 is a pigment-cell protein, and the target of the first bispecific drug to improve survival in a solid tumour, uveal melanoma.Open in Atlas onco.cc
GPAA1: GPAA1 (GPI-anchor transamidase component GPAA1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial...Open in Atlas onco.cc
GPC5: GPC5 (Glypican-5) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Ovarian cancer and B...Open in Atlas onco.cc
GPR161: GPR161 (G protein-coupled receptor 161) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Medulloblastoma.Open in Atlas onco.cc
GPRC5D: GPRC5D is a second myeloma target used when BCMA-directed drugs stop working.Open in Atlas onco.cc
GRB2: GRB2 (Growth factor receptor-bound protein 2) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Myeloproliferative neoplasms and Chronic myeloid le...Open in Atlas onco.cc
GRB7: GRB7 is an adaptor protein gene that sits next to HER2 on chromosome 17 and is copied along with it in HER2-positive cancers.Open in Atlas onco.cc
GREM1: GREM1 (Gremlin-1) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Colorectal cancer.Open in Atlas onco.cc
GRHL2: GRHL2 (Grainyhead-like protein 2 homolog) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Breast cancer.Open in Atlas onco.cc
GRHPR: GRHPR (Glyoxylate reductase/hydroxypyruvate reductase) is an enzyme. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.Open in Atlas onco.cc
GRIN2A: GRIN2A (Glutamate receptor ionotropic, NMDA 2A) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or...Open in Atlas onco.cc
GRM3: GRM3 (Metabotropic glutamate receptor 3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied...Open in Atlas onco.cc
GRPR (gastrin-releasing peptide receptor): GRPR is a hormone receptor abundant in early and hormone-sensitive prostate cancer, imaged and treated with bombesin-like radioligands.Open in Atlas onco.cc
GSK3B: GSK3B (Glycogen synthase kinase-3 beta) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a tumour suppressor, and clinical evidence ties its variants to diagnosis,...Open in Atlas onco.cc
GSTP1: GSTP1 (Glutathione S-transferase P) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer and Ovarian cancer.Open in Atlas onco.cc
GTF2I: GTF2I (General transcription factor II-I) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Thymoma.Open in Atlas onco.cc

H

H1-2: H1-2 (Histone H1.2) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.Open in Atlas onco.cc
H1-3: H1-3 (Histone H1.3) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.Open in Atlas onco.cc
H1-5: H1-5 (Histone H1.5) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.Open in Atlas onco.cc
H2AC17: H2AC17 (Histone H2A type 1) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.Open in Atlas onco.cc
H2AC6: H2AC6 (Histone H2A type 1-C) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.Open in Atlas onco.cc
H2BC12: H2BC12 (Histone H2B type 1-K) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.Open in Atlas onco.cc
H2BC5: H2BC5 (Histone H2B type 1-D) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.Open in Atlas onco.cc
H3-3B: H3-3B (Histone H3.3) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Melanoma and Diffuse midline glioma, H3 K27-altered.Open in Atlas onco.cc
H3C14: H3C14 (Histone H3.2) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse midline glioma, H3 K27-altered.Open in Atlas onco.cc
H3C2: H3C2 (Histone H3.1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Bre...Open in Atlas onco.cc
H3C4: H3C4 (Histone H3.1) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.Open in Atlas onco.cc
H4C9: H4C9 (Histone H4) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Chronic lymphocytic leukaemia.Open in Atlas onco.cc
HABP2: HABP2 (Factor VII-activating protease) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Thyroid cancer.Open in Atlas onco.cc
HBB: HBB (Haemoglobin subunit beta) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.Open in Atlas onco.cc
HBEGF: HBEGF (Proheparin-binding EGF-like growth factor) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.Open in Atlas onco.cc
HCAR3: HCAR3 (Hydroxycarboxylic acid receptor 3) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Acute myeloid leukaemia.Open in Atlas onco.cc
HCK kinase: HCK is a SRC-family kinase of white blood cells that dasatinib and bosutinib inhibit; it drives growth in some leukaemias and in Waldenstrom macroglobulinaemia, where ibrutinib also hits it.Open in Atlas onco.cc
HDAC10: HDAC10 (Polyamine deacetylase HDAC10) is an enzyme. The public catalogues list it as a drug target and a DNA repair gene, and an approved or late-stage drug is recorded against it. Tied to Non-Hodgkin lymphoma and Multiple myeloma.Open in Atlas onco.cc
HDAC11: HDAC11 (Histone deacetylase 11) is a protein that switches other genes on and off. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Non-Hodgkin lymphoma, Skin cancer and Multiple myeloma.Open in Atlas onco.cc
HDAC4: HDAC4 (Histone deacetylase 4) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target and an oncogene driver, and an approved or late-stage drug is recorded against it. Tied to Skin cancer, Non-Hodgkin lymphoma,...Open in Atlas onco.cc
HDAC5: HDAC5 (Histone deacetylase 5) is a protein that switches other genes on and off. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Non-Hodgkin lymphoma and Multiple myeloma.Open in Atlas onco.cc
HDAC7: HDAC7 (Histone deacetylase 7) is a protein that switches other genes on and off. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Non-Hodgkin lymphoma and Multiple myeloma.Open in Atlas onco.cc
HDAC8: HDAC8 (Histone deacetylase 8) is a protein that switches other genes on and off. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Non-Hodgkin lymphoma and Multiple myeloma.Open in Atlas onco.cc
HDAC9: HDAC9 (Histone deacetylase 9) is a protein that switches other genes on and off. The public catalogues list it as a drug target, a biomarker and a fusion partner, and an approved or late-stage drug is recorded against it. Tied to Breast cancer, Oesophageal...Open in Atlas onco.cc
HER2: A growth-signal receptor. Some cancers make far too much of it, and drugs that block it or use it as a docking site have transformed those cancers.Open in Atlas onco.cc
HER3: HER3 is a cousin of HER2 that cancers use as an escape route when HER2 or EGFR are blocked.Open in Atlas onco.cc
HER4 (ERBB4): The fourth member of the HER family, hit by the irreversible pan-HER inhibitors afatinib, dacomitinib and neratinib along with EGFR and HER2. It has no approved drug of its own, and its role in cancer is less clear than that of its siblings.Open in Atlas onco.cc
HERPUD1: HERPUD1 (Homocysteine-responsive endoplasmic reticulum-resident ubiquitin-like domain member 1 protein) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
HEY1: HEY1 (Hairy/enhancer-of-split related with YRPW motif protein 1) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Sarcomas and Chondrosarcoma.Open in Atlas onco.cc
HGF: HGF (Hepatocyte growth factor) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied t...Open in Atlas onco.cc
HHIP: HHIP (Hedgehog-interacting protein) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Colorectal cancer.Open in Atlas onco.cc
HHLA2 (B7-H7): HHLA2 is a B7 relative found on gut, kidney and lung tissue and on many tumours; it can both encourage and restrain T cells depending on the receptor. No drug against it is in the corpus yet.Open in Atlas onco.cc
HIF-1α (HIF1A): HIF-1α is the sensor that lets a tumour cope with low oxygen by switching on blood-vessel growth and sugar burning. It has no direct drug yet; belzutifan hits its sibling HIF-2α, and the mTOR inhibitor temsirolimus lowers HIF-1α levels indirectly.Open in Atlas onco.cc
HIF-2α: A master switch that kidney cancer cells leave permanently on when they lose the VHL gene; belzutifan blocks it.Open in Atlas onco.cc
HIP1: HIP1 (Huntingtin-interacting protein 1) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohort...Open in Atlas onco.cc
Histone deacetylases (HDAC): Histone deacetylases tighten the packaging of DNA so that genes are switched off. Drugs that block them loosen the packaging and can wake up genes that make lymphoma cells stop growing or die.Open in Atlas onco.cc
Histone H3.3 (H3-3A): H3.3 is one of the histone proteins DNA wraps around; a single change at position 27 (K27M) locks brain-stem and midline gliomas in an immature state and defines the diagnosis.Open in Atlas onco.cc
HLA-A: HLA-A is the molecule that holds up short pieces of a cell's proteins for T cells to inspect. Engineered T-cell receptor therapies such as tebentafusp and afami-cel only work in people with the HLA-A*02 variant, because the receptor recognises the tumour pe...Open in Atlas onco.cc
HLA-B: HLA-B (HLA class I histocompatibility antigen, B alpha chain) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis o...Open in Atlas onco.cc
HLA-C: HLA-C (HLA class I histocompatibility antigen, C alpha chain) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnos...Open in Atlas onco.cc
HLA-DQA1: HLA-DQA1 (HLA class II histocompatibility antigen, DQ alpha 1 chain) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to...Open in Atlas onco.cc
HLA-DR: HLA-DR is the display case that antigen-presenting cells use to show fragments to helper T cells. When monocytes lose it, the immune system is suppressed, which happens in advanced cancer and severe illness.Open in Atlas onco.cc
HLA-DRA: HLA-DRA (HLA class II histocompatibility antigen, DR alpha chain) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Melanoma.Open in Atlas onco.cc
HLA-E: HLA-E is the self badge that NKG2A on NK cells reads. Tumours raise it to escape NK cells; monalizumab blocks the reader rather than the badge.Open in Atlas onco.cc
HLF: HLF (Transcription factor HLF) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role.Open in Atlas onco.cc
HMGA1: HMGA1 (High mobility group protein HMG-I/HMG-Y) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role.Open in Atlas onco.cc
HMGA2: HMGA2 (High mobility group protein HMGI-C) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Breast cancer and Oral cavity cancer.Open in Atlas onco.cc
HMGCR: HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase) is an enzyme. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.Open in Atlas onco.cc
HMOX1: HMOX1 (Heme oxygenase 1) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Renal cell carcinoma.Open in Atlas onco.cc
HNF1A: HNF1A (Hepatocyte nuclear factor 1-alpha) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Renal...Open in Atlas onco.cc
HNF1B: HNF1B (Hepatocyte nuclear factor 1-beta) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Renal cell carcinoma and Ovarian cancer.Open in Atlas onco.cc
HNF4G: HNF4G (Hepatocyte nuclear factor 4-gamma) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
HNRNPA2B1: HNRNPA2B1 (Heterogeneous nuclear ribonucleoproteins A2/B1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocel...Open in Atlas onco.cc
HNRNPH1: HNRNPH1 (Heterogeneous nuclear ribonucleoprotein H) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Mantle cell lymphoma.Open in Atlas onco.cc
HNRNPU: HNRNPU (Heterogeneous nuclear ribonucleoprotein U) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Burkitt lymphoma.Open in Atlas onco.cc
HOOK3: HOOK3 (Protein Hook homolog 3) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
HOXA11: HOXA11 (Homeobox protein Hox-A11) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
HOXA13: HOXA13 (Homeobox protein Hox-A13) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
HOXA9: HOXA9 is an embryonic growth gene that some leukaemias keep switched on so their cells never mature. Menin inhibitors such as revumenib and ziftomenib do not touch HOXA9 itself; they pull menin off the DNA so the gene switches off and the cells grow up.Open in Atlas onco.cc
HOXB13: HOXB13 (Homeobox protein Hox-B13) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer and Gastric & gastro...Open in Atlas onco.cc
HOXC10: HOXC10 (Homeobox protein Hox-C10) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.Open in Atlas onco.cc
HOXC11: HOXC11 (Homeobox protein Hox-C11) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Colorectal cancer.Open in Atlas onco.cc
HOXC13: HOXC13 (Homeobox protein Hox-C13) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer.Open in Atlas onco.cc
HOXD11: HOXD11 (Homeobox protein Hox-D11) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Colorectal cancer.Open in Atlas onco.cc
HOXD13: HOXD13 (Homeobox protein Hox-D13) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
HOXD8: HOXD8 (Homeobox protein Hox-D8) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Melanoma.Open in Atlas onco.cc
HRAS: HRAS (GTPase HRas) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Bladder &...Open in Atlas onco.cc
HSP90AA1: HSP90AA1 (Heat shock protein HSP 90-alpha) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target and a tumour suppressor, and clinical evidence ties its variants to diagnosis, prognosis or drug response....Open in Atlas onco.cc
HSP90AB1: HSP90AB1 (Heat shock protein HSP 90-beta) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Melanoma.Open in Atlas onco.cc
HSP90B1: HSP90B1 (Endoplasmin) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.Open in Atlas onco.cc
HSPA5: HSPA5 (Endoplasmic reticulum chaperone BiP) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer.Open in Atlas onco.cc
HSPB1: HSPB1 (Heat shock protein beta-1) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pancreatic ductal adenocarcinoma.Open in Atlas onco.cc
HSPG2: HSPG2 (Basement membrane-specific heparan sulfate proteoglycan core protein) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts....Open in Atlas onco.cc
HSPH1: HSPH1 (Heat shock protein 105 kDa) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer and Colorect...Open in Atlas onco.cc
HVCN1: HVCN1 (Voltage-gated hydrogen channel 1) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.Open in Atlas onco.cc

I

ICOS: ICOS (Inducible T-cell costimulator) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.Open in Atlas onco.cc
ID3: ID3 (DNA-binding protein inhibitor ID-3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied...Open in Atlas onco.cc
IDH1 / IDH2: A metabolic enzyme whose mutant form produces a molecule that scrambles how genes are read; blocking it slows brain tumours and leukaemias.Open in Atlas onco.cc
IDO1: IDO1 is an enzyme tumours use to burn up tryptophan, starving T cells and producing by-products that switch them off. Epacadostat blocked it but its programme ended in failure; the IO102-IO103 vaccine instead teaches T cells to attack the IDO1-expressing ce...Open in Atlas onco.cc
IFNA2: IFNA2 (Interferon alpha-2) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.Open in Atlas onco.cc
IFNAR2: IFNAR2 (Interferon alpha/beta receptor 2) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Myeloproliferative neoplasms, Leukaemia, Non-Hodgkin lymphoma and 5 more.Open in Atlas onco.cc
IFNGR1: IFNGR1 (Interferon gamma receptor 1) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Melanoma.Open in Atlas onco.cc
IGF-1 receptor (IGF1R): The IGF-1 receptor is a growth-factor receptor that many cancers use to survive; a decade of antibodies and kinase inhibitors against it failed in trials, a cautionary tale in oncology drug development.Open in Atlas onco.cc
IGF2: IGF2 (Insulin-like growth factor 2) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer, Ovarian cancer and Pancreatic ductal ad...Open in Atlas onco.cc
IGF2R: IGF2R (Cation-independent mannose-6-phosphate receptor) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
IKBKB: IKBKB (Inhibitor of nuclear factor kappa-B kinase subunit beta) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and an oncogene driver, and clinical evidence ties its...Open in Atlas onco.cc
IKZF1 (Ikaros): Ikaros is a transcription factor that myeloma cells depend on. Lenalidomide, pomalidomide and the newer CELMoDs work by gluing Ikaros to the cell's disposal machinery so it is destroyed, which kills the plasma cell and wakes up T cells.Open in Atlas onco.cc
IKZF3 (Aiolos): Aiolos is Ikaros' partner transcription factor in B cells and plasma cells. The myeloma drugs lenalidomide, pomalidomide and golcadomide destroy Aiolos and Ikaros together by rerouting them to the cell's protein-disposal system.Open in Atlas onco.cc
IL-11 receptor alpha: The IL-11 receptor was the target of oprelvekin, the first drug approved to prevent the severe platelet falls that chemotherapy causes; the drug was withdrawn in 2011 and thrombopoietin agonists took over the problem.Open in Atlas onco.cc
IL2RB: IL2RB (Interleukin-2 receptor subunit beta) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Skin cancer, Leukaemia, Renal cell carcinoma and 3 more.Open in Atlas onco.cc
IL2RG: IL2RG (Cytokine receptor common subunit gamma) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Skin cancer, Renal cell carcinoma, Leukaemia and 3 more.Open in Atlas onco.cc
IL33: IL33 (Interleukin-33) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.Open in Atlas onco.cc
IL4R: IL4R (Interleukin-4 receptor subunit alpha) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.Open in Atlas onco.cc
IL6ST: IL6ST (Interleukin-6 receptor subunit beta) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to...Open in Atlas onco.cc
IL7R: IL7R (Interleukin-7 receptor subunit alpha) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or dr...Open in Atlas onco.cc
IMP dehydrogenase (IMPDH2): IMPDH is the bottleneck enzyme for making guanine nucleotides; mycophenolate blocks it to hold back the donor T cells that cause graft-versus-host disease after stem cell transplantation, and the enzyme is over-expressed in fast-growing tumours.Open in Atlas onco.cc
IMPDH1: IMPDH1 (Inosine-5'-monophosphate dehydrogenase 1) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Non-Hodgkin lymphoma, Myeloproliferative neoplasms and 2 more.Open in Atlas onco.cc
INCENP: INCENP (Inner centromere protein) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
ING1: ING1 (Inhibitor of growth protein 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Head and neck squamous c...Open in Atlas onco.cc
INHBB: INHBB (Inhibin beta B chain) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer.Open in Atlas onco.cc
INPPL1: INPPL1 (Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tie...Open in Atlas onco.cc
Interferon alpha receptor (IFNAR1): The receptor through which interferon alpha alerts immune cells and slows tumour growth. Interferon was one of the first immunotherapies, used in melanoma, hairy cell leukaemia and chronic myeloid leukaemia, and has largely given way to targeted drugs and c...Open in Atlas onco.cc
Interleukin-10 (IL10): IL-10 is a calming signal that many immune cells release; tumours and the viruses behind them raise it to keep the immune system quiet. Oddly, the main cancer drug built on it gave more IL-10 rather than less, and failed.Open in Atlas onco.cc
Interleukin-6 and IL-6 receptor: Interleukin-6 is an inflammation messenger. Blocking it treats Castleman disease, a lymph node disorder, and calms the dangerous immune storm that CAR-T cell therapy can trigger.Open in Atlas onco.cc
IQGAP1: IQGAP1 (Ras GTPase-activating-like protein IQGAP1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
IRAK1: IRAK1 (Interleukin-1 receptor-associated kinase 1) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a tumour suppressor, and an approved or late-stage drug is recor...Open in Atlas onco.cc
IRF1: IRF1 (Interferon regulatory factor 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Gastric & gastro-oesoph...Open in Atlas onco.cc
IRF4: IRF4 is a master transcription factor of plasma cells and a protein myeloma cells cannot do without. Lenalidomide and its successors lower IRF4 by destroying the two factors, Ikaros and Aiolos, that keep it switched on.Open in Atlas onco.cc
IRF5: IRF5 (Interferon regulatory factor 5) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
IRF8: IRF8 (Interferon regulatory factor 8) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Non-Hodgkin lymphoma...Open in Atlas onco.cc
IRS1: IRS1 (Insulin receptor substrate 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
IRS2: IRS2 (Insulin receptor substrate 2) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer and Prostate cancer.Open in Atlas onco.cc
IRS4: IRS4 (Insulin receptor substrate 4) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bl...Open in Atlas onco.cc
IRX4: IRX4 (Iroquois-class homeodomain protein IRX-4) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer.Open in Atlas onco.cc
ITGA2B: ITGA2B (Integrin alpha-IIb) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
ITGA6: ITGA6 (Integrin alpha-6) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer.Open in Atlas onco.cc
ITGAV: ITGAV (Integrin alpha-V) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Gastric & gastro-oesophageal junctio...Open in Atlas onco.cc
ITGB3: ITGB3 (Integrin beta-3) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.Open in Atlas onco.cc
ITK: ITK (Tyrosine-protein kinase ITK/TSK) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Renal cell ca...Open in Atlas onco.cc
ITPKB: ITPKB (Inositol-trisphosphate 3-kinase B) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug respon...Open in Atlas onco.cc
ITPR1: ITPR1 (Inositol 1,4,5-trisphosphate-gated calcium channel ITPR1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc

J

JAG1: JAG1 (jagged canonical Notch ligand 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
JAG2: JAG2 (jagged canonical Notch ligand 2) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
JAK1: JAK1 is one of the kinases that pass cytokine and interferon signals inside immune and blood cells. Ruxolitinib and momelotinib block JAK1 together with JAK2 to calm the inflammation of myelofibrosis; golidocitinib is the first JAK1-only inhibitor approved...Open in Atlas onco.cc
JAK2: The signalling enzyme that tells marrow cells to make red cells and platelets; a single mutation (V617F) leaves it switched on in most myeloproliferative neoplasms.Open in Atlas onco.cc
JAK3: JAK3 (Tyrosine-protein kinase JAK3) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and an approved or late-stage drug is recorded...Open in Atlas onco.cc
JAZF1: JAZF1 (Juxtaposed with another zinc finger protein 1) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Skin cancer and Prostate ca...Open in Atlas onco.cc
JUN: JUN (Transcription factor Jun) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Sk...Open in Atlas onco.cc

K

KANK1: KANK1 (KN motif and ankyrin repeat domain-containing protein 1) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
KAT2A: KAT2A (Histone acetyltransferase KAT2A) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
KAT2B: KAT2B (Histone acetyltransferase KAT2B) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
KAT5: KAT5 (Histone acetyltransferase KAT5) is a protein that switches other genes on and off. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role.Open in Atlas onco.cc
KAT6A: KAT6A (Histone acetyltransferase KAT6A) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to...Open in Atlas onco.cc
KAT6B: KAT6B (Histone acetyltransferase KAT6B) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohort...Open in Atlas onco.cc
KAT7: KAT7 (Histone acetyltransferase KAT7) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a DNA repair gene, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to B...Open in Atlas onco.cc
KCNA3: KCNA3 (Potassium voltage-gated channel subfamily A member 3) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.Open in Atlas onco.cc
KCNA4: KCNA4 (Potassium voltage-gated channel subfamily A member 4) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.Open in Atlas onco.cc
KCNB2: KCNB2 (Potassium voltage-gated channel subfamily B member 2) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.Open in Atlas onco.cc
KCNC2: KCNC2 (Voltage-gated potassium channel KCNC2) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.Open in Atlas onco.cc
KCND2: KCND2 (A-type voltage-gated potassium channel KCND2) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.Open in Atlas onco.cc
KCND3: KCND3 (A-type voltage-gated potassium channel KCND3) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.Open in Atlas onco.cc
KCNF1: KCNF1 (Voltage-gated potassium channel regulatory subunit KCNF1) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.Open in Atlas onco.cc
KCNH1: KCNH1 (Voltage-gated delayed rectifier potassium channel KCNH1) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.Open in Atlas onco.cc
KCNH7: KCNH7 (Voltage-gated inwardly rectifying potassium channel KCNH7) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.Open in Atlas onco.cc
KCNH8: KCNH8 (Voltage-gated delayed rectifier potassium channel KCNH8) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.Open in Atlas onco.cc
KCNQ1: KCNQ1 (Potassium voltage-gated channel subfamily KQT member 1) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.Open in Atlas onco.cc
KCNQ3: KCNQ3 (Potassium voltage-gated channel subfamily KQT member 3) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.Open in Atlas onco.cc
KCNQ5: KCNQ5 (Potassium voltage-gated channel subfamily KQT member 5) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.Open in Atlas onco.cc
KDM3B: KDM3B (Lysine-specific demethylase 3B) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Medulloblastoma and Pa...Open in Atlas onco.cc
KDM5A: KDM5A (Lysine-specific demethylase 5A) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Skin can...Open in Atlas onco.cc
KDM5C: KDM5C (Lysine-specific demethylase 5C) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosi...Open in Atlas onco.cc
KDM5D: KDM5D (Lysine-specific demethylase 5D) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer.Open in Atlas onco.cc
KDM6A: KDM6A (Lysine-specific demethylase 6A) is an enzyme. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Bladder &...Open in Atlas onco.cc
KDM7A: KDM7A (Lysine-specific demethylase 7A) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
KEAP1: KEAP1 (Kelch-like ECH-associated protein 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagn...Open in Atlas onco.cc
Ki-67 (MKI67): Ki-67 is a protein present only in cells that are dividing, so the share of tumour cells that stain for it is a direct read of how fast the cancer is growing.Open in Atlas onco.cc
KIAA1549: KIAA1549 (UPF0606 protein KIAA1549) is a gene. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role.Open in Atlas onco.cc
KIF23: KIF23 (Kinesin-like protein KIF23) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Hepatocellular carcinoma.Open in Atlas onco.cc
KIF5B: KIF5B (Kinesin-1 heavy chain) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target and an oncogene driver, and an approved or late-stage drug is recorded against it. Tied to Lung cancer, Thyroid cancer, Neuroe...Open in Atlas onco.cc
KIR2DL1 (inhibitory KIR): Inhibitory KIRs are the receptors NK cells use to recognise a person's own HLA-C and stand down. Lirilumab, an antibody that blocks three of them, reached phase 2 but was dropped for blood cancers.Open in Atlas onco.cc
KIT: KIT mutation is the driver behind most gastrointestinal stromal tumours, and the reason imatinib turned a sarcoma with a median survival of about a year into a chronic disease.Open in Atlas onco.cc
KITLG: KITLG (Kit ligand) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Testicular germ cell tumours.Open in Atlas onco.cc
KLC1: KLC1 (Kinesin light chain 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
KLF2: KLF2 (Krueppel-like factor 2) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.Open in Atlas onco.cc
KLF4: KLF4 (Krueppel-like factor 4) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied...Open in Atlas onco.cc
KLF5: KLF5 (Krueppel-like factor 5) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied...Open in Atlas onco.cc
KLF6: KLF6 (Krueppel-like factor 6) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer, Skin cancer an...Open in Atlas onco.cc
KLHDC8B: KLHDC8B (Kelch domain-containing protein 8B) is a gene. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Hodgkin lymphoma.Open in Atlas onco.cc
KLHL14: KLHL14 (Kelch-like protein 14) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.Open in Atlas onco.cc
KLHL6: KLHL6 (Kelch-like protein 6) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug respon...Open in Atlas onco.cc
KLK2 (kallikrein-2): A relative of PSA that stays attached to prostate cancer cells, used as a T-cell engager address by J&J.Open in Atlas onco.cc
KLK3: KLK3 (Prostate-specific antigen) is an enzyme. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer.Open in Atlas onco.cc
KLLN: KLLN (Killin) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer and Renal cell carcinoma.Open in Atlas onco.cc
KMT2A (MLL) rearrangement: A gene fusion that drives an aggressive leukaemia in infants and adults. It cannot be blocked directly, but the scaffold protein it depends on (menin) can.Open in Atlas onco.cc
KMT2B: KMT2B (Histone-lysine N-methyltransferase 2B) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or...Open in Atlas onco.cc
KMT2C: KMT2C (Histone-lysine N-methyltransferase 2C) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, p...Open in Atlas onco.cc
KMT2D: KMT2D (Histone-lysine N-methyltransferase 2D) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, p...Open in Atlas onco.cc
KMT5A: KMT5A (N-lysine methyltransferase KMT5A) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer.Open in Atlas onco.cc
KNL1: KNL1 (Outer kinetochore KNL1 complex subunit KNL1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohort...Open in Atlas onco.cc
KNSTRN: KNSTRN (Small kinetochore-associated protein) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Melanoma.Open in Atlas onco.cc
KRAS: KRAS is the most commonly mutated cancer gene, called 'undruggable' for 40 years until 2021.Open in Atlas onco.cc
KRT18: KRT18 (Keratin, type I cytoskeletal 18) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer.Open in Atlas onco.cc
KRT5: KRT5 (Keratin, type II cytoskeletal 5) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Skin cancer and Basal cell carcinoma.Open in Atlas onco.cc
KSR1: KSR1 (Kinase suppressor of Ras 1) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
KSR2: KSR2 (Kinase suppressor of Ras 2) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
KTN1: KTN1 (Kinectin) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc

L

L3MBTL3: L3MBTL3 (Lethal(3)malignant brain tumour-like protein 3) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Breast cancer.Open in Atlas onco.cc
LAG-3: LAG-3 is the third immune brake to reach approval, combined with PD-1 blockade in melanoma.Open in Atlas onco.cc
LAMA5: LAMA5 (Laminin subunit alpha-5) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
LAMC1: LAMC1 (Laminin subunit gamma-1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
LATS1: LATS1 (Serine/threonine-protein kinase LATS1) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutatio...Open in Atlas onco.cc
LATS2: LATS2 (Serine/threonine-protein kinase LATS2) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutatio...Open in Atlas onco.cc
LCK: LCK (Tyrosine-protein kinase Lck) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a fusion partner, and an approved or late-stage drug is recorded against it. Tied...Open in Atlas onco.cc
LDB1: LDB1 (LIM domain-binding protein 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Medulloblastoma and Paedi...Open in Atlas onco.cc
LEF1: LEF1 (Lymphoid enhancer-binding factor 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Leukaemia, Non-Hodg...Open in Atlas onco.cc
LEPR: LEPR (Leptin receptor) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Meningioma.Open in Atlas onco.cc
LGR5: LGR5 (Leucine-rich repeat-containing G protein-coupled receptor 5) is a protein on the cell surface. The public catalogues list it as a drug target, a biomarker and an antigen, and clinical evidence ties its variants to diagnosis, prognosis or drug response...Open in Atlas onco.cc
LIFR: LIFR (Leukaemia inhibitory factor receptor) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Mel...Open in Atlas onco.cc
LIG4: LIG4 (DNA ligase 4) is an enzyme. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role.Open in Atlas onco.cc
LILRB1 (ILT2): LILRB1 is a brake on macrophages, dendritic cells and some NK and T cells that reads ordinary HLA class I, so any cell showing HLA is protected. Antibodies that block it, with or without LILRB2, are in early trials.Open in Atlas onco.cc
LILRB2 (ILT4): LILRB2 is a brake on monocytes and dendritic cells that reads HLA-G and other HLA class I molecules and keeps them in a tolerant, tumour-friendly state. The antibody MK-4830 blocks it and is in phase 2 with pembrolizumab.Open in Atlas onco.cc
LIV-1 (SLC39A6): LIV-1 is an oestrogen-regulated zinc transporter on most breast cancers; the ADC against it (ladiratuzumab vedotin) showed activity in triple-negative disease but was discontinued in 2024.Open in Atlas onco.cc
LMNA: LMNA (Prelamin-A/C) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
LMO1: LMO1 (Rhombotin-1) is a gene. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Colorectal cancer.Open in Atlas onco.cc
LMO2: LMO2 (Rhombotin-2) is a gene. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Breast cancer.Open in Atlas onco.cc
LMO7: LMO7 (LIM domain only protein 7) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
LMX1B: LMX1B (LIM homeobox transcription factor 1-beta) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
LPA: LPA (Apolipoprotein(a)) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Pancreatic ductal adenocarcinoma.Open in Atlas onco.cc
LPP: LPP (Lipoma-preferred partner) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Skin cancer, Breast cancer, Non-Hodgkin lymphoma a...Open in Atlas onco.cc
LRATD2: LRATD2 (LRAT domain containing 2) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
LRFN2: LRFN2 (Leucine-rich repeat and fibronectin type-III domain-containing protein 2) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
LRIG3: LRIG3 (Leucine-rich repeats and immunoglobulin-like domains protein 3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts...Open in Atlas onco.cc
LRP1B: LRP1B (Low-density lipoprotein receptor-related protein 1B) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variant...Open in Atlas onco.cc
LRP5: LRP5 (Low-density lipoprotein receptor-related protein 5) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
LRRFIP1: LRRFIP1 (Leucine-rich repeat flightless-interacting protein 1) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Leukaemia.Open in Atlas onco.cc
LSM14A: LSM14A (Protein LSM14 homolog A) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Endometrial cancer.Open in Atlas onco.cc
LSP1: LSP1 (Lymphocyte-specific protein 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Breast cancer.Open in Atlas onco.cc
LTB: LTB (Lymphotoxin-beta) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.Open in Atlas onco.cc
LYL1: LYL1 (LYL1 basic helix-loop-helix family member) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role.Open in Atlas onco.cc
LYN kinase: LYN is a SRC-family kinase that sits under the B-cell receptor; dasatinib and bosutinib inhibit it alongside BCR-ABL, and LYN over-activity is one way chronic myeloid leukaemia escapes imatinib.Open in Atlas onco.cc
LZTR1: LZTR1 (Leucine-zipper-like transcriptional regulator 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosi...Open in Atlas onco.cc

M

MACC1: MACC1 (Metastasis-associated in colon cancer protein 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Non-s...Open in Atlas onco.cc
MAF: MAF (Transcription factor Maf) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cance...Open in Atlas onco.cc
MAFB: MAFB (Transcription factor MafB) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Colorectal cancer.Open in Atlas onco.cc
MAGE-A4: A protein normally only in testis that some sarcomas and other tumours switch on; T cells can be engineered to recognise fragments of it.Open in Atlas onco.cc
MAGEH1: MAGEH1 (Melanoma-associated antigen H1) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.Open in Atlas onco.cc
MALT1: MALT1 (Mucosa-associated lymphoid tissue lymphoma translocation protein 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis...Open in Atlas onco.cc
MAML1: MAML1 (Mastermind-like protein 1) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
MAML2: MAML2 (Mastermind-like protein 2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Lung c...Open in Atlas onco.cc
MAML3: MAML3 (Mastermind-like protein 3) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
MAMLD1: MAMLD1 (Mastermind-like domain-containing protein 1) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
MAP2K4: MAP2K4 is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis,...Open in Atlas onco.cc
MAP2K7: MAP2K7 is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug re...Open in Atlas onco.cc
MAP3K1: MAP3K1 is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis,...Open in Atlas onco.cc
MAP3K13: MAP3K13 (Mitogen-activated protein kinase kinase kinase 13) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. In the public catalogues the evidence so far is association rather than a proven role. Tied to Skin cancer...Open in Atlas onco.cc
MAPK1: MAPK1 is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, p...Open in Atlas onco.cc
MAPK11: MAPK11 (Mitogen-activated protein kinase 11) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Colore...Open in Atlas onco.cc
MAPK3: MAPK3 (Mitogen-activated protein kinase 3) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug res...Open in Atlas onco.cc
MAPK8: MAPK8 (Mitogen-activated protein kinase 8) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug res...Open in Atlas onco.cc
MAPK9: MAPK9 (Mitogen-activated protein kinase 9) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug res...Open in Atlas onco.cc
MARK2: MARK2 (Serine/threonine-protein kinase MARK2) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient c...Open in Atlas onco.cc
MARK3: MARK3 (MAP/microtubule affinity-regulating kinase 3) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
MAX: MAX (MYC associated transcriptional regulator X) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied t...Open in Atlas onco.cc
MB21D2: MB21D2 (Nucleotidyltransferase MB21D2) is an enzyme. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Head and neck squamous cell carcinoma, Sarcom...Open in Atlas onco.cc
MBD4: MBD4 (Methyl-CpG-binding domain protein 4) is an enzyme. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Leukaemi...Open in Atlas onco.cc
MC1R: MC1R (Melanocyte-stimulating hormone receptor) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Skin cancer, Melanoma and Basal cell carcinoma.Open in Atlas onco.cc
MCL1: MCL1 (Induced myeloid leukaemia cell differentiation protein Mcl-1) is a gene. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma.Open in Atlas onco.cc
MCM7: MCM7 (DNA replication licensing factor MCM7) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Cervical cancer.Open in Atlas onco.cc
MCM8: MCM8 (DNA helicase MCM8) is an enzyme. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role.Open in Atlas onco.cc
MDGA2: MDGA2 (MAM domain-containing glycosylphosphatidylinositol anchor protein 2) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts....Open in Atlas onco.cc
MDM2: MDM2 is the protein that degrades p53; blocking it reactivates p53 in tumours where the gene is intact, especially the liposarcomas that carry extra copies of MDM2.Open in Atlas onco.cc
MDM4: MDM4 (MDM4 regulator of p53) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Breast cancer, Prostate cancer and 1 more.Open in Atlas onco.cc
MECOM: MECOM (Histone-lysine N-methyltransferase MECOM) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagno...Open in Atlas onco.cc
MED12: MED12 (Mediator of RNA polymerase II transcription subunit 12) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient c...Open in Atlas onco.cc
MED23: MED23 (Mediator of RNA polymerase II transcription subunit 23) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied t...Open in Atlas onco.cc
MEF2B: MEF2B (Myocyte-specific enhancer factor 2B) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug...Open in Atlas onco.cc
MEF2C: MEF2C (Myocyte-specific enhancer factor 2C) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymph...Open in Atlas onco.cc
MEF2D: MEF2D (Myocyte-specific enhancer factor 2D) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.Open in Atlas onco.cc
MEIS1: MEIS1 is HOXA9's partner in keeping leukaemia cells immature. The two are switched on together in KMT2A-rearranged and NPM1-mutant leukaemia, and switched off together when a menin inhibitor works.Open in Atlas onco.cc
MEK1/2: MEK is the relay in the growth-signal chain that sits just below RAS and RAF. Blocking it starves BRAF- and RAS-driven tumours of their go signal.Open in Atlas onco.cc
Menin: A scaffold protein that certain leukaemias need to keep their genes switched on; the first drug against it was approved in 2024.Open in Atlas onco.cc
MERTK: MERTK (Tyrosine-protein kinase Mer) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or...Open in Atlas onco.cc
Mesothelin: Mesothelin is a surface protein on mesothelioma, ovarian, and pancreatic cancers, targeted by ADCs, CAR-T, and T-cell engagers.Open in Atlas onco.cc
MET: A receptor that is either mutated in some lung cancers or amplified as an escape route when other lung cancer drugs fail.Open in Atlas onco.cc
MGA: MGA (MAX gene-associated protein) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Mes...Open in Atlas onco.cc
MGMT (O6-methylguanine-DNA methyltransferase): MGMT is a DNA repair enzyme that removes the damage temozolomide causes; when the gene is switched off by methylation the tumour cannot repair itself and the drug works better.Open in Atlas onco.cc
MIB2: MIB2 (E3 ubiquitin-protein ligase MIB2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Head and neck squamou...Open in Atlas onco.cc
MIEN1: MIEN1 is a small HER2-amplicon gene whose protein promotes cell migration and is strongly raised in breast and prostate cancers.Open in Atlas onco.cc
MINPP1: MINPP1 (Multiple inositol polyphosphate phosphatase 1) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Thyroid cancer.Open in Atlas onco.cc
MIR21: MIR21 (microRNA 21) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-small-cell lung cancer.Open in Atlas onco.cc
MIR218-1: MIR218-1 (microRNA 218-1) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer and Pancreatic ductal adenocarcinoma.Open in Atlas onco.cc
Mismatch repair proteins (MLH1, MSH2, MSH6, PMS2): The four mismatch repair proteins proofread newly copied DNA; when a tumour loses one of them its DNA fills with small errors, and that state (dMMR or MSI-high) is what lets immunotherapy work across many cancers.Open in Atlas onco.cc
MITF: MITF (Microphthalmia-associated transcription factor) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied t...Open in Atlas onco.cc
MLF1: MLF1 (Myeloid leukaemia factor 1) is a gene. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Lung cancer.Open in Atlas onco.cc
MLH1: MLH1 (DNA mismatch repair protein Mlh1) is a gene. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Ovarian cancer...Open in Atlas onco.cc
MLH3: MLH3 (DNA mismatch repair protein Mlh3) is a gene. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role. Tied to Colorectal cancer and Endometrial cancer.Open in Atlas onco.cc
MLLT1: MLLT1 (MLLT1 super elongation complex subunit) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to...Open in Atlas onco.cc
MLLT10: MLLT10 (MLLT10 histone lysine methyltransferase DOT1L cofactor) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Breast cancer, Ov...Open in Atlas onco.cc
MLLT3: MLLT3 (MLLT3 super elongation complex subunit) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Leukaemia, Non-Hodgkin lym...Open in Atlas onco.cc
MLLT6: MLLT6 (MLLT6, PHD finger containing) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient...Open in Atlas onco.cc
MLPH: MLPH (Melanophilin) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
MMP1: MMP1 (Interstitial collagenase) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to HR-positive / HER2-negative breast cancer.Open in Atlas onco.cc
MMP2: MMP2 (72 kDa type IV collagenase) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.Open in Atlas onco.cc
MMP7: MMP7 (Matrilysin) is an enzyme. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.Open in Atlas onco.cc
MMP9: MMP9 (Matrix metalloproteinase-9) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.Open in Atlas onco.cc
MN1: MN1 (Transcriptional activator MN1) is a protein that switches other genes on and off. The public catalogues list it as a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer...Open in Atlas onco.cc
MOV10: MOV10 (RNA helicase MOV-10) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
MPEG1: MPEG1 (Macrophage-expressed gene 1 protein) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.Open in Atlas onco.cc
MPL (thrombopoietin receptor): MPL is the receptor that tells the bone marrow to make platelets. Romiplostim and eltrombopag switch it on to raise platelet counts; in some myeloproliferative neoplasms a mutant partner protein, calreticulin, grips it and keeps it on.Open in Atlas onco.cc
MPRIP: MPRIP (Myosin phosphatase Rho-interacting protein) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Colorectal cancer and Renal cell carcinoma.Open in Atlas onco.cc
MPS1 (TTK): MPS1 arms the checkpoint that holds a dividing cell until its chromosomes are attached. Blocking it lets cancer cells divide carelessly and die; one inhibitor is in phase 1/2 in breast cancer.Open in Atlas onco.cc
MRE11: MRE11 (Double-strand break repair protein MRE11) is an enzyme. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer, Endo...Open in Atlas onco.cc
MRTFA: MRTFA (Myocardin-related transcription factor A) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Breast cancer, Skin cancer, Lung...Open in Atlas onco.cc
MSH2: MSH2 (DNA mismatch repair protein Msh2) is a gene. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Endometrial ca...Open in Atlas onco.cc
MSH3: MSH3 (DNA mismatch repair protein Msh3) is a gene. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Endometrial cancer and Colorectal...Open in Atlas onco.cc
MSH6: MSH6 (DNA mismatch repair protein Msh6) is a gene. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Endometrial ca...Open in Atlas onco.cc
MSI2: MSI2 (RNA-binding protein Musashi homolog 2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tie...Open in Atlas onco.cc
MSMB: MSMB (Beta-microseminoprotein) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer.Open in Atlas onco.cc
MSN: MSN (Moesin) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Oesophageal cancer, Renal...Open in Atlas onco.cc
MSR1: MSR1 (Macrophage scavenger receptor types I and II) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
MT-CO1: MT-CO1 (Cytochrome c oxidase subunit 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Myelodysplastic syndromes / neoplasms and Colorectal cancer.Open in Atlas onco.cc
MT-CYB: MT-CYB (Cytochrome b) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
MT-ND1: MT-ND1 (NADH-ubiquinone oxidoreductase chain 1) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.Open in Atlas onco.cc
MT-ND6: MT-ND6 (NADH-ubiquinone oxidoreductase chain 6) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.Open in Atlas onco.cc
MTCP1: MTCP1 (Protein p13 MTCP-1) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Breast cancer.Open in Atlas onco.cc
MTHFR: MTHFR (Methylenetetrahydrofolate reductase (NADPH)) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction...Open in Atlas onco.cc
mTOR: mTOR is the cell's master growth controller, deciding whether to build proteins and divide. Rapamycin-like drugs clamp it down in kidney, breast and neuroendocrine cancers and in rare tumours driven by TSC gene loss.Open in Atlas onco.cc
Mu-opioid receptor: The mu-opioid receptor is the target of morphine and the other strong opioids that control most severe cancer pain; the same receptor in the gut causes opioid constipation, which methylnaltrexone and naloxegol relieve by blocking it outside the brain.Open in Atlas onco.cc
MUC16 (CA-125): The giant mucin that is shed into blood as the CA-125 ovarian cancer marker; its membrane stalk is being targeted by ADCs and T-cell engagers.Open in Atlas onco.cc
MUC6: MUC6 (Mucin-6) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcinoma, Acute myeloid leukaemia and...Open in Atlas onco.cc
MUS81: MUS81 (Structure-specific endonuclease subunit MUS81) is an enzyme. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer.Open in Atlas onco.cc
MUTYH: MUTYH (Adenine DNA glycosylase) is an enzyme. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role. Tied to Colorectal cancer, Gastric & gastro-oesophageal junction cancer, Breast cancer and 5...Open in Atlas onco.cc
MX2: MX2 (Interferon-induced GTP-binding protein Mx2) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Skin cancer and Melanoma.Open in Atlas onco.cc
MXI1: MXI1 (Max-interacting protein 1) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer.Open in Atlas onco.cc
MYB: MYB (Transcriptional activator Myb) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Breast cancer, Colore...Open in Atlas onco.cc
MYBL1: MYBL1 (Myb-related protein A) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.Open in Atlas onco.cc
MYC: MYC (Myc proto-oncogene protein) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnos...Open in Atlas onco.cc
MYCL: MYCL (MYCL proto-oncogene, bHLH transcription factor) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Multiple myeloma, Skin cancer and Mela...Open in Atlas onco.cc
MYCN (N-myc): MYCN is a growth-driving gene that some neuroblastomas copy many times over; that amplification is one of the strongest signs the tumour is aggressive and sets the intensity of treatment.Open in Atlas onco.cc
MYD88: MYD88 (Myeloid differentiation primary response protein MyD88) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, pr...Open in Atlas onco.cc
MYEOV: MYEOV (Myeloma-overexpressed gene protein) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer.Open in Atlas onco.cc
MYH11: MYH11 (Myosin-11) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Pr...Open in Atlas onco.cc
MYH9: MYH9 (Myosin-9) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Head and neck squamous...Open in Atlas onco.cc
MYO18A: MYO18A (Putative TGFB1-induced anti-apoptotic factor 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Leukaemia.Open in Atlas onco.cc
MYO5A: MYO5A (Unconventional myosin-Va) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast canc...Open in Atlas onco.cc
MYOD1: MYOD1 (Myoblast determination protein 1) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Sarcomas, Colorectal cancer a...Open in Atlas onco.cc
MYSM1: MYSM1 (Deubiquitinase MYSM1) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Myelodysplastic syndromes / neoplasms.Open in Atlas onco.cc

N

N4BP2: N4BP2 (NEDD4-binding protein 2) is an enzyme. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcinoma, Bladder & urothelial cance...Open in Atlas onco.cc
NAB2: NAB2 (NGFI-A-binding protein 2) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
NACA: NACA (Nascent polypeptide-associated complex subunit alpha, muscle-specific form) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient coh...Open in Atlas onco.cc
NAF1: NAF1 (H/ACA ribonucleoprotein complex non-core subunit NAF1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
NAPRT: NAPRT (Nicotinate phosphoribosyltransferase) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.Open in Atlas onco.cc
NBEA: NBEA (Neurobeachin) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular car...Open in Atlas onco.cc
NBN: NBN (Nibrin) is a gene. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Leukaemia, Breast cancer and 5 more.Open in Atlas onco.cc
NCAPH: NCAPH (Condensin complex subunit 2) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Acute myeloid leukaemia.Open in Atlas onco.cc
NCKIPSD: NCKIPSD (NCK-interacting protein with SH3 domain) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts...Open in Atlas onco.cc
NCOA1: NCOA1 (Nuclear receptor coactivator 1) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Pancreatic ductal adenocarcinoma.Open in Atlas onco.cc
NCOA2: NCOA2 (Nuclear receptor coactivator 2) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Oesophag...Open in Atlas onco.cc
NCOA3: NCOA3 (Nuclear receptor coactivator 3) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer...Open in Atlas onco.cc
NCOA4: NCOA4 (Nuclear receptor coactivator 4) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Thyroid cancer.Open in Atlas onco.cc
NCOR1: NCOR1 (Nuclear receptor corepressor 1) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast c...Open in Atlas onco.cc
NCOR2: NCOR2 (Nuclear receptor corepressor 2) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorect...Open in Atlas onco.cc
NCSTN: NCSTN (Nicastrin) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Desmoid tumour.Open in Atlas onco.cc
NDRG1: NDRG1 (N-myc downstream regulated 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Breast cancer, Lung cancer, Colorectal cancer and 1 more.Open in Atlas onco.cc
NDUFA13: NDUFA13 (NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.Open in Atlas onco.cc
Nectin-4: Nectin-4 is an adhesion protein plentiful on bladder cancer cells, used as the docking site for the ADC enfortumab vedotin.Open in Atlas onco.cc
NEDD9: NEDD9 (Enhancer of filamentation 1) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Hepatocellular carcinoma.Open in Atlas onco.cc
NEIL1: NEIL1 (Endonuclease 8-like 1) is an enzyme. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role.Open in Atlas onco.cc
NEK10: NEK10 (Serine/threonine-protein kinase Nek10) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. In the public catalogues the evidence so far is association rather than a proven role. Tied to Breast cancer.Open in Atlas onco.cc
NF1 (neurofibromin): NF1 makes neurofibromin, the protein that switches RAS off. People born with one faulty copy develop neurofibromatosis type 1, whose plexiform neurofibromas are now treated with the MEK inhibitors selumetinib and mirdametinib, which cut the RAS signal one s...Open in Atlas onco.cc
NF2: NF2 (Merlin) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug respons...Open in Atlas onco.cc
NFATC2: NFATC2 (Nuclear factor of activated T-cells, cytoplasmic 2) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient coho...Open in Atlas onco.cc
NFE2L2: NFE2L2 (Nuclear factor erythroid 2-related factor 2) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagn...Open in Atlas onco.cc
NFIB: NFIB (Nuclear factor 1 B-type) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Breast cancer, Oral cavity cancer and Adenoid cystic carcinoma.Open in Atlas onco.cc
NFKB2: NFKB2 (Nuclear factor NF-kappa-B p100 subunit) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient...Open in Atlas onco.cc
NFKBIA: NFKBIA (NF-kappa-B inhibitor alpha) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to N...Open in Atlas onco.cc
NFKBIE: NFKBIE (NF-kappa-B inhibitor epsilon) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or dr...Open in Atlas onco.cc
NFKBIZ: NFKBIZ (NF-kappa-B inhibitor zeta) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.Open in Atlas onco.cc
NIN: NIN (Ninein) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer, Mesoth...Open in Atlas onco.cc
NIPBL: NIPBL (Nipped-B-like protein) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Non-small-cell lung cancer.Open in Atlas onco.cc
NK1 receptor (TACR1): The substance P receptor that drives the delayed nausea felt in the days after chemotherapy. Aprepitant and netupitant block it and are combined with a 5-HT3 blocker and dexamethasone for the most nausea-provoking regimens.Open in Atlas onco.cc
NKG2A (KLRC1): NKG2A is the brake on NK cells and some killer T cells that is pressed by HLA-E, a molecule tumours raise to look like self. Monalizumab blocks it and is in phase 3 with durvalumab in lung cancer and with cetuximab in head and neck cancer.Open in Atlas onco.cc
NKTR: NKTR (NK-tumour recognition protein) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Acute myeloid leukaemia.Open in Atlas onco.cc
NKX2-1: NKX2-1 (Homeobox protein Nkx-2.1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Thyroid cancer, Lung cancer...Open in Atlas onco.cc
NKX3-1: NKX3-1 (Homeobox protein Nkx-3.1) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer.Open in Atlas onco.cc
NOL9: NOL9 (Polynucleotide 5'-hydroxyl-kinase NOL9) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug re...Open in Atlas onco.cc
NOTCH1: NOTCH1 (Neurogenic locus notch homolog protein 1) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosi...Open in Atlas onco.cc
NOTCH2: NOTCH2 (Neurogenic locus notch homolog protein 2) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosi...Open in Atlas onco.cc
NOTCH3: NOTCH3 (Neurogenic locus notch homolog protein 3) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pa...Open in Atlas onco.cc
NOX4: NOX4 (NADPH oxidase 4) is an enzyme. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.Open in Atlas onco.cc
NPM1 mutation: NPM1 is the most common mutation in adult leukaemia. It moves a nuclear protein into the cytoplasm and, it turns out, makes the leukaemia dependent on menin.Open in Atlas onco.cc
NPRL2: NPRL2 (GATOR1 complex protein NPRL2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Pancreatic ductal adenoc...Open in Atlas onco.cc
NPTXR: NPTXR (Neuronal pentraxin receptor) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer.Open in Atlas onco.cc
NQO1: NQO1 (NAD(P)H dehydrogenase [quinone] 1) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer and Pancreatic ductal adenocarcinoma.Open in Atlas onco.cc
NR2F2: NR2F2 (COUP transcription factor 2) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer.Open in Atlas onco.cc
NR4A2: NR4A2 (Nuclear receptor subfamily 4 group A member 2) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied t...Open in Atlas onco.cc
NR4A3: NR4A3 (Nuclear receptor subfamily 4 group A member 3) is a protein that switches other genes on and off. The public catalogues list it as a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tie...Open in Atlas onco.cc
NR5A2: NR5A2 (Nuclear receptor subfamily 5 group A member 2) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
NRAS: NRAS is one of the three RAS switch proteins that pass growth signals into the cell. When a mutation jams it on, as in a share of melanomas, the cell keeps dividing; today's drugs reach it indirectly through MEK or RAF, and pan-RAS inhibitors that bind the...Open in Atlas onco.cc
NRG1: NRG1 (Pro-neuregulin-1, membrane-bound isoform) is a protein on the cell surface. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker, a fusion partner and an antigen, and an approved or late-stage drug is re...Open in Atlas onco.cc
NRG2: NRG2 (Pro-neuregulin-2, membrane-bound isoform) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
NRG3: NRG3 (Pro-neuregulin-3, membrane-bound isoform) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
NRG4: NRG4 (Pro-neuregulin-4, membrane-bound isoform) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
NRIP1: NRIP1 (Nuclear receptor-interacting protein 1) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Breast cancer.Open in Atlas onco.cc
NRK: NRK (Nik-related protein kinase) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied...Open in Atlas onco.cc
NSD1: NSD1 (Histone-lysine N-methyltransferase, H3 lysine-36 specific) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation a...Open in Atlas onco.cc
NSD2: NSD2 (Histone-lysine N-methyltransferase NSD2) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosi...Open in Atlas onco.cc
NSD3: NSD3 (Histone-lysine N-methyltransferase NSD3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. T...Open in Atlas onco.cc
NT5C2: NT5C2 (Cytosolic purine 5'-nucleotidase) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Non-Hodgkin lymphoma, Breast cancer a...Open in Atlas onco.cc
NT5C3A: NT5C3A (Cytosolic 5'-nucleotidase 3A) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Acute myeloid leukaemia.Open in Atlas onco.cc
NTHL1: NTHL1 (Endonuclease III-like protein 1) is an enzyme. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role. Tied to Colorectal cancer.Open in Atlas onco.cc
NTRK: Rare gene fusions found across dozens of cancer types; the first target where a drug was approved for any tumour carrying it.Open in Atlas onco.cc
NUDT15: NUDT15 (Nucleotide triphosphate diphosphatase NUDT15) is an enzyme. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it.Open in Atlas onco.cc
NUMA1: NUMA1 (Nuclear mitotic apparatus protein 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Oe...Open in Atlas onco.cc
NUP214: NUP214 (Nuclear pore complex protein Nup214) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Le...Open in Atlas onco.cc
NUP98: NUP98 (Nuclear pore complex protein Nup98-Nup96) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied t...Open in Atlas onco.cc
NUTM1: NUTM1 (NUT family member 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Skin cancer,...Open in Atlas onco.cc
NUTM2B: NUTM2B (NUT family member 2B) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Sarcomas.Open in Atlas onco.cc
NUTM2D: NUTM2D (NUT family member 2D) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Nasopharyngeal carcinoma.Open in Atlas onco.cc
NVL: NVL (Nuclear valosin-containing protein-like) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Glioma & glioblastoma.Open in Atlas onco.cc
NXF1: NXF1 (Nuclear RNA export factor 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Chronic lymphocytic leukae...Open in Atlas onco.cc

O

OCA2: OCA2 (P protein) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Skin cancer, Melanoma and Basal cell carcinoma.Open in Atlas onco.cc
OGG1: OGG1 (N-glycosylase/DNA lyase) is an enzyme. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role.Open in Atlas onco.cc
OLIG2: OLIG2 (Oligodendrocyte transcription factor 2) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Colorectal cancer.Open in Atlas onco.cc
ORC1: ORC1 (Origin recognition complex subunit 1) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Triple-negative breast cancer.Open in Atlas onco.cc
OSBPL10: OSBPL10 (Oxysterol-binding protein-related protein 10) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.Open in Atlas onco.cc
OTX1: OTX1 (Homeobox protein OTX1) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer.Open in Atlas onco.cc
OVOL2: OVOL2 (Transcription factor Ovo-like 2) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.Open in Atlas onco.cc
OX40 (TNFRSF4): OX40 is an accelerator that appears on T cells once they are switched on; pressing it makes them multiply and survive longer. Agonist antibodies against it are in trials, including a phase 3 in head and neck cancer.Open in Atlas onco.cc

P

P2RY8: P2RY8 (S-geranylgeranyl-glutathione receptor P2RY8) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognos...Open in Atlas onco.cc
PABPC1: PABPC1 (Polyadenylate-binding protein 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcinoma, M...Open in Atlas onco.cc
PALB2: PALB2 (Partner and localizer of BRCA2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, a tumour suppressor, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis,...Open in Atlas onco.cc
PALD1 (paladin): PALD1 encodes paladin, a protein built like a tyrosine phosphatase that in blood-vessel cells removes a phosphate from a membrane lipid and so tunes VEGF receptor signalling. It is not an established cancer gene: one study ties it to colon cancer spread, an...Open in Atlas onco.cc
PAPPA2: PAPPA2 (Pappalysin-2) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-small-cell lung cancer.Open in Atlas onco.cc
PAPSS1: PAPSS1 (Bifunctional 3'-phosphoadenosine 5'-phosphosulfate synthase 1) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
PARP: PARP inhibitors block DNA repair. Some cancers with defective repair are especially vulnerable, but the gene, disease setting and treatment combination determine which evidence applies.Open in Atlas onco.cc
PARP2: PARP2 (Poly [ADP-ribose] polymerase 2) is an enzyme. The public catalogues list it as a drug target and a DNA repair gene, and an approved or late-stage drug is recorded against it. Tied to Ovarian cancer, Breast cancer and Prostate cancer.Open in Atlas onco.cc
PARP3: PARP3 (Protein mono-ADP-ribosyltransferase PARP3) is an enzyme. The public catalogues list it as a drug target and a DNA repair gene, and an approved or late-stage drug is recorded against it. Tied to Ovarian cancer and Prostate cancer.Open in Atlas onco.cc
PARP4: PARP4 (Protein mono-ADP-ribosyltransferase PARP4) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer,...Open in Atlas onco.cc
PATZ1: PATZ1 (POZ-, AT hook-, and zinc finger-containing protein 1) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Skin cancer and Colo...Open in Atlas onco.cc
PAX3: PAX3 (Paired box protein Pax-3) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Sarcomas and Rhabdomyosarcoma.Open in Atlas onco.cc
PAX5: PAX5 (Paired box protein Pax-5) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or...Open in Atlas onco.cc
PAX6: PAX6 (Paired box protein Pax-6) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Renal cell carcinoma.Open in Atlas onco.cc
PAX7: PAX7 (Paired box protein Pax-7) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Sarcomas and Rhabdomyosarcoma.Open in Atlas onco.cc
PAX8: PAX8 (Paired box protein Pax-8) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Thyroid cancer.Open in Atlas onco.cc
PAX9: PAX9 (Paired box protein Pax-9) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
PBK: PBK (Lymphokine-activated killer T-cell-originated protein kinase) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its vari...Open in Atlas onco.cc
PBLD: PBLD (Phenazine biosynthesis-like domain-containing protein) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Hepatocellular carcinoma.Open in Atlas onco.cc
PBRM1: PBRM1 (polybromo 1) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response....Open in Atlas onco.cc
PBX1: PBX1 (Pre-B-cell leukaemia transcription factor 1) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Non-Hodgkin lymphoma, Leukaemi...Open in Atlas onco.cc
PCBP1: PCBP1 (Poly(rC)-binding protein 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug respon...Open in Atlas onco.cc
PCM1: PCM1 (Pericentriolar material 1 protein) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to...Open in Atlas onco.cc
PCMTD1: PCMTD1 (Protein-L-isoaspartate O-methyltransferase domain-containing protein 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patien...Open in Atlas onco.cc
PCNA: PCNA (DNA sliding clamp PCNA) is a gene. The public catalogues list it as a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Neuroblastoma.Open in Atlas onco.cc
PCNX2: PCNX2 (Pecanex-like protein 2) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
PD-1: PD-1 is a brake on T cells. Blocking it releases the immune system against the tumour and has cured some previously incurable cancers.Open in Atlas onco.cc
PD-L1: PD-L1 is the tumour's side of the PD-1 brake, and also the biomarker that decides who gets immunotherapy.Open in Atlas onco.cc
PDCD1LG2: PDCD1LG2 (Programmed cell death 1 ligand 2) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a biomarker and an antigen, and an approved or late-stage drug is recorded against it. Tied...Open in Atlas onco.cc
PDCD4: PDCD4 (Programmed cell death protein 4) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer.Open in Atlas onco.cc
PDE3A: PDE3A (cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Myeloproliferative neoplasms and Essential thrombocythaemia.Open in Atlas onco.cc
PDE3B: PDE3B (cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Myeloproliferative neoplasms and Essential thrombocythaemia.Open in Atlas onco.cc
PDGFB: PDGFB (Platelet-derived growth factor subunit B) is a gene. The public catalogues list it as a drug target, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Sarcomas and Dermatofibro...Open in Atlas onco.cc
PDGFRA: PDGFRA is a growth-factor receptor mutated in about 10% of GISTs, including the D842V mutation that resists imatinib but responds to avapritinib.Open in Atlas onco.cc
PDGFRB: A growth receptor on connective-tissue and blood-vessel cells. Imatinib works in rare cancers driven by PDGFRB fusions, such as dermatofibrosarcoma protuberans and some chronic myeloid neoplasms with eosinophilia.Open in Atlas onco.cc
PDGFRL: PDGFRL (Platelet-derived growth factor receptor-like protein) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Colorectal cancer.Open in Atlas onco.cc
PDLIM5: PDLIM5 (PDZ and LIM domain protein 5) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer.Open in Atlas onco.cc
PDPK1: PDPK1 (3-phosphoinositide-dependent protein kinase 1) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis...Open in Atlas onco.cc
PDZD2: PDZD2 (PDZ domain-containing protein 2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Mesothelioma and Pleu...Open in Atlas onco.cc
PEG3: PEG3 (Paternally-expressed gene 3 protein) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Pancreatic ductal...Open in Atlas onco.cc
PER1: PER1 (Period circadian protein homolog 1) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Skin cancer, Lung cancer, Gastric & gastro-oesophageal junction cance...Open in Atlas onco.cc
PER3: PER3 (Period circadian protein homolog 3) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Non-small-cell lung cancer.Open in Atlas onco.cc
PGAP3: PGAP3 is an enzyme gene in the HER2 amplicon that remodels the lipid anchors of cell-surface proteins.Open in Atlas onco.cc
PHF6: PHF6 (PHD finger protein 6) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Leukaemia, Non-Hodg...Open in Atlas onco.cc
PHLDA1: PHLDA1 is a growth-factor-responsive gene involved in cell death; it is high in benign moles and falls as melanoma progresses.Open in Atlas onco.cc
PHLPP2: PHLPP2 is a phosphatase that switches AKT off; it is lost in most colorectal cancers, which leaves the survival pathway on.Open in Atlas onco.cc
PHOX2B: PHOX2B (Paired mesoderm homeobox protein 2B) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Skin cancer, Colorectal cancer, Lung cancer and 2 more.Open in Atlas onco.cc
PI3K delta (PIK3CD): The blood-cell version of the PI3K survival signal that keeps B cells alive. Idelalisib, duvelisib and copanlisib block it in chronic lymphocytic leukaemia and follicular lymphoma, at the price of immune-related colitis, liver inflammation and infections th...Open in Atlas onco.cc
PI4KA: PI4KA (Phosphatidylinositol 4-kinase alpha) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient coho...Open in Atlas onco.cc
PICALM: PICALM (Phosphatidylinositol-binding clathrin assembly protein) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of p...Open in Atlas onco.cc
PIK3CA / PI3K-alpha: PIK3CA is the most commonly mutated gene in hormone-driven breast cancer. Drugs against it work, but hitting it cleanly without raising blood sugar took years.Open in Atlas onco.cc
PIK3CB: PIK3CB is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis,...Open in Atlas onco.cc
PIK3CG: PIK3CG (Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage...Open in Atlas onco.cc
PIK3R1: PIK3R1 (Phosphatidylinositol 3-kinase regulatory subunit alpha) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties i...Open in Atlas onco.cc
PIK3R2: PIK3R2 (Phosphatidylinositol 3-kinase regulatory subunit beta) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Melanoma.Open in Atlas onco.cc
PIK3R3: PIK3R3 (Phosphatidylinositol 3-kinase regulatory subunit gamma) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer.Open in Atlas onco.cc
PIK3R5: PIK3R5 (Phosphoinositide 3-kinase regulatory subunit 5) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.Open in Atlas onco.cc
PIM1: PIM1 is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, pr...Open in Atlas onco.cc
PIM2: PIM2 (Serine/threonine-protein kinase pim-2) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug res...Open in Atlas onco.cc
PLAG1: PLAG1 (Zinc finger protein PLAG1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer...Open in Atlas onco.cc
PLCG1: PLCG1 (1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, progno...Open in Atlas onco.cc
PLCG2: PLCG2 (1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Chronic lymphoc...Open in Atlas onco.cc
PLK1: PLK1 (Serine/threonine-protein kinase PLK1) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug resp...Open in Atlas onco.cc
PLXNB2: PLXNB2 (Plexin-B2) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
PLXNC1: PLXNC1 (Plexin-C1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Melanoma.Open in Atlas onco.cc
PML: PML (PML nuclear body scaffold) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, a tumour suppressor, a biomarker and a fusion partner, and an approved or late-stage drug is recorded against it. Tie...Open in Atlas onco.cc
PMS1: PMS1 (PMS1 protein homolog 1) is a gene. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role. Tied to Colorectal cancer.Open in Atlas onco.cc
PMS2: PMS2 (Mismatch repair endonuclease PMS2) is an enzyme. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Endometria...Open in Atlas onco.cc
PNMT: PNMT makes adrenaline from noradrenaline in the adrenal gland; in breast cancer it matters only because it lies inside the HER2 amplicon.Open in Atlas onco.cc
PNPLA3: PNPLA3 (1-acylglycerol-3-phosphate O-acyltransferase PNPLA3) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Hepatocellular carcinoma.Open in Atlas onco.cc
POGLUT3: POGLUT3 (Protein O-glucosyltransferase 3) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer.Open in Atlas onco.cc
POLA2: POLA2 (DNA polymerase alpha subunit B) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Non-Hodgkin lymphoma, Lung cancer and 5 more.Open in Atlas onco.cc
POLD1: POLD1 (DNA polymerase delta catalytic subunit) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, a tumour suppressor, a biomarker and a DNA repair gene, and an approved or late-stage drug is recorded...Open in Atlas onco.cc
POLD2: POLD2 (DNA polymerase delta subunit 2) is a gene. The public catalogues list it as a drug target and a DNA repair gene, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Non-Hodgkin lymphoma, Lung cancer and 5 more.Open in Atlas onco.cc
POLD3: POLD3 (DNA polymerase delta subunit 3) is a gene. The public catalogues list it as a drug target and a DNA repair gene, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Non-Hodgkin lymphoma, Lung cancer and 5 more.Open in Atlas onco.cc
POLD4: POLD4 (DNA polymerase delta subunit 4) is a gene. The public catalogues list it as a drug target and a DNA repair gene, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Non-Hodgkin lymphoma, Lung cancer and 5 more.Open in Atlas onco.cc
POLE: POLE (DNA polymerase epsilon catalytic subunit A) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a biomarker and a DNA repair gene, and an approved or late-stage drug is recorded aga...Open in Atlas onco.cc
POLE2: POLE2 (DNA polymerase epsilon subunit 2) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Non-Hodgkin lymphoma, Leukaemia, Lung cancer and 5 more.Open in Atlas onco.cc
POLE3: POLE3 (DNA polymerase epsilon subunit 3) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Non-Hodgkin lymphoma, Lung cancer and 5 more.Open in Atlas onco.cc
POLE4: POLE4 (DNA polymerase epsilon subunit 4) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-small-cell lung cancer.Open in Atlas onco.cc
POLK: POLK (DNA polymerase kappa) is an enzyme. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role. Tied to Prostate cancer.Open in Atlas onco.cc
POLQ: POLQ (DNA polymerase theta) is an enzyme. The public catalogues list it as an oncogene driver, a tumour suppressor and a DNA repair gene, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Lung cancer, Endometrial cancer, Brea...Open in Atlas onco.cc
POT1: POT1 (Protection of telomeres protein 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug...Open in Atlas onco.cc
POU2AF1: POU2AF1 (POU domain class 2-associating factor 1) is a protein that switches other genes on and off. The public catalogues list it as a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to...Open in Atlas onco.cc
POU2F2: POU2F2 (POU domain, class 2, transcription factor 2) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis...Open in Atlas onco.cc
POU5F1: POU5F1 (POU domain, class 5, transcription factor 1) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to...Open in Atlas onco.cc
POU5F1B: POU5F1B (POU domain, class 5, transcription factor 1B) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer and Colorectal cancer.Open in Atlas onco.cc
PPARG: PPARG (Peroxisome proliferator-activated receptor gamma) is a protein that switches other genes on and off. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal...Open in Atlas onco.cc
PPAT: PPAT (Amidophosphoribosyltransferase) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Non-Hodgkin lymphoma and Acute lymphoblastic leukaemia.Open in Atlas onco.cc
PPFIBP1: PPFIBP1 (Liprin-beta-1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
PPM1B: PPM1B (Protein phosphatase 1B) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
PPM1D: PPM1D (Protein phosphatase 1D) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Ovarian cancer,...Open in Atlas onco.cc
PPP1R14A: PPP1R14A (Protein phosphatase 1 regulatory subunit 14A) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer.Open in Atlas onco.cc
PPP1R15A: PPP1R15A (Protein phosphatase 1 regulatory subunit 15A) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer.Open in Atlas onco.cc
PPP2CA: PPP2CA (Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform) is an enzyme. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.Open in Atlas onco.cc
PPP2CB: PPP2CB (Serine/threonine-protein phosphatase 2A catalytic subunit beta isoform) is an enzyme. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.Open in Atlas onco.cc
PPP2R1A: PPP2R1A is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.Open in Atlas onco.cc
PPP2R1B: PPP2R1B (Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A beta isoform) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
PPP2R2A: PPP2R2A (Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B alpha isoform) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to...Open in Atlas onco.cc
PPP2R5A: PPP2R5A (Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit alpha isoform) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
PPP2R5B: PPP2R5B (Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit beta isoform) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
PPP2R5C: PPP2R5C (Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit gamma isoform) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
PPP2R5D: PPP2R5D (Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit delta isoform) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
PPP2R5E: PPP2R5E (Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit epsilon isoform) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
PPP3CA: PPP3CA (Protein phosphatase 3 catalytic subunit alpha) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Gastri...Open in Atlas onco.cc
PPP6C: PPP6C (Serine/threonine-protein phosphatase 6 catalytic subunit) is an enzyme. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Skin cancer, Melano...Open in Atlas onco.cc
PRAME: PRAME is a cancer-testis antigen: a protein normally confined to the testis that about 90% of cutaneous melanomas and substantial fractions of ovarian, lung, endometrial and uveal cancers switch on. Because it sits inside the cell, drugs reach it only as pe...Open in Atlas onco.cc
PRC1: PRC1 (Protein regulator of cytokinesis 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Breast cancer.Open in Atlas onco.cc
PRCC: PRCC (Proline-rich protein PRCC) is a gene. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role.Open in Atlas onco.cc
PRDM1: PRDM1 (PR domain zinc finger protein 1) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug resp...Open in Atlas onco.cc
PRDM16: PRDM16 (Histone-lysine N-methyltransferase PRDM16) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Multiple myeloma, Brea...Open in Atlas onco.cc
PRDM2: PRDM2 (PR domain zinc finger protein 2) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatoc...Open in Atlas onco.cc
PREX2: PREX2 is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.Open in Atlas onco.cc
PRF1: PRF1 (Perforin-1) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Non-Hodgkin lymphoma, Leukaemia, Skin cancer and 2 more.Open in Atlas onco.cc
PRIM1: PRIM1 (DNA primase small subunit) is a protein that switches other genes on and off. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Breast cancer, Leukaemia, Non-Hodgkin lymphoma and 5 more.Open in Atlas onco.cc
PRIM2: PRIM2 (DNA primase large subunit) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Lung cancer, Leukaemia, Non-Hodgkin lymphoma and 5 more.Open in Atlas onco.cc
PRKAA2: PRKAA2 (5'-AMP-activated protein kinase catalytic subunit alpha-2) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its vari...Open in Atlas onco.cc
PRKACA: PRKACA (cAMP-dependent protein kinase catalytic subunit alpha) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. In the public catalogues the evidence so far is association rather than a proven role. Tied to Hepatoce...Open in Atlas onco.cc
PRKAR1A: PRKAR1A (cAMP-dependent protein kinase type I-alpha regulatory subunit) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its vari...Open in Atlas onco.cc
PRKCB: PRKCB (Protein kinase C beta type) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and an approved or late-stage drug is recorded...Open in Atlas onco.cc
PRKCD: PRKCD (Protein kinase C delta type) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a tumour suppressor, and an approved or late-stage drug is recorded against it....Open in Atlas onco.cc
PRKCE: PRKCE (Protein kinase C epsilon type) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, My...Open in Atlas onco.cc
PRKCG: PRKCG (Protein kinase C gamma type) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myel...Open in Atlas onco.cc
PRKCH: PRKCH (PRKCH upstream open reading frame 2) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myeloproliferative neoplasms, Systemic mastocytosis and 1 more.Open in Atlas onco.cc
PRKCI: PRKCI (Protein kinase C iota type) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myelo...Open in Atlas onco.cc
PRKCQ: PRKCQ (Protein kinase C theta type) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myel...Open in Atlas onco.cc
PRKCZ: PRKCZ (Protein kinase C zeta type) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myelo...Open in Atlas onco.cc
PRKD1: PRKD1 (Serine/threonine-protein kinase D1) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver and a tumour suppressor, and an approved or late-stage d...Open in Atlas onco.cc
PRKD2: PRKD2 (Serine/threonine-protein kinase D2) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohor...Open in Atlas onco.cc
PRKD3: PRKD3 (Serine/threonine-protein kinase D3) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemi...Open in Atlas onco.cc
PRKDC: PRKDC (DNA-dependent protein kinase catalytic subunit) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties i...Open in Atlas onco.cc
PRKN: PRKN (E3 ubiquitin-protein ligase parkin) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cance...Open in Atlas onco.cc
PRMT5 (MTAP-deleted cancers): An enzyme that cancers lacking the MTAP gene (about 10-15% of all tumours) depend on more than normal cells do; new inhibitors designed to exploit that difference are in late trials.Open in Atlas onco.cc
PRNCR1: PRNCR1 (prostate cancer associated non-coding RNA 1) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer.Open in Atlas onco.cc
Progesterone receptor (PGR): The progesterone receptor is the hormone receptor that, alongside the oestrogen receptor, marks breast cancers likely to respond to hormone therapy, and it is the target of the progestins megestrol and medroxyprogesterone used in endometrial and breast cancer.Open in Atlas onco.cc
PROM1: PROM1 (Prominin-1) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Hepatocellular carcinoma.Open in Atlas onco.cc
Prostatic acid phosphatase (ACP3, PAP): Prostatic acid phosphatase is an enzyme made almost only by the prostate; the cell vaccine sipuleucel-T trains a patient's immune cells against it.Open in Atlas onco.cc
Proteasome (PSMB5): The cell's protein shredder. Myeloma cells make huge amounts of antibody protein and depend on the proteasome to clear the waste, so blocking it kills them.Open in Atlas onco.cc
Protein kinase C family (PKC): Protein kinase C is a family of signalling enzymes; the AML drug midostaurin started life as a PKC inhibitor and still hits the family alongside FLT3.Open in Atlas onco.cc
PRPS1: PRPS1 (Ribose-phosphate pyrophosphokinase 1) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, pro...Open in Atlas onco.cc
PRUNE2: PRUNE2 (Protein prune homolog 2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Neuroblastoma.Open in Atlas onco.cc
PSCA: PSCA (Prostate stem cell antigen) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer.Open in Atlas onco.cc
PSEN2: PSEN2 (Presenilin-2) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Desmoid tumour.Open in Atlas onco.cc
PSENEN: PSENEN (Gamma-secretase subunit PEN-2) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Desmoid tumour.Open in Atlas onco.cc
PSIP1: PSIP1 (PC4 and SFRS1-interacting protein) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied t...Open in Atlas onco.cc
PSMA: A protein on prostate cancer cells that lets doctors both see the cancer on a PET scan and hit it with a radioactive drug.Open in Atlas onco.cc
PSMA1: PSMA1 (Proteasome subunit alpha type-1) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.Open in Atlas onco.cc
PSMA2: PSMA2 (Proteasome subunit alpha type-2) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.Open in Atlas onco.cc
PSMA3: PSMA3 (Proteasome subunit alpha type-3) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.Open in Atlas onco.cc
PSMA4: PSMA4 (Proteasome subunit alpha type-4) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.Open in Atlas onco.cc
PSMA5: PSMA5 (Proteasome subunit alpha type-5) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.Open in Atlas onco.cc
PSMA6: PSMA6 (Proteasome subunit alpha type-6) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.Open in Atlas onco.cc
PSMA7: PSMA7 (Proteasome subunit alpha type-7) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.Open in Atlas onco.cc
PSMA8: PSMA8 (Proteasome subunit alpha-type 8) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.Open in Atlas onco.cc
PSMB1: PSMB1 (Proteasome subunit beta type-1) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.Open in Atlas onco.cc
PSMB10: PSMB10 (Proteasome subunit beta type-10) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.Open in Atlas onco.cc
PSMB11: PSMB11 (Proteasome subunit beta type-11) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.Open in Atlas onco.cc
PSMB2: PSMB2 (Proteasome subunit beta type-2) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.Open in Atlas onco.cc
PSMB3: PSMB3 (Proteasome subunit beta type-3) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.Open in Atlas onco.cc
PSMB4: PSMB4 (Proteasome subunit beta type-4) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.Open in Atlas onco.cc
PSMB6: PSMB6 (Proteasome subunit beta type-6) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.Open in Atlas onco.cc
PSMB7: PSMB7 (Proteasome subunit beta type-7) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.Open in Atlas onco.cc
PSMB8: PSMB8 (Proteasome subunit beta type-8) is an enzyme. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Gastric & gastro-oesophageal junction cancer, Non-Hodgk...Open in Atlas onco.cc
PSMB9: PSMB9 (Proteasome subunit beta type-9) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.Open in Atlas onco.cc
PSMC1: PSMC1 (26S proteasome regulatory subunit 4) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.Open in Atlas onco.cc
PSMC2: PSMC2 (26S proteasome regulatory subunit 7) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.Open in Atlas onco.cc
PSMC3: PSMC3 (26S proteasome regulatory subunit 6A) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.Open in Atlas onco.cc
PSMC4: PSMC4 (26S proteasome regulatory subunit 6B) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.Open in Atlas onco.cc
PSMC5: PSMC5 (26S proteasome regulatory subunit 8) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.Open in Atlas onco.cc
PSMC6: PSMC6 (26S proteasome regulatory subunit 10B) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.Open in Atlas onco.cc
PSMD1: PSMD1 (26S proteasome non-ATPase regulatory subunit 1) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.Open in Atlas onco.cc
PSMD11: PSMD11 (26S proteasome non-ATPase regulatory subunit 11) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.Open in Atlas onco.cc
PSMD12: PSMD12 (26S proteasome non-ATPase regulatory subunit 12) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.Open in Atlas onco.cc
PSMD13: PSMD13 (26S proteasome non-ATPase regulatory subunit 13) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.Open in Atlas onco.cc
PSMD14: PSMD14 (Ubiquitin C-terminal hydrolase PSMD14) is an enzyme. The public catalogues list it as a drug target and a DNA repair gene, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymp...Open in Atlas onco.cc
PSMD2: PSMD2 (26S proteasome non-ATPase regulatory subunit 2) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.Open in Atlas onco.cc
PSMD3: PSMD3 (26S proteasome non-ATPase regulatory subunit 3) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.Open in Atlas onco.cc
PSMD4: PSMD4 (26S proteasome non-ATPase regulatory subunit 4) is a gene. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Colorectal cancer, Breast cancer and 2 more.Open in Atlas onco.cc
PSMD6: PSMD6 (26S proteasome non-ATPase regulatory subunit 6) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.Open in Atlas onco.cc
PSMD7: PSMD7 (26S proteasome non-ATPase regulatory subunit 7) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.Open in Atlas onco.cc
PSMD8: PSMD8 (26S proteasome non-ATPase regulatory subunit 8) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.Open in Atlas onco.cc
PSPC1: PSPC1 (Paraspeckle component 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Non-small-cell lung cancer.Open in Atlas onco.cc
PTCH1 (Patched 1): PTCH1 is the brake on the hedgehog growth pathway. When it is lost, as in nearly all basal cell carcinomas and in Gorlin syndrome, the pathway runs unchecked; vismodegib and sonidegib put the brake back one step down, at smoothened.Open in Atlas onco.cc
PTEN: PTEN is the brake on the PI3K growth pathway; when a tumour loses it the pathway runs unchecked, which is why PTEN loss now selects patients for the AKT inhibitor capivasertib.Open in Atlas onco.cc
PTGS1: PTGS1 (Prostaglandin G/H synthase 1) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.Open in Atlas onco.cc
PTK6 (BRK): PTK6, also called breast tumour kinase, is over-expressed in most breast cancers and is one of the off-targets of dasatinib; drugs made specifically against it are still experimental.Open in Atlas onco.cc
PTK7: PTK7 is a cell-surface protein being studied as an address for cancer-directed treatments.Open in Atlas onco.cc
PTMA: PTMA (Prothymosin alpha) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Testicular germ cell tumours.Open in Atlas onco.cc
PTP4A3: PTP4A3 (Protein tyrosine phosphatase type IVA 3) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer.Open in Atlas onco.cc
PTPN12: PTPN12 (Tyrosine-protein phosphatase non-receptor type 12) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Triple-negative breast cancer.Open in Atlas onco.cc
PTPN13: PTPN13 (Tyrosine-protein phosphatase non-receptor type 13) is an enzyme. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial canc...Open in Atlas onco.cc
PTPN14: PTPN14 (Tyrosine-protein phosphatase non-receptor type 14) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Ba...Open in Atlas onco.cc
PTPN22: PTPN22 (Tyrosine-protein phosphatase non-receptor type 22) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
PTPN3: PTPN3 (Tyrosine-protein phosphatase non-receptor type 3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Panc...Open in Atlas onco.cc
PTPN6: PTPN6 (Tyrosine-protein phosphatase non-receptor type 6) is an enzyme. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Hepato...Open in Atlas onco.cc
PTPRB: PTPRB (Receptor-type tyrosine-protein phosphatase beta) is an enzyme. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response....Open in Atlas onco.cc
PTPRC: PTPRC (Receptor-type tyrosine-protein phosphatase C) is an enzyme. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Anal cancer, Hepatocellular car...Open in Atlas onco.cc
PTPRD: PTPRD (Receptor-type tyrosine-protein phosphatase delta) is an enzyme. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response....Open in Atlas onco.cc
PTPRF: PTPRF (Receptor-type tyrosine-protein phosphatase F) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-small-cell lung cancer.Open in Atlas onco.cc
PTPRK: PTPRK (Receptor-type tyrosine-protein phosphatase kappa) is an enzyme. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Bladder & ur...Open in Atlas onco.cc
PTPRT: PTPRT (Receptor-type tyrosine-protein phosphatase T) is an enzyme. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tie...Open in Atlas onco.cc
PTTG1: PTTG1 (Securin) is a gene. The public catalogues list it as a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Meningioma.Open in Atlas onco.cc
PVRIG (CD112R): PVRIG is a brake on killer T cells and NK cells that reads CD112 on tumour cells, a cousin of the TIGIT pair. The antibody COM701 blocks it and is being tested in ovarian cancer.Open in Atlas onco.cc
PWWP2A: PWWP2A (PWWP domain-containing protein 2A) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Gastric & gastro-o...Open in Atlas onco.cc
PXDNL: PXDNL (Probable oxidoreductase PXDNL) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-small-cell lung cancer.Open in Atlas onco.cc

Q

QKI: QKI (KH domain-containing RNA-binding protein QKI) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient coho...Open in Atlas onco.cc

R

RABL3: RABL3 (Rab-like protein 3) is an enzyme. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pancreatic ductal adenocarcinoma.Open in Atlas onco.cc
RAC1: RAC1 (Ras-related C3 botulinum toxin substrate 1) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or dr...Open in Atlas onco.cc
RAD21: RAD21 (Double-strand-break repair protein rad21 homolog) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a DNA repair gene, and it is called a cancer driver by mutation analysis...Open in Atlas onco.cc
RAD23B: RAD23B (Lysine-specific demethylase RAD23B) is an enzyme. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Sarcomas.Open in Atlas onco.cc
RAD50: RAD50 (DNA repair protein RAD50) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or...Open in Atlas onco.cc
RAD51: RAD51 (DNA repair protein RAD51 homolog 1) is an enzyme. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role. Tied to Breast cancer.Open in Atlas onco.cc
RAD51B: RAD51B (DNA repair protein RAD51 homolog 2) is a gene. The public catalogues list it as a drug target, a biomarker, a fusion partner and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast canc...Open in Atlas onco.cc
RAD51C: RAD51C (DNA repair protein RAD51 homolog 3) is a gene. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer, Breast cancer...Open in Atlas onco.cc
RAD51D: RAD51D (DNA repair protein RAD51 homolog 4) is a gene. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer, Breast cancer...Open in Atlas onco.cc
RAD54L: RAD54L (DNA repair and recombination protein RAD54-like) is an enzyme. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer.Open in Atlas onco.cc
RANBP2: RANBP2 (E3 SUMO-protein ligase RanBP2) is an enzyme. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Lung cancer, Hepatocellular...Open in Atlas onco.cc
RANK ligand (RANKL): RANK ligand is the signal that tells bone-dissolving cells to get to work. Cancers in the bone hijack it; denosumab blocks it to prevent fractures and other bone complications.Open in Atlas onco.cc
RAP1A: RAP1A (Ras-related protein Rap-1A) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
RAP1B: RAP1B (Ras-related protein Rap-1b) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial cancer.Open in Atlas onco.cc
RAP1GDS1: RAP1GDS1 (Rap1 GTPase-GDP dissociation stimulator 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation anal...Open in Atlas onco.cc
RARB: RARB (Retinoic acid receptor beta) is a protein that switches other genes on and off. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myeloproliferative neoplasms, Acute myeloid l...Open in Atlas onco.cc
RARG: RARG (Retinoic acid receptor gamma) is a protein that switches other genes on and off. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myeloproliferative neoplasms, Acute myeloid...Open in Atlas onco.cc
RASA1: RASA1 (Ras GTPase-activating protein 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug...Open in Atlas onco.cc
RASA2: RASA2 (Ras GTPase-activating protein 2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Diffuse large B-cell...Open in Atlas onco.cc
RASSF6: RASSF6 (Ras association domain-containing protein 6) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer.Open in Atlas onco.cc
RB1: RB1 (Retinoblastoma-associated protein) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognos...Open in Atlas onco.cc
RBBP7: RBBP7 (Histone-binding protein RBBP7) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
RBBP8: RBBP8 (DNA endonuclease RBBP8) is an enzyme. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role.Open in Atlas onco.cc
RBFOX1: RBFOX1 (RNA binding protein fox-1 homolog 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer.Open in Atlas onco.cc
RBM10: RBM10 (Ribosome biogenesis inhibitor MINAS-60) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts....Open in Atlas onco.cc
RBM15: RBM15 (RNA-binding protein 15) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Non-small...Open in Atlas onco.cc
RBM38: RBM38 (RNA-binding protein 38) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Diffuse large B-cell lymphoma.Open in Atlas onco.cc
RBM39: RBM39 (RNA-binding protein 39) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Endometrial cancer.Open in Atlas onco.cc
RBPJ: RBPJ (Recombining binding protein suppressor of hairless) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
RBX1: RBX1 (E3 ubiquitin-protein ligase RBX1) is an enzyme. The public catalogues list it as a drug target and a DNA repair gene, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma, Myelodysplastic syndromes...Open in Atlas onco.cc
RCC2: RCC2 (regulator of chromosome condensation 2) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
RECQL4: RECQL4 (ATP-dependent DNA helicase Q4) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Sarcomas, Gastric & ga...Open in Atlas onco.cc
REL: REL (Proto-oncogene c-Rel) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer and Diffuse large B-cell lym...Open in Atlas onco.cc
RELA: RELA (Transcription factor p65) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Gastric...Open in Atlas onco.cc
REST: REST (RE1-silencing transcription factor) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Wilms tumour.Open in Atlas onco.cc
RET: RET is a kinase altered in thyroid cancer and a small slice of lung cancer, treatable with one selective pill regardless of where the tumour is.Open in Atlas onco.cc
Retinoic acid receptor alpha (RARA): The retinoic acid receptor that, fused to PML in acute promyelocytic leukaemia, blocks white blood cells from maturing. All-trans retinoic acid releases the block and arsenic trioxide destroys the fusion protein, turning a once rapidly fatal leukaemia into...Open in Atlas onco.cc
Retinoid X receptor (RXR): The retinoid X receptor is a switch inside cells that vitamin A-like molecules turn on to change which genes are active; bexarotene uses it to make lymphoma cells in the skin mature and die.Open in Atlas onco.cc
RFWD3: RFWD3 (E3 ubiquitin-protein ligase RFWD3) is an enzyme. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role.Open in Atlas onco.cc
RFX7: RFX7 (DNA-binding protein RFX7) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer and Burkitt lymphoma.Open in Atlas onco.cc
RGPD3: RGPD3 (RanBP2-like and GRIP domain-containing protein 3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patien...Open in Atlas onco.cc
RGS17: RGS17 (Regulator of G protein signalling 17) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer.Open in Atlas onco.cc
RGS7: RGS7 (Regulator of G protein signalling 7) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to B...Open in Atlas onco.cc
RHEB: RHEB (GTP-binding protein Rheb) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Renal cell carcinoma.Open in Atlas onco.cc
RHOA: RHOA (Transforming protein RhoA) is an enzyme. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Gastric...Open in Atlas onco.cc
RHOBTB2: RHOBTB2 (Rho-related BTB domain-containing protein 2) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
RHOH: RHOH (Rho-related GTP-binding protein RhoH) is an enzyme. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Breast cancer.Open in Atlas onco.cc
RHPN2: RHPN2 (Rhophilin-2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer and...Open in Atlas onco.cc
Ribonucleotide reductase (RRM1): The enzyme that makes DNA building blocks from RNA building blocks. Gemcitabine's active form shuts it down and hydroxyurea quenches its catalytic radical, starving dividing cells of the nucleotides they need.Open in Atlas onco.cc
RICTOR: RICTOR (Rapamycin-insensitive companion of mTOR) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cance...Open in Atlas onco.cc
RIPK1: RIPK1 (Receptor-interacting serine/threonine-protein kinase 1) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation anal...Open in Atlas onco.cc
RIT1: RIT1 (GTP-binding protein Rit1) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Endometrial cancer and Non-small-cell lung cancer.Open in Atlas onco.cc
RMI1: RMI1 (RecQ-mediated genome instability protein 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
RMI2: RMI2 (RecQ-mediated genome instability protein 2) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Non-Hodgkin lymphoma, Breast cancer, Lung cancer and 1 more.Open in Atlas onco.cc
RNASEL: RNASEL (2-5A-dependent ribonuclease) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer.Open in Atlas onco.cc
RNASET2: RNASET2 (Ribonuclease T2) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Basal cell carcinoma.Open in Atlas onco.cc
RNF213: RNF213 (E3 ubiquitin-protein ligase RNF213) is an enzyme. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer, Bladd...Open in Atlas onco.cc
RNF43: RNF43 (E3 ubiquitin-protein ligase RNF43) is an enzyme. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Pancreatic ductal adenocarcinoma, Colorect...Open in Atlas onco.cc
RNF6: RNF6 (E3 ubiquitin-protein ligase RNF6) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer and...Open in Atlas onco.cc
ROBO2: ROBO2 (Roundabout homolog 2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts....Open in Atlas onco.cc
ROBO4: ROBO4 (Roundabout homolog 4) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.Open in Atlas onco.cc
RON receptor (MST1R): RON is a receptor kinase from the same family as MET; multi-kinase drugs such as crizotinib and cabozantinib hit it as well as their main targets.Open in Atlas onco.cc
ROR1: ROR1 is a fetal pseudo-kinase receptor re-expressed on over 90% of chronic lymphocytic leukaemias, 30 to 50% of diffuse large B-cell lymphomas and 40 to 60% of triple-negative breast cancers, and largely absent from healthy adult tissue. Zilovertamab vedoti...Open in Atlas onco.cc
ROS1: A gene fusion in about 1-2% of lung cancers that responds for years to targeted pills, now in their third generation.Open in Atlas onco.cc
RPL10: RPL10 (Large ribosomal subunit protein uL16) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target and an oncogene driver, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied...Open in Atlas onco.cc
RPL22: RPL22 (Large ribosomal subunit protein eL22) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target and a tumour suppressor, and clinical evidence ties its variants to diagnosis, prognosis or drug response...Open in Atlas onco.cc
RPL5: RPL5 (Large ribosomal subunit protein uL18) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver and a tumour suppressor, and clinical evidence ties its variants to diagnosis, prognos...Open in Atlas onco.cc
RPS19: RPS19 (Small ribosomal subunit protein eS19) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.Open in Atlas onco.cc
RPS24: RPS24 (Small ribosomal subunit protein eS24) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.Open in Atlas onco.cc
RPS26: RPS26 (Small ribosomal subunit protein eS26) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.Open in Atlas onco.cc
RPS27: RPS27 (Small ribosomal subunit protein eS27) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.Open in Atlas onco.cc
RPS27A: RPS27A (Ubiquitin-ribosomal protein eS31 fusion protein) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.Open in Atlas onco.cc
RPS29: RPS29 (Small ribosomal subunit protein uS14) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia and Myeloproliferative neoplasms.Open in Atlas onco.cc
RPS3A: RPS3A (Small ribosomal subunit protein eS1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Multiple myeloma.Open in Atlas onco.cc
RPS6: RPS6 (Small ribosomal subunit protein eS6) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer.Open in Atlas onco.cc
RPS6KA3: RPS6KA3 (Ribosomal protein S6 kinase alpha-3) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient c...Open in Atlas onco.cc
RPS7: RPS7 (Small ribosomal subunit protein eS7) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.Open in Atlas onco.cc
RRAGC: RRAGC (Ras-related GTP-binding protein C) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Non-Hodgkin lymphoma.Open in Atlas onco.cc
RRAS2: RRAS2 (Ras-related protein R-Ras2) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Endometri...Open in Atlas onco.cc
RRM2: RRM2 (Ribonucleoside-diphosphate reductase subunit M2) is an enzyme. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Lung cancer, Leukaemia, Breast cancer and 5 more.Open in Atlas onco.cc
RRM2B: RRM2B (Ribonucleoside-diphosphate reductase subunit M2 B) is an enzyme. The public catalogues list it as a drug target and a DNA repair gene, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Non-Hodgkin lymphoma, Breast cancer a...Open in Atlas onco.cc
RRN3: RRN3 (RNA polymerase I-specific transcription initiation factor RRN3) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied t...Open in Atlas onco.cc
RSF1: RSF1 (Remodeling and spacing factor 1) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer.Open in Atlas onco.cc
RSPO2: RSPO2 (R-spondin-2) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer, Breast cancer and Colorectal ca...Open in Atlas onco.cc
RSPO3: RSPO3 (R-spondin-3) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Breast cancer and Lung cancer.Open in Atlas onco.cc
RTEL1: RTEL1 (Regulator of telomere elongation helicase 1) is an enzyme. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role. Tied to Leukaemia, Myeloproliferative neoplasms and Acute myeloid leukaemia.Open in Atlas onco.cc
RUNX1: RUNX1 (Runt-related transcription factor 1) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants...Open in Atlas onco.cc
RUNX1T1: RUNX1T1 (RUNX1 partner transcriptional co-repressor 1) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of...Open in Atlas onco.cc

S

S100B: S100B (S100 calcium binding protein B) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.Open in Atlas onco.cc
S1PR1: S1PR1 (Sphingosine 1-phosphate receptor 1) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Mantle cell lymphoma.Open in Atlas onco.cc
S1PR2: S1PR2 (Sphingosine 1-phosphate receptor 2) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.Open in Atlas onco.cc
SALL4: SALL4 (Sal-like protein 4) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Skin cancer, Colorectal cancer, Gastric &...Open in Atlas onco.cc
SAMD9: SAMD9 (Sterile alpha motif domain-containing protein 9) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Myelodysplastic syndromes / neoplasms.Open in Atlas onco.cc
SAMD9L: SAMD9L (Sterile alpha motif domain-containing protein 9-like) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Myelodysplastic syndromes / neoplasms.Open in Atlas onco.cc
SAMHD1: SAMHD1 (Deoxynucleoside triphosphate triphosphohydrolase SAMHD1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a DNA repair gene, and it is called a cancer driver by mutation analysis of...Open in Atlas onco.cc
SBDS: SBDS (Ribosome maturation protein SBDS) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Leukaemia, Myeloproliferative neoplasms and Acute myeloid leukaemia.Open in Atlas onco.cc
SCN10A: SCN10A (Sodium channel protein type 10 subunit alpha) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.Open in Atlas onco.cc
SCN11A: SCN11A (Sodium channel protein type 11 subunit alpha) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.Open in Atlas onco.cc
SCN1A: SCN1A (Sodium channel protein type 1 subunit alpha) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.Open in Atlas onco.cc
SCN2A: SCN2A (Sodium channel protein type 2 subunit alpha) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.Open in Atlas onco.cc
SCN3A: SCN3A (Sodium channel protein type 3 subunit alpha) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.Open in Atlas onco.cc
SCN4A: SCN4A (Sodium channel protein type 4 subunit alpha) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.Open in Atlas onco.cc
SCN5A: SCN5A (Sodium channel protein type 5 subunit alpha) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.Open in Atlas onco.cc
SCN7A: SCN7A (Sodium channel protein type 7 subunit alpha) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.Open in Atlas onco.cc
SCN8A: SCN8A (Sodium channel protein type 8 subunit alpha) is a gene. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Non-small-cell lung cancer.Open in Atlas onco.cc
SCN9A: SCN9A (Sodium channel protein type 9 subunit alpha) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.Open in Atlas onco.cc
SDC4: SDC4 (Syndecan-4) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Lung cancer and Non-small-cell lung cancer.Open in Atlas onco.cc
SDCBP: SDCBP (Syntenin-1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Head and neck squamous cell carcinoma.Open in Atlas onco.cc
SDCCAG8: SDCCAG8 (Serologically defined colon cancer antigen 8) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Thyroid cancer.Open in Atlas onco.cc
SDHA: SDHA (Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis,...Open in Atlas onco.cc
SDHAF2: SDHAF2 (Succinate dehydrogenase assembly factor 2, mitochondrial) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Neuroendocrine tumours and Ovarian cancer.Open in Atlas onco.cc
SDHB: SDHB (Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Neuroendoc...Open in Atlas onco.cc
SDHC: SDHC (Succinate dehydrogenase cytochrome b560 subunit, mitochondrial) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Neuroendocrine tumours, Breast cancer, Colorectal cancer and 1 more.Open in Atlas onco.cc
SDHD: SDHD (Succinate dehydrogenase [ubiquinone] cytochrome b small subunit, mitochondrial) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Neuroendocrine tumours.Open in Atlas onco.cc
SEM1: SEM1 (26S proteasome complex subunit SEM1) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.Open in Atlas onco.cc
SET: SET (SET nuclear proto-oncogene) is a gene. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Leukaemia, Non-Hodgkin lymphoma and Acute lymphoblastic leukaemia.Open in Atlas onco.cc
SETBP1: SETBP1 (SET-binding protein) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied...Open in Atlas onco.cc
SETD1B: SETD1B (Histone-lysine N-methyltransferase SETD1B) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis o...Open in Atlas onco.cc
SETD2: SETD2 (Histone-lysine N-methyltransferase SETD2) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker and a DNA repair gene, and an approved or late-stage dru...Open in Atlas onco.cc
SETDB1: SETDB1 (Histone-lysine N-methyltransferase SETDB1) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied...Open in Atlas onco.cc
SF3B1: SF3B1 (Splicing factor 3B subunit 1) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognos...Open in Atlas onco.cc
SFPQ: SFPQ (Splicing factor, proline- and glutamine-rich) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner and a DNA repair gene, and the evidence so far is association rather than a proven role.Open in Atlas onco.cc
SFRP4: SFRP4 (Secreted frizzled-related protein 4) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Colorectal cancer, Gastric & gastro-oesophageal junction cancer and Skin cancer.Open in Atlas onco.cc
SGK1: SGK1 (Serine/threonine-protein kinase Sgk1) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evid...Open in Atlas onco.cc
SH2B3: SH2B3 (SH2B adapter protein 3) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal ca...Open in Atlas onco.cc
SH3GL1: SH3GL1 (Endophilin-A2) is a gene. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role.Open in Atlas onco.cc
SHC1: SHC1 (SHC-transforming protein 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
SHP2 (PTPN11): SHP2 is an enzyme that sits between growth-factor receptors and RAS and keeps the RAS signal flowing. Blocking it removes the route by which KRAS-driven tumours bounce back from a KRAS inhibitor, which is why SHP2 inhibitors are being paired with KRAS G12C...Open in Atlas onco.cc
SHTN1: SHTN1 (Shootin-1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Mesothelioma and Pleural mesothelioma.Open in Atlas onco.cc
SIDT1: SIDT1 (SID1 transmembrane family member 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
Siglec-10: Siglec-10 is the receptor on macrophages and other blood cells that reads the CD24 'don't eat me' badge on tumour cells and calls off the attack.Open in Atlas onco.cc
SIM2: SIM2 (Single-minded homolog 2) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer.Open in Atlas onco.cc
SIN3A: SIN3A (Paired amphipathic helix protein Sin3a) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response...Open in Atlas onco.cc
SIRPA: SIRPA (Tyrosine-protein phosphatase non-receptor type substrate 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of pa...Open in Atlas onco.cc
SIRT1: SIRT1 (NAD-dependent protein deacetylase sirtuin-1) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to...Open in Atlas onco.cc
SIX1: SIX1 (Homeobox protein SIX1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer and Wilms tumour.Open in Atlas onco.cc
SKIL: SKIL (Ski-like protein) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer.Open in Atlas onco.cc
SKP1: SKP1 (S-phase kinase-associated protein 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
SLAMF7 (CS1): A surface protein found on myeloma cells and on natural killer cells. Elotuzumab tags myeloma cells with it while also switching on the natural killer cells that carry it.Open in Atlas onco.cc
SLC12A2: SLC12A2 (Solute carrier family 12 member 2) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Glioma & glioblastoma.Open in Atlas onco.cc
SLC14A1: SLC14A1 (Urea transporter 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
SLC22A3: SLC22A3 (Solute carrier family 22 member 3) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer.Open in Atlas onco.cc
SLC24A5: SLC24A5 (Sodium/potassium/calcium exchanger 5) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Skin cancer.Open in Atlas onco.cc
SLC25A11: SLC25A11 (Mitochondrial 2-oxoglutarate/malate carrier protein) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Neuroendocrine tumours.Open in Atlas onco.cc
SLC29A1: SLC29A1 (Equilibrative nucleoside transporter 1) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pancreatic ductal adenocarcinoma.Open in Atlas onco.cc
SLC34A2: SLC34A2 (Sodium-dependent phosphate transport protein 2B) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a fusion partner, and clinical evidence ties its vari...Open in Atlas onco.cc
SLC45A2: SLC45A2 (Membrane-associated transporter protein) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Skin cancer, Melanoma and Basal cell carcinoma.Open in Atlas onco.cc
SLC67A1: SLC67A1 (Solute carrier family 67 member A1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
SLC6A2: SLC6A2 (Sodium-dependent noradrenaline transporter) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Neuroendocrine tumours.Open in Atlas onco.cc
SLC6A3: SLC6A3 (Sodium-dependent dopamine transporter) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.Open in Atlas onco.cc
SLC6A4: SLC6A4 (Sodium-dependent serotonin transporter) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.Open in Atlas onco.cc
SLCO1B1: SLCO1B1 (Solute carrier organic anion transporter family member 1B1) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.Open in Atlas onco.cc
SLFN11: SLFN11 (Schlafen family member 11) is an enzyme. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Ewing sarcoma an...Open in Atlas onco.cc
SLX4: SLX4 (Structure-specific endonuclease subunit SLX4) is a gene. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role. Tied to Myelodysplastic syndromes / neoplasms, Leukaemia, Myeloproliferative...Open in Atlas onco.cc
SMAD2: SMAD2 (SMAD family member 2) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Color...Open in Atlas onco.cc
SMAD3: SMAD3 (SMAD family member 3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorect...Open in Atlas onco.cc
SMAD4: SMAD4 (SMAD family member 4) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug...Open in Atlas onco.cc
SMAD7: SMAD7 (SMAD family member 7) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Colorectal cancer.Open in Atlas onco.cc
SMARCA2: SMARCA2 (SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 2) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a biomarker, and clinical evidence ties its...Open in Atlas onco.cc
SMARCA4: SMARCA4 is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.Open in Atlas onco.cc
SMARCB1: SMARCB1 is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.Open in Atlas onco.cc
SMARCD1: SMARCD1 (SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily D member 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mut...Open in Atlas onco.cc
SMARCE1: SMARCE1 (SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily E member 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Meningioma.Open in Atlas onco.cc
SMC1A: SMC1A (Structural maintenance of chromosomes protein 1A) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a DNA repair gene, and it is called a cancer driver by mutation analysis of patient cohort...Open in Atlas onco.cc
Smoothened (hedgehog pathway): The switch in the hedgehog developmental pathway that is stuck on in basal cell carcinoma and some medulloblastomas; three approved pills block it.Open in Atlas onco.cc
SNAP25: SNAP25 (Synaptosomal-associated protein 25) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.Open in Atlas onco.cc
SNCAIP: SNCAIP (Synphilin-1) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.Open in Atlas onco.cc
SND1: SND1 (Staphylococcal nuclease domain-containing protein 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Cervical...Open in Atlas onco.cc
SNTB1: SNTB1 (Beta-1-syntrophin) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
SNW1: SNW1 (SNW domain-containing protein 1) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
SNX29: SNX29 (Sorting nexin-29) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & uro...Open in Atlas onco.cc
SOCS1: SOCS1 (Suppressor of cytokine signalling 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or dr...Open in Atlas onco.cc
Somatostatin receptor 2: Somatostatin receptor 2 is a hormone receptor densely present on neuroendocrine tumours, and was the first theranostic target to reach routine care.Open in Atlas onco.cc
SORCS3: SORCS3 (VPS10 domain-containing receptor SorCS3) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
SOS1: SOS1 (Son of sevenless homolog 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Endometria...Open in Atlas onco.cc
SOX10: SOX10 (Transcription factor SOX-10) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Melanoma.Open in Atlas onco.cc
SOX17: SOX17 (Transcription factor SOX-17) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Endometrial cancer.Open in Atlas onco.cc
SOX2: SOX2 (Transcription factor SOX-2) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Colorectal cancer, Skin cancer and Lung cancer.Open in Atlas onco.cc
SOX21: SOX21 (Transcription factor SOX-21) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer.Open in Atlas onco.cc
SOX9: SOX9 (Transcription factor SOX-9) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer.Open in Atlas onco.cc
SP140: SP140 (Nuclear body protein SP140) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Mu...Open in Atlas onco.cc
SPDL1: SPDL1 (spindle apparatus coiled-coil protein 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer.Open in Atlas onco.cc
SPEN: SPEN (Msx2-interacting protein) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Ti...Open in Atlas onco.cc
SPHK1: SPHK1 (Sphingosine kinase 1) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to C...Open in Atlas onco.cc
SPOP: SPOP (Speckle-type POZ protein) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response....Open in Atlas onco.cc
SPRY2: SPRY2 (Protein sprouty homolog 2) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer.Open in Atlas onco.cc
SPRY4: SPRY4 is a feedback brake on growth-factor signalling that the MAPK pathway switches on, so its expression is a read-out of how active that pathway is.Open in Atlas onco.cc
SPTBN1: SPTBN1 (Spectrin beta chain, non-erythrocytic 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
SQSTM1: SQSTM1 (Sequestosome-1) is a gene. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Sarcomas and Osteosarcoma.Open in Atlas onco.cc
SRC family kinases: The first cancer gene ever identified, a kinase that relays growth, adhesion and movement signals. Dasatinib and bosutinib were designed as BCR::ABL1 drugs but also hit SRC-family kinases, part of the reason they work when imatinib has failed.Open in Atlas onco.cc
SRD5A1: SRD5A1 (3-oxo-5-alpha-steroid 4-dehydrogenase 1) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Prostate cancer.Open in Atlas onco.cc
SRD5A3: SRD5A3 (Polyprenal reductase) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Prostate cancer.Open in Atlas onco.cc
SRGAP1: SRGAP1 (SLIT-ROBO Rho GTPase-activating protein 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Thyroid cancer.Open in Atlas onco.cc
SRGAP3: SRGAP3 (SLIT-ROBO Rho GTPase-activating protein 3) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied...Open in Atlas onco.cc
SRMS: SRMS (Tyrosine-protein kinase Srms) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myel...Open in Atlas onco.cc
SRSF2: SRSF2 (Serine/arginine-rich splicing factor 2) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug...Open in Atlas onco.cc
SRSF3: SRSF3 (Serine/arginine-rich splicing factor 3) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
SS18: SS18 (SS18 subunit of BAF chromatin remodeling complex) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Sarcomas and Synovial sar...Open in Atlas onco.cc
SSTR1: SSTR1 (Somatostatin receptor type 1) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Neuroendocrine tumours.Open in Atlas onco.cc
SSTR3: SSTR3 (Somatostatin receptor type 3) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Neuroendocrine tumours.Open in Atlas onco.cc
SSTR4: SSTR4 (Somatostatin receptor type 4) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Neuroendocrine tumours.Open in Atlas onco.cc
SSTR5: SSTR5 (Somatostatin receptor type 5) is a gene. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Neuroendocrine tumours.Open in Atlas onco.cc
SSX1: SSX1 (SSX family member 1) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Sarcomas and Synovial sarcoma.Open in Atlas onco.cc
SSX2: SSX2 (SSX family member 2) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Sarcomas and Synovial sarcoma.Open in Atlas onco.cc
STAG2: STAG2 (Cohesin subunit SA-2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. T...Open in Atlas onco.cc
STAG2-AS1: STAG2-AS1 (STAG2 antisense RNA 1) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Acute myeloid leukaemia.Open in Atlas onco.cc
STAG3: STAG3 (Cohesin subunit SA-3) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Melanoma.Open in Atlas onco.cc
STARD3: STARD3 (MLN64) moves cholesterol between cell compartments and is co-amplified with HER2 in breast cancer.Open in Atlas onco.cc
STAT1: STAT1 (Signal transducer and activator of transcription 1-alpha/beta) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug...Open in Atlas onco.cc
STAT3: STAT3 (Signal transducer and activator of transcription 3) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, progno...Open in Atlas onco.cc
STAT5 (STAT5A, STAT5B): STAT5 is the messenger that carries growth signals from FLT3, JAK2 and BCR::ABL1 into the nucleus and switches on survival genes in leukaemia cells. No drug hits STAT5 directly yet; the FLT3 and ABL inhibitors work by cutting off the signal above it.Open in Atlas onco.cc
STAT6: STAT6 (Signal transducer and activator of transcription 6) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug res...Open in Atlas onco.cc
STEAP1: STEAP1 is a protein on the surface of most prostate cancer cells, now the address for a T-cell engager in phase 3.Open in Atlas onco.cc
STIL: STIL (SCL-interrupting locus protein) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Non-Hodgkin lymphoma, Skin cancer and Leukaemia.Open in Atlas onco.cc
STK11: STK11 is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker and a DNA repair gene, and clinical evidence ties its varia...Open in Atlas onco.cc
STMN1: STMN1 (Stathmin) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Endometrial cancer.Open in Atlas onco.cc
STN1: STN1 (CST complex subunit STN1) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Melanoma.Open in Atlas onco.cc
STRN: STRN (Striatin) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Thyroid cancer and Lung cancer.Open in Atlas onco.cc
SUFU: SUFU (Suppressor of fused homolog) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug respo...Open in Atlas onco.cc
SUSD2: SUSD2 (Sushi domain-containing protein 2) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Non-small-cell lung cancer.Open in Atlas onco.cc
SUZ12: SUZ12 (Polycomb protein SUZ12) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied t...Open in Atlas onco.cc
SYK: SYK (Tyrosine-protein kinase SYK) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to O...Open in Atlas onco.cc

T

TAF15: TAF15 (TATA-binding protein-associated factor 2N) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts...Open in Atlas onco.cc
TAF1L: TAF1L (Transcription initiation factor TFIID subunit 1-like) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to...Open in Atlas onco.cc
TAL1: TAL1 (T-cell acute lymphocytic leukaemia protein 1) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcin...Open in Atlas onco.cc
TAL2: TAL2 (T-cell acute lymphocytic leukaemia protein 2) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tie...Open in Atlas onco.cc
TBK1: TBK1 (Serine/threonine-protein kinase TBK1) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prog...Open in Atlas onco.cc
TBL1XR1: TBL1XR1 (F-box-like/WD repeat-containing protein TBL1XR1) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prog...Open in Atlas onco.cc
TBPL1: TBPL1 (TATA box-binding protein-like 1) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
TBX1: TBX1 (T-box transcription factor TBX1) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
TBX3: TBX3 (T-box transcription factor TBX3) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast c...Open in Atlas onco.cc
TBXT: TBXT (T-box transcription factor T) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Chordoma.Open in Atlas onco.cc
TCEA1: TCEA1 (Transcription elongation factor A protein 1) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Oral cavity cancer.Open in Atlas onco.cc
TCF12: TCF12 (Transcription factor 12) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Glioma & glioblastoma.Open in Atlas onco.cc
TCF19: TCF19 (Transcription factor 19) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Melanoma.Open in Atlas onco.cc
TCF3: TCF3 (Transcription factor E2-alpha) is a protein that switches other genes on and off. The public catalogues list it as a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, N...Open in Atlas onco.cc
TCF4: TCF4 (Transcription factor 4) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Medulloblastoma and Paediatric...Open in Atlas onco.cc
TCF7L2: TCF7L2 (Transcription factor 7-like 2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer, Bre...Open in Atlas onco.cc
TCL1A: TCL1A (T-cell leukaemia/lymphoma protein 1A) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tie...Open in Atlas onco.cc
TDO2: TDO2 does the same job as IDO1, breaking down tryptophan into kynurenine, which quietens T cells. It is one reason IDO1 inhibitors alone may not have been enough; no TDO2 drug has reached late trials.Open in Atlas onco.cc
TEC: TEC (Tyrosine-protein kinase Tec) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and an oncogene driver, and an approved or late-stage drug is recorded against it. Ti...Open in Atlas onco.cc
TENT4A: TENT4A (Terminal nucleotidyltransferase 4A) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
TENT5C: TENT5C (Terminal nucleotidyltransferase 5C) is an enzyme. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Multiple myeloma, Skin cancer, Colorecta...Open in Atlas onco.cc
TERT: TERT (Telomerase reverse transcriptase) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Myeloprolife...Open in Atlas onco.cc
TET1: TET1 (Methylcytosine dioxygenase TET1) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to d...Open in Atlas onco.cc
TET2: TET2 is an enzyme that helps erase methyl marks from DNA so genes can be switched back on. Losing it is one of the commonest first steps toward blood cancer; mutant IDH blocks it indirectly, which is part of how ivosidenib works when it restores normal matu...Open in Atlas onco.cc
TF: TF (Serotransferrin) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Melanoma.Open in Atlas onco.cc
TFAP4: TFAP4 (Transcription factor AP-4) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response....Open in Atlas onco.cc
TFE3: TFE3 (Transcription factor E3) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a fusion partner, and the evidence so far is association rather than a proven role. Tied to Renal cell carcinoma, Sarcomas,...Open in Atlas onco.cc
TFEB: TFEB (Transcription factor EB) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Breast cancer and Melanoma.Open in Atlas onco.cc
TFF3: TFF3 (Trefoil factor 3) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer.Open in Atlas onco.cc
TFG: TFG (trafficking from ER to golgi regulator) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to He...Open in Atlas onco.cc
TFRC: TFRC (Transferrin receptor protein 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to...Open in Atlas onco.cc
TG: TG (Thyroglobulin) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Thyroid cancer.Open in Atlas onco.cc
TGFA: TGFA (Protransforming growth factor alpha) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Head and neck squamous cell carcinoma.Open in Atlas onco.cc
TGFB1: TGFB1 (Transforming growth factor beta-1 proprotein) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Myelodysplastic syndromes / neoplasms.Open in Atlas onco.cc
TGFB2: TGFB2 (Transforming growth factor beta-2 proprotein) is a gene. The public catalogues list it as a drug target and a fusion partner, and an approved or late-stage drug is recorded against it. Tied to Myelodysplastic syndromes / neoplasms.Open in Atlas onco.cc
TGFB3: TGFB3 (Transforming growth factor beta-3 proprotein) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Myelodysplastic syndromes / neoplasms.Open in Atlas onco.cc
TGFBR1: TGFBR1 (TGF-beta receptor type-1) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a tumour suppressor, and clinical evidence ties its variants to diagnosis, progno...Open in Atlas onco.cc
TGFBR2: TGFBR2 (TGF-beta receptor type-2) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis o...Open in Atlas onco.cc
TGFBR3: TGFBR3 (Transforming growth factor beta receptor type 3) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer.Open in Atlas onco.cc
TGIF1: TGIF1 (Homeobox protein TGIF1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer.Open in Atlas onco.cc
TGM3: TGM3 (Protein-glutamine gamma-glutamyltransferase E) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Skin cancer and Basal cell carcinoma.Open in Atlas onco.cc
THBS2: THBS2 (Thrombospondin-2) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer.Open in Atlas onco.cc
Thioredoxin reductase 1: Thioredoxin reductase keeps cells' antioxidant defences charged; arsenic trioxide, the drug that cures most acute promyelocytic leukaemia with ATRA, inhibits it as one of its several actions.Open in Atlas onco.cc
THRA: THRA (Thyroid hormone receptor alpha) is a protein that switches other genes on and off. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Thyroid cancer.Open in Atlas onco.cc
THRAP3: THRAP3 (Thyroid hormone receptor-associated protein 3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Acute...Open in Atlas onco.cc
THRB: THRB (Thyroid hormone receptor beta) is a protein that switches other genes on and off. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Thyroid cancer.Open in Atlas onco.cc
Thymidylate synthase (TYMS): The enzyme that makes the thymine building block of DNA. Fluorouracil, capecitabine and pemetrexed jam it, starving dividing cells of thymidine.Open in Atlas onco.cc
TIE2 receptor (TEK): TIE2 is the angiopoietin receptor that keeps blood vessels stable; regorafenib and cabozantinib block it as part of their attack on the tumour's blood supply.Open in Atlas onco.cc
TIGIT: TIGIT is an inhibitory receptor on T and natural killer cells that binds PVR (CD155) on tumour cells, so blocking it was expected to amplify PD-1 and PD-L1 inhibitors. Tiragolumab, domvanalimab and others then failed to add benefit in phase 3 lung cancer tr...Open in Atlas onco.cc
TIM-3: An immune checkpoint on exhausted T cells and on leukaemic stem cells; antibodies against it failed in lung cancer and MDS after strong preclinical promise.Open in Atlas onco.cc
TIMP1: TIMP1 (Metalloproteinase inhibitor 1) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer.Open in Atlas onco.cc
Tissue factor: Tissue factor is a clotting protein that cancers abnormally display on their surface, used as an ADC target in cervical cancer.Open in Atlas onco.cc
TLK2: TLK2 (Serine/threonine-protein kinase tousled-like 2) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties it...Open in Atlas onco.cc
TLN1: TLN1 (Talin-1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
TLX1: TLX1 (T-cell leukaemia homeobox protein 1) is a gene. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role.Open in Atlas onco.cc
TLX3: TLX3 (T-cell leukaemia homeobox protein 3) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
TMEM127: TMEM127 (Transmembrane protein 127) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Neuroendocrine tumours and Melanoma.Open in Atlas onco.cc
TMEM17: TMEM17 (Transmembrane protein 17) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer.Open in Atlas onco.cc
TMEM238L: TMEM238L (Transmembrane protein 238-like) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Colorectal cancer.Open in Atlas onco.cc
TMPRSS2: TMPRSS2 (Transmembrane protease serine 2) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer.Open in Atlas onco.cc
TMSB4X: TMSB4X (Thymosin beta-4) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response....Open in Atlas onco.cc
TNC: TNC (Tenascin) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. T...Open in Atlas onco.cc
TNFAIP3: TNFAIP3 (Tumour necrosis factor alpha-induced protein 3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or dru...Open in Atlas onco.cc
TNFRSF10B: TNFRSF10B (Tumour necrosis factor receptor superfamily member 10B) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.Open in Atlas onco.cc
TNFRSF13B: TNFRSF13B (Tumour necrosis factor receptor superfamily member 13B) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Multiple myeloma.Open in Atlas onco.cc
TNFRSF14: TNFRSF14 (Tumour necrosis factor receptor superfamily member 14) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosi...Open in Atlas onco.cc
TNFSF10: TNFSF10 (Tumour necrosis factor ligand superfamily member 10) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
TNS1: TNS1 (Tensin-1) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
TNS3: TNS3 (Tensin-3) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer and Basal cell carcinoma.Open in Atlas onco.cc
TOE1: TOE1 (Target of EGR1 protein 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
Toll-like receptor 7 (TLR7): TLR7 is an innate immune sensor for viral RNA; the cream imiquimod switches it on to make the skin's immune cells attack superficial basal cell carcinoma.Open in Atlas onco.cc
TOP2B: TOP2B (DNA topoisomerase 2-beta) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Lung cancer, Neuroendocrine tumours, Breast cancer and 1 more.Open in Atlas onco.cc
TOP3A: TOP3A (DNA topoisomerase 3-alpha) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
Topoisomerase I (TOP1): The enzyme that nicks one DNA strand to relieve twisting while DNA is copied. Camptothecins and the payloads of several antibody-drug conjugates trap it on the DNA so the nick becomes a permanent break when the cell replicates.Open in Atlas onco.cc
Topoisomerase II alpha (TOP2A): The enzyme that cuts both DNA strands to untangle chromosomes before cell division. Etoposide and the anthracyclines hold it in the cut state, filling dividing cells with double-strand breaks.Open in Atlas onco.cc
TOX: TOX (Thymocyte selection-associated high mobility group box protein TOX) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied...Open in Atlas onco.cc
TOX3: TOX3 (TOX high mobility group box family member 3) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Breast cancer.Open in Atlas onco.cc
TP53: TP53 is the 'guardian of the genome', broken in half of all cancers. Fixing it directly has so far defeated every attempt, so drugs exploit what its loss makes cancers depend on.Open in Atlas onco.cc
TP53BP1: TP53BP1 (TP53-binding protein 1) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, a fusion partner and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied...Open in Atlas onco.cc
TP63: TP63 (Tumour protein 63) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Lung cancer, Skin canc...Open in Atlas onco.cc
TPCN2: TPCN2 (Two pore channel protein 2) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Skin cancer.Open in Atlas onco.cc
TPH2: TPH2 (Tryptophan 5-hydroxylase 2) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Neuroendocrine tumours.Open in Atlas onco.cc
TPM3: TPM3 (Tropomyosin alpha-3 chain) is a gene. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Lung cancer, Colorectal cancer and Non-small-cell lung cancer.Open in Atlas onco.cc
TPM4: TPM4 (Tropomyosin alpha-4 chain) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
TPR: TPR (Nucleoprotein TPR) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied...Open in Atlas onco.cc
TPT1: TPT1 (Translationally-controlled tumour protein) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Melanoma.Open in Atlas onco.cc
TRAF3: TRAF3 (TNF receptor-associated factor 3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Multiple myeloma.Open in Atlas onco.cc
TRAF7: TRAF7 (E3 ubiquitin-protein ligase TRAF7) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Mesothelioma, Skin cancer,...Open in Atlas onco.cc
TRAK1: TRAK1 (Trafficking kinesin-binding protein 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
TRIM24: TRIM24 (Transcription intermediary factor 1-alpha) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied...Open in Atlas onco.cc
TRIM27: TRIM27 (Zinc finger protein RFP) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role.Open in Atlas onco.cc
TRIM28: TRIM28 (Transcription intermediary factor 1-beta) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Wilms tumour.Open in Atlas onco.cc
TRIM33: TRIM33 (E3 ubiquitin-protein ligase TRIM33) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied...Open in Atlas onco.cc
TRIM49C: TRIM49C (Tripartite motif-containing protein 49C) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Gastric & gastro-o...Open in Atlas onco.cc
TRIP11: TRIP11 (Thyroid receptor-interacting protein 11) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts....Open in Atlas onco.cc
TROP2: TROP2 is a surface glycoprotein present at high levels on most epithelial cancers (breast, lung, urothelial, gastric, pancreatic) and at low levels on normal tissue. It does not drive the cancer; it is a delivery address, used by the approved ADCs sacituzum...Open in Atlas onco.cc
TRPS1: TRPS1 (Zinc finger transcription factor Trps1) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Breast cancer.Open in Atlas onco.cc
TRRAP: TRRAP (Transformation/transcription domain-associated protein) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient c...Open in Atlas onco.cc
Tryptophan hydroxylase 1: Tryptophan hydroxylase makes serotonin, the hormone that neuroendocrine tumours pour out in carcinoid syndrome; telotristat ethyl blocks the enzyme to cut the diarrhoea that somatostatin analogues leave uncontrolled.Open in Atlas onco.cc
TSC1: TSC1 (Hamartin) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, a tumour suppressor and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Bladder & urothelial cancer,...Open in Atlas onco.cc
TSC2: TSC2 (Tuberin) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Hepatocell...Open in Atlas onco.cc
TSH receptor (TSHR): The TSH receptor tells thyroid cells to take up iodine; recombinant TSH (thyrotropin alfa) stimulates it so that radioactive iodine can find and destroy leftover thyroid cancer.Open in Atlas onco.cc
TSPYL1: TSPYL1 (Testis-specific Y-encoded-like protein 1) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer.Open in Atlas onco.cc
TTF1: TTF1 (Transcription termination factor 1) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-small-cell lung cancer.Open in Atlas onco.cc
TUBA1A: TUBA1A (Tubulin alpha-1A chain) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Breast cancer, Lung cancer, Non-Hodgkin lymphoma and 5 more.Open in Atlas onco.cc
TUBA1B: TUBA1B (Tubulin alpha-1B chain) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Breast cancer, Lung cancer, Prostate cancer and 5 more.Open in Atlas onco.cc
TUBA1C: TUBA1C (Tubulin alpha-1C chain) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Prostate cancer, Breast cancer, Lung cancer and 5 more.Open in Atlas onco.cc
TUBA3C: TUBA3C (Tubulin alpha-3C chain) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Breast cancer, Lung cancer, Non-Hodgkin lymphoma and 5 more.Open in Atlas onco.cc
TUBA3E: TUBA3E (Tubulin alpha-3E chain) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Breast cancer, Lung cancer, Non-Hodgkin lymphoma and 5 more.Open in Atlas onco.cc
TUBA4A: TUBA4A (Tubulin alpha-4A chain) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Breast cancer, Lung cancer, Non-Hodgkin lymphoma and 5 more.Open in Atlas onco.cc
TUBB1: TUBB1 (Tubulin beta-1 chain) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Breast cancer, Lung cancer, Non-Hodgkin lymphoma and 5 more.Open in Atlas onco.cc
TUBB2A: TUBB2A (Tubulin beta-2A chain) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Breast cancer, Lung cancer, Non-Hodgkin lymphoma and 5 more.Open in Atlas onco.cc
TUBB2B: TUBB2B (Tubulin beta-2B chain) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Breast cancer, Lung cancer, Sarcomas and 5 more.Open in Atlas onco.cc
TUBB3: TUBB3 (Tubulin beta-3 chain) is a gene. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Breast cancer, Lung cancer, Prostate cancer and 5 more.Open in Atlas onco.cc
TUBB4A: TUBB4A (Tubulin beta-4A chain) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Prostate cancer, Breast cancer, Lung cancer and 5 more.Open in Atlas onco.cc
TUBB4B: TUBB4B (Tubulin beta-4B chain) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Lung cancer, Breast cancer, Non-Hodgkin lymphoma and 5 more.Open in Atlas onco.cc
TUBB6: TUBB6 (Tubulin beta-6 chain) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Lung cancer, Breast cancer, Non-Hodgkin lymphoma and 5 more.Open in Atlas onco.cc
TUBB8: TUBB8 (Tubulin beta-8 chain) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Breast cancer, Lung cancer, Non-Hodgkin lymphoma and 5 more.Open in Atlas onco.cc
Tubulin (microtubules): The protein that builds the microtubule scaffolding a cell needs to pull its chromosomes apart. Taxanes freeze the scaffold and vinca alkaloids and eribulin stop it forming; either way the dividing cell stalls and dies.Open in Atlas onco.cc
TYK2: TYK2 (Non-receptor tyrosine-protein kinase TYK2) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded agains...Open in Atlas onco.cc
TYMP: TYMP (Thymidine phosphorylase) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Colorectal cancer.Open in Atlas onco.cc
TYR: TYR (Tyrosinase) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Skin cancer, Melanoma and Basal cell carcinoma.Open in Atlas onco.cc
TYRP1: TYRP1 (5,6-dihydroxyindole-2-carboxylic acid oxidase) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Skin cancer.Open in Atlas onco.cc
TYW2: TYW2 (tRNA wybutosine-synthesising protein 2 homolog) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Salivary gland...Open in Atlas onco.cc

U

U2AF1: U2AF1 (Splicing factor U2AF 35 kDa subunit) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to...Open in Atlas onco.cc
U2AF2: U2AF2 (Splicing factor U2AF 65 kDa subunit) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Acute myeloid leukaemia.Open in Atlas onco.cc
UBA52: UBA52 (Ubiquitin-ribosomal protein eL40 fusion protein) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
UBB: UBB (Polyubiquitin-B) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
UBC: UBC (Polyubiquitin-C) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
UBE2A: UBE2A (Ubiquitin-conjugating enzyme E2 A) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or...Open in Atlas onco.cc
UBR5: UBR5 (E3 ubiquitin-protein ligase UBR5) is an enzyme. The public catalogues list it as an oncogene driver, a tumour suppressor, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gast...Open in Atlas onco.cc
UBTF: UBTF (Nucleolar transcription factor 1) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Acute myeloid leukaemia.Open in Atlas onco.cc
UBXN11: UBXN11 (UBX domain-containing protein 11) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Glioma & glioblastoma.Open in Atlas onco.cc
UGT1A: UGT1A (UDP glucuronosyltransferase family 1 member A complex locus) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer.Open in Atlas onco.cc
UGT1A1: UGT1A1 (UDP-glucuronosyltransferase 1A1) is an enzyme. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it.Open in Atlas onco.cc
USP28: USP28 (Ubiquitin carboxyl-terminal hydrolase 28) is an enzyme. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role. Tied to Prostate cancer.Open in Atlas onco.cc
USP6: USP6 (Ubiquitin carboxyl-terminal hydrolase 6) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to...Open in Atlas onco.cc
USP7: USP7 (Ubiquitin C-terminal hydrolase 7) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or d...Open in Atlas onco.cc
USP8: USP8 (Ubiquitin carboxyl-terminal hydrolase 8) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcin...Open in Atlas onco.cc
USP9X: USP9X (Ubiquitin carboxyl-terminal hydrolase 9X) is an enzyme. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Thyroid cancer, Hepatocellular carc...Open in Atlas onco.cc

V

VAV1: VAV1 (Proto-oncogene vav) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Non-small-cell lung cancer.Open in Atlas onco.cc
VCL: VCL (Vinculin) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
VDR: VDR (Vitamin D3 receptor) is a protein that switches other genes on and off. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.Open in Atlas onco.cc
VEGF / VEGFR: The signal tumours use to grow their own blood supply. Blocking it starves tumours and, surprisingly, helps immunotherapy work.Open in Atlas onco.cc
VEGFC: VEGFC (Vascular endothelial growth factor C) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Hepatocellular carcinoma.Open in Atlas onco.cc
VHL: VHL (von Hippel-Lindau disease tumour suppressor) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to...Open in Atlas onco.cc
VISTA: An immune checkpoint on myeloid cells that works at the acidic pH inside tumours and is a suspected escape route after PD-1 therapy; antibodies are in early trials.Open in Atlas onco.cc
VPS37A: VPS37A (Vacuolar protein sorting-associated protein 37A) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer.Open in Atlas onco.cc
VPS53: VPS53 (Vacuolar protein sorting-associated protein 53 homolog) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer.Open in Atlas onco.cc
VTI1A: VTI1A (Vesicle transport through interaction with t-SNAREs homolog 1A) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
VWF: VWF (von Willebrand factor) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc

W

WAS: WAS (Actin nucleation-promoting factor WAS) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Skin cancer, Medulloblas...Open in Atlas onco.cc
WDCP: WDCP (WD repeat and coiled-coil-containing protein) is a gene. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role.Open in Atlas onco.cc
WDR12: WDR12 (Ribosome biogenesis protein WDR12) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Glioma & glioblastoma.Open in Atlas onco.cc
WEE1: A checkpoint kinase that gives cells time to fix DNA before dividing. Removing it forces damaged cancer cells into a fatal division.Open in Atlas onco.cc
WIF1: WIF1 (Wnt inhibitory factor 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Breast cancer and Oral cavity cancer.Open in Atlas onco.cc
WNK1: WNK1 (Serine/threonine-protein kinase WNK1) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug resp...Open in Atlas onco.cc
WNK2: WNK2 (Serine/threonine-protein kinase WNK2) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation...Open in Atlas onco.cc
WNT1: WNT1 (Proto-oncogene Wnt-1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Uterine carcinosarcoma.Open in Atlas onco.cc
WNT11: WNT11 (Wnt family member 11) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer.Open in Atlas onco.cc
WNT6: WNT6 (Wnt family member 6) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer.Open in Atlas onco.cc
WRAP53: WRAP53 (Telomerase Cajal body protein 1) is a gene. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role.Open in Atlas onco.cc
WRN helicase (MSI-high cancers): A DNA-unwinding enzyme that mismatch-repair-deficient cancers cannot live without; the first WRN inhibitors are in trials as a chemotherapy-free option for MSI-high tumours that fail immunotherapy.Open in Atlas onco.cc
WT1: WT1 (Wilms tumour protein) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, pr...Open in Atlas onco.cc
WWOX: WWOX (WW domain-containing oxidoreductase) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Oesophageal cancer.Open in Atlas onco.cc
WWTR1: WWTR1 (WW domain-containing transcription regulator protein 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Ovari...Open in Atlas onco.cc

X

Xanthine oxidase (XDH): Xanthine oxidase makes uric acid from the breakdown of DNA; allopurinol blocks it to prevent the kidney damage of tumour lysis syndrome when chemotherapy kills many cancer cells at once.Open in Atlas onco.cc
XPA: XPA (DNA repair protein complementing XP-A cells) is a gene. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role. Tied to Skin cancer, Colorectal cancer and Basal cell carcinoma.Open in Atlas onco.cc
XPC: XPC (DNA repair protein complementing XP-C cells) is a protein that switches other genes on and off. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role. Tied to Lung cancer and Prostate cancer.Open in Atlas onco.cc
XRCC1: XRCC1 (DNA repair protein XRCC1) is a gene. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Cervical cancer and Non-small-cell lung...Open in Atlas onco.cc
XRCC2: XRCC2 (DNA repair protein XRCC2) is a gene. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role.Open in Atlas onco.cc
XRCC3: XRCC3 (DNA repair protein XRCC3) is a gene. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Triple-negative breast cancer.Open in Atlas onco.cc

Y

YAP1: YAP1 (Transcriptional coactivator YAP1) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Oesophageal...Open in Atlas onco.cc
YES1: YES1 (Tyrosine-protein kinase Yes) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to...Open in Atlas onco.cc
YWHAB: YWHAB (14-3-3 protein beta/alpha) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
YWHAE: YWHAE (14-3-3 protein epsilon) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Sarcomas.Open in Atlas onco.cc

Z

ZBTB10: ZBTB10 (Zinc finger and BTB domain-containing protein 10) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Basal cell carcinoma.Open in Atlas onco.cc
ZBTB16: ZBTB16 (Zinc finger and BTB domain-containing protein 16) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis...Open in Atlas onco.cc
ZBTB20: ZBTB20 (Zinc finger and BTB domain-containing protein 20) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts.Open in Atlas onco.cc
ZBTB48: ZBTB48 (Zinc finger and BTB domain-containing protein 48) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Angiosarcoma.Open in Atlas onco.cc
ZBTB7B: ZBTB7B (Zinc finger and BTB domain-containing protein 7B) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Ute...Open in Atlas onco.cc
ZC3HAV1: ZC3HAV1 (Zinc finger CCCH-type antiviral protein 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
ZCCHC8: ZCCHC8 (Zinc finger CCHC domain-containing protein 8) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Gastric & gast...Open in Atlas onco.cc
ZCRB1: ZCRB1 (Zinc finger CCHC-type and RNA-binding motif-containing protein 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tie...Open in Atlas onco.cc
ZEB1: ZEB1 (Zinc finger E-box-binding homeobox 1) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, pro...Open in Atlas onco.cc
ZFHX3: ZFHX3 (Zinc finger homeobox protein 3) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate...Open in Atlas onco.cc
ZFHX4: ZFHX4 (Zinc finger homeobox protein 4) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role.Open in Atlas onco.cc
ZFP36L1: ZFP36L1 (mRNA decay activator protein ZFP36L1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, progno...Open in Atlas onco.cc
ZFPM2: ZFPM2 (Zinc finger protein ZFPM2) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Breast cancer.Open in Atlas onco.cc
ZHX2: ZHX2 (Zinc fingers and homeoboxes protein 2) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Papilla...Open in Atlas onco.cc
ZMIZ1: ZMIZ1 (Zinc finger MIZ domain-containing protein 1) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Breast cancer, Prostate cancer and Colorectal cancer.Open in Atlas onco.cc
ZMYM2: ZMYM2 (Zinc finger MYM-type protein 2) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Leukaemi...Open in Atlas onco.cc
ZMYM3: ZMYM3 (Zinc finger MYM-type protein 3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patien...Open in Atlas onco.cc
ZNF208: ZNF208 (Zinc finger protein 208) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Oesophageal cancer and Oesophageal...Open in Atlas onco.cc
ZNF217: ZNF217 (Zinc finger protein 217) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Ovar...Open in Atlas onco.cc
ZNF274: ZNF274 (Neurotrophin receptor-interacting factor homolog) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Medullobla...Open in Atlas onco.cc
ZNF292: ZNF292 (Zinc finger protein 292) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.Open in Atlas onco.cc
ZNF331: ZNF331 (Zinc finger protein 331) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Nasopharyngeal carcinoma, Skin canc...Open in Atlas onco.cc
ZNF395: ZNF395 (Zinc finger protein 395) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Non-small-cell lung cancer.Open in Atlas onco.cc
ZNF429: ZNF429 (Zinc finger protein 429) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urot...Open in Atlas onco.cc
ZNF462: ZNF462 (Zinc finger protein 462) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.Open in Atlas onco.cc
ZNF521: ZNF521 (Zinc finger protein 521) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied...Open in Atlas onco.cc
ZNF626: ZNF626 (Zinc finger protein 626) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Nasopharyngeal carcinoma.Open in Atlas onco.cc
ZNF680: ZNF680 (Zinc finger protein 680) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Nasopharyngeal carcinoma.Open in Atlas onco.cc
ZNF703: ZNF703 (Zinc finger protein 703) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer.Open in Atlas onco.cc
ZNF721: ZNF721 (Zinc finger protein 721) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Nasopharyngeal carcinoma.Open in Atlas onco.cc
ZNF750: ZNF750 (Zinc finger protein 750) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Oesophageal cancer, Oesophag...Open in Atlas onco.cc
ZNF780A: ZNF780A (Zinc finger protein 780A) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Nasopharyngeal carcinoma.Open in Atlas onco.cc
ZNF814: ZNF814 (Zinc finger protein 814) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Gastric & gastro-oesophageal juncti...Open in Atlas onco.cc
ZNF90: ZNF90 (Zinc finger protein 90) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Nasopharyngeal carcinoma.Open in Atlas onco.cc
ZNF93: ZNF93 (Zinc finger protein 93) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Nasopharyngeal carcinoma.Open in Atlas onco.cc
ZNRF3: ZNRF3 (E3 ubiquitin-protein ligase ZNRF3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Adrenocortical carc...Open in Atlas onco.cc
ZRSR2: ZRSR2 (U2 small nuclear ribonucleoprotein auxiliary factor 35 kDa subunit-related protein 2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its var...Open in Atlas onco.cc
ZXDB: ZXDB (Zinc finger X-linked protein ZXDB) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer.Open in Atlas onco.cc

#

5-alpha-reductase type 2 (SRD5A2): 5-alpha-reductase turns testosterone into the more potent dihydrotestosterone inside the prostate; finasteride and dutasteride block it, and two large trials showed they cut prostate cancer diagnoses by about a quarter while raising concern about high-grade...Open in Atlas onco.cc
5-HT3 receptor (HTR3A): The serotonin receptor on the gut's vagus nerve endings and in the brainstem vomiting centre that chemotherapy triggers. Ondansetron and palonosetron block it, the foundation of modern anti-sickness treatment.Open in Atlas onco.cc